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1 INTRODUCTION AND AIMS 
The postnatal period is known to be crucial for tolerance development after birth. 
However the underlying mechanisms of the process remain unclear. Former avoidance 
strategies are under debate and epidemiological studies describe an inverse association 
between the level of environmental endotoxin exposure within the first months of life 
and the prevalence of allergic disease in children. 
Cord blood derived mononuclear cells, and in specific T cells, respond to ubiquitous 
environmental antigens by proliferation upon antigen exposure. This has been mainly 
attributed to trans-placental priming. Thornton and Upham et al. suggested that 
proliferative reactivity in cord blood does not refer to the conventional memory T cell 
population present in cord blood. In addition this type of response was characterized by 
an antigen-driven apoptosis exceeding those detected in peripheral blood mononuclear 
cells (PBMCs) from adult individuals on the one hand and the generation of 
CD4+CD25+ regulatory cells on the other hand. More recent publications suggest that 
antigen-specific response in cord blood differ markedly from those occurring later in 
life and may be less specific than originally suggested. Thus allergen-specific 
proliferative response in cord blood may reflect a functional immature state of the 
regulatory T cell (Treg) compartment. To date it remains unclear whether these 
“heightened” responses can be explained by endotoxin contamination detected in 
commercially available allergen preparations, by transplacental priming, by the recent 
thymic emigrants or whether this increased proliferation may relate to diminished, 
immature functional properties of the regulatory T cell compartment.  
Cord blood was used as a model system for a naïve, human system, unexperienced to 
antigens. Peripheral blood derived mononuclear cells of adult donors were used as 
control to delineate Tregs in an adult system as well. Endotoxin contaminations in 
allergen preparations (in particular beta-lactoglobulin (BLG), the major milk allergen) 
have been proved to affect antigen-specific proliferative response in the murine system. 
Impact of such potential confounders remains to be described for the naïve human 
system. The properties of the regulatory T cells in cord blood in the presence of 
endotoxins and allergens are poorly defined and will be assessed in detail in this thesis. 
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The aim of this thesis is to define the nature of allergen-specific T cell responses in 
cord blood in vitro and to delineate differences in adults. Special emphasis will be put 
on nutritional allergens from milk (β-lactoglobulin (BLG)) and peanut (Ara h 1), which 
represent the most important group of allergens within the first years of life. The 
recombinant birch pollen allergen rBet v1 will serve representative for inhalational and 
recombinant allergens. 
Moreover the control mechanisms will be of interest to investigate differences in the 
regulatory T cell subset in cord and peripheral blood at a phenotypic (Treg surface (e.g. 
CD25 and CD127) and intracellular (e.g. FoxP3) markers and a functional level 
(inhibition assays).  
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2 LITERATURE REVIEW 
2.1 Allergy 
In 1906 the Viennese pediatrician Clemens von 
Pirquet conceived the term “αλλεργία” (allergy) from the 
Greek άλλο (allos; changed or altered state) and έργο 
(ergon; reaction or reactivity) 3. Allergy is defined as “the 
immune system’s hypersensitivity to a foreign substance. 
Typically harmless substances, such as pollen, food, 
animal dander, stings, mould or drugs lead to a switch in 
the reactivity of an individual. Upon re-stimulation with 
this antigen the immune system reacts as if the substance 
was harmful whereas no response occurs in non-allergic 
people" 3, 4 (Figure 1). 
The prevalence of allergies has risen extensively in the 
past two decades in industrial nations 5 and asthma has 
become the most common chronic disease 6 making 
allergy a significant public health burden. However, 
recent studies could show a plateau or abatement in these 
prevalence rates 7, 8.  
In Austria per contra, in contrast to other European countries, Schernhammer et al 
(2008) reported a significant increase in the prevalence rates of allergy such as asthma, 
allergic rhinitis, and eczema in schoolchildren (ISAAC study) 9. Additionally, the 
prevalence of allergic sensitization also increased significantly from 1996 to 2006 in a 
Swedish cohort 10 as well as in Greenland 11 and Ghana 11.  
The underlying cause has not been clarified yet and although it is known that the 
development of allergies are influenced by genetic, developmental, and environmental 
factors the influence of allergens and lipopolysaccharide on neonatal tolerance induction 
remains to be answered.  
Atopy:  
“an exaggerated tendency to 
mount IgE responses to a 
wide variety of common 
environmental allergens 1”.  
 
Allergy: 
“an enhanced or inappropriate 
immune response initiated by 
exposures to antigens such as 
mould spores, pollen, or 
certain drugs and foods 
together with an increased 
IgE level.  
It may cause symptoms such 
as allergic conjunctivitis, 
pruritus, urticaria, runny nose, 
and asthma 1.” 
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Figure 1 A simplified schema for the immune system’s response to become allergic 
or non-allergic 
1
 
The naïve immune system responds to foreign, harmless substances (cat dander, pollen, food…) with an 
exaggerated immune response, for instance IgE overproduction, as a preliminary stage to allergy. In case 
of a “normal” immune response the foreign substance is eliminated without an allergic reaction. 
 
2.1.1 Immunological Sensitization 
An immunological sensitization always precedes allergy, although not every 
sensitization necessarily succeeds in clinically manifest allergy. The underlying 
mechanisms leading to immunological sensitization are very complex and not yet 
completely understood. 
Sensitization most likely occurs via the inhalational or gastrointestinal route. After 
entering the mucosa antigen presenting cells (APC) incorporate the protein, process it 
very efficiently and present peptide epitopes on the major histocompatibility complex 
(MHC) class II for T helper (Th) cells. This may form the initial event to induce the 
differentiation of a naïve CD4+ T cell with the respective T cell receptor (TCR) 
direction towards Th2. These CD4+ T helper cells with the characteristic Th2-type 
cytokine production (interleukin (IL)-4, IL-13 and IL-5) are the first step towards 
immune system 
foreign substance  
(cat dander, pollen, food...) 
exaggerated immune response  
IgE overproduction in response to 
cat dander, pollen, and other 
harmless allergens 
 
 
subsequent exposure results in an 
allergic reaction 
 
 
 
allergic individual  
normal immune response         
IgM, IgG, IgA, IgD and various 
immune cells respond to attack 
 
 
 
foreign substance is eliminated 
 
 
 
 
non-allergic individual  
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sensitization 12. IL-4 and IL-13 lead to an isotype switch from IgG to IgE production in 
B lymphocytes and IL-5 recruits and activates eosinophils 1. Antigens that selectively 
evoke Th2 cells that drive an IgE response are known as allergens. Presence of very low 
antigen doses favour the activation of Th2 cells over T helper 1 (Th1) cells. 
Additionally, peptides that bind strongly to the TCR are more likely to stimulate a Th1- 
like response. On the other hand, peptides that interact weakly with the TCR provoke a 
Th2 response. Since allergens commonly cross the mucosal barrier in low doses, a Th2 
response is more likely 1. 
The IgE antibody binds with its Fc part to the high affinity receptor (FcεRI) which is 
located on mast cells, basophile granulocytes, and activated eosinophils. IgE production 
can be further amplified as these cells produce IL-4 and CD40 ligand upon activation. 
Cells are thereby “sensitized” and can survive for a long time due to the stability of the 
IgE-receptor-complex. Re-exposure leads to cross linking of IgE molecules and the 
release of inflammatory mediators (e.g. histamine – responsible for a prompt increase in 
the local blood flow and vessel permeability, mast-cell chymase, tryptase, and serine 
esterases) that cause the allergic reaction (Figure 2). The likelihood for an increased IgE 
production is influenced by hereditary factors. Due to a predisposition to develop Th2 
type responses, atopic individuals are more prone to develop allergies. 
 
 
 
 
Figure 2 An IgE induced mast cell 
13
 
IgE binds to the FcεR on mast cells and basophils and therefore 
leads to a mediator release which causes allergic symptoms 
such as rashes, wheezing and even vomiting. 
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2.1.2 Food Allergy 
Food allergies have significantly increased over the last few decades 14. Speaking of 
which, it is necessary to differentiate between food allergy and food intolerance. Food 
allergy derives from failing to establish and/or maintain oral tolerance in infancy 15 
whereas food intolerance is not immune-mediated and represents a negative reaction to 
foods. This is caused by the lack of enzymes or chemicals to digest food (e.g. lactase 
deficiency in lactose intolerance). 
Allergies can be classified into an IgE, non-IgE or a mixed response. Clinical 
symptoms range from milder IgE-mediated responses like rhinoconjunctivitis, 
gastrointestinal symptoms, urticaria, and exacerbation of atopic dermatitis to life 
threatening conditions like angioedema, asthma, or even anaphylaxis.  
Mast-cell degranulation, as first-line defence after allergen encounter of allergic 
patients, follows a more persistent inflammation the late phase response. Thise phase is 
characterized by the recruitment of Th2 cells, basophils as well as eosinophils and are 
crucial for the severity of the allergic response. Lipid mediators (e.g. leukotrienes) 
synthesized by mast cells are able to cause smoothe muscle contraction, mucus 
secretion, an increased vascular permeability and importantly also the activation of 
leukocytes, which are responsible for the late-phase response. On account of these 
mechanisms diarrhoea and vomiting are likely to occur because of the smooth muscle 
contraction and transepithelial fluid loss. In the dermis urticaria can result from 
activation of connective tissue mast cells 1. In case of allergens that are rapidly absorbed 
from the gut or directly enter the bloodstream, activation of the connective tissue mast 
cells that are associated with all blood vessels, can cause the life-threatening systemic 
anaphylaxis. The increase of the vascular permeability can cause loss of blood pressure, 
difficulties in breathing because of airways constrict, and most fatal suffocation by 
swelling of the epiglottis: the anaphylactic shock. 
Food allergy is one of the primary causes for anaphylactic shock medicated in 
emergency departments, in children. Approximately 30,000 anaphylactic shock 
reactions are reported in the United States every year, including 200 deaths. The 
anaphylactic shock can be controlled by an immediate injection of epinephrine, which 
instantly relaxes the smooth muscle and inhibits cardiovascular effects. 
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Food allergy is fairly common in childhood and data from the 90’s suggests that 
approximately 6-8% of infants would be affected in the first three years of life 16. 
However this data had to be adjusted to a lower prevalence in the recent years. The 
perceived, self-reported prevalence is always more frequent than allergies evaluated 
through objective measures objective measures and may vary from 3.24% to up to 
34.9% surveyed by Madsen in 2005 17. This can be explained by that in most cases no 
difference is made between food allergy and food intolerance. In a meta-analysis of 
2007 the prevalence of food allergy varied from 1.2% to 17% for milk, 0.2% to 7% for 
egg, 0% to 2% for peanuts and fish, 0% to 10% for shellfish, and 3% to 35% for any 
other food 18. In a randomized telephone survey conducted in 10 European countries 
(Austria, Belgium, Denmark, Finland, Germany, Greece, Italy, Poland, Slovenia and 
Switzerland) parents were interviewed with a standard questionnaire about their 
children’s allergies. 8,825 children could be reached resulting in a parentally perceived 
food allergy prevalence of 4.7%. Still, great differences between the countries could be 
observed and the prevalenced ranged from 1.7% in Austria to 11.7% in Finland. 
Medical treatment was only reported for 75.7% of the allergic children and so an actual 
3.55% food allergy was calculated 19. 
Cow’s milk and hen’s egg are the most frequent food allergens in infants and the 
corresponding allergic diseases often resolve spontaneously. In adolescence and 
adulthood peanut and tree nuts are the most prominent food allergens. They are taking 
place later in life, are more likely to persist and are more severe as even trace amounts 
can cause an anaphylactic shock 20. Thus, peanut allergy is a significant public health 
problem, especially in schools, when children are unintentionally exposed to peanuts 
1.The Multicenter Allergy Study (MAS) recorded specific IgE levels of 216 children to 
a panel of allergens in yearly intervals. During the first six years of life, sensitization to 
food allergens decreased from 10% (at 1 year) to 3% (at 6 years) 21.  
Oral tolerance is most likely to develop to food proteins with epitopes that are 
grouped in a conformational structure (as in milk, egg, wheat, and soy). Vice versa it is 
also more unlikely to outgrow food allergy when the epitopes are arranged in linear 
binding epitopes (as in nuts, seeds, and fish) 22. Several methods are used to verify a 
suspected food allergy: patient’s history, the measurement of specific immunoglobulin 
E antibodies (sIgE) via RAST (radioallergosorbent test), the newer ImmunCAP, skin 
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prick testing (SPT), and the atopy patch test. The golden standard to determine food 
allergy still is the double-blind, p      lacebo-controlled food challenge (DBPCFC) 23. 
Food allergen-specific CD4+ T lymphocytes synthesize high levels of IL-4 and IL-13 
which are known to initiate IgE synthesis and to be involved in determining the site of 
allergic inflammation 24. Regulatory T cells in particular, such as TGF-β producing Th3 
cells, IL-10-producing Tr1 cells as well as natural killer T (NKT) cells are involved in 
oral tolerance induction 25. Natural Tregs have become of the focus of increased interest 
as they may be involved in the prevention of sensitization to allergens. Feeding 
experiments with mice and guinea pigs showed that repeated allergen application 
induced activation of functional Tregs and therefore prevented anaphylaxis 26-28. At 
present no definitive treatment for food allergy is available 29. Two ways of treating 
food allergy are used in clinical practice: desensitization on the one hand and blockade 
of the effector pathways on the other hand 1.  
Specific immunotherapies (SIT) such as subcutaneous immunotherapy (SCIT) and 
the non-invasive sublingual immunotherapy (SLIT) are acknowledged methods to 
induce tolerance. However not for food allergies. The underlying mechanism why SIT 
does not work for food allergies is still an enigma. The efficacy is well documented 
only for grass pollen- and mite-allergies as reviewed in Cox et al (2006) 30. SLIT at an 
early stage could decrease the risk by 3.8 fold of getting asthma as documented in a 
multicenter study 31. For food allergy SIT is not recommended because of an 
unacceptable high rate of adverse systemic reactions 32. Moreover, daily allergen 
application is mandatory, because cassative of applicatiojn impaires the tolerance 33. 
Additionally, in some patients not even the highest dilution of the allergen is tolerated 
so that not all patients completed the immunosensitization. However increased allergen 
doses, compared to the beginning, are tolerated in most studies 34. Based on existing 
data the underlying mechansisms to induce tolerance may differ for SCIT or SLIT. 
It could be shown in mice that a continuous feeding of an allergen induces 
suppression of Th1 and Th2 type responses 35. Moreover, a significant decrease of 
specific IgE together with an increase of specific IgG4 after 6 and 18 months, 
respectively, was observed 34. Oral immunotherapy appears to be a promising approach 
in treating food therapy, however new, optimized protocols with fewer side effects have 
to be established.  
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2.1.2.1 Cow’s Milk Allergy 
Cow’s milk allergy (CMA) is very common in infancy. Five to 15% of infants show 
symptoms of CMA 36. IgE specific to milk, is together with egg, the earliest serological 
marker for atopic immunoreactivity in infancy 21. Cow’s milk contains 3.3% total 
protein. Milk protein has two main components which can be distinguished according to 
their chemical composition and physical properties. Caseins contain phosphorus and 
comprise about 83% of the milk proteins. Whey (serum), unlike caseins, remains in 
solution at pH 4.6 and comprises the remaining 17%. The major cow’s milk allergens, 
all proteins, are α-casein, β-casein, κ-casein, and the whey proteins β-lactoglobulin 
(BLG) and α-lactalbumin 37 (Table 1). As BLG can be detected in breast milk, 
sensitization is possible even in the first months of life 38. Proteins from cow’s milk and 
hen’s egg are the main cause for anaphylactic shock in infants 39, 40. 
CMA’s commonly resolved within the first five years of life and consequently forms 
an interesting model for the development of oral tolerance.  
 
Component % Total  % Casein % Whey 
 Caseins 83     
Alpha s1 casein 36 44   
Alpha s2 casein 9 11   
 Whey 17     
Beta-lactoglobulin 10   58 
Alpha-lactalbumin 2   13 
Table 1 Components of milk protein 
41
 
The major cow’s milk proteins are listed in this table.  
 
2.1.2.1.1 β-lactoglobulin 
Βeta-lactoglobulin (BLG) is the most allergenic and most abundant protein in whey. 
It comprises 10% of the total milk protein and 55–65% of the total whey protein 42. It 
encloses 162 amino acids with approximately 18,300 Da and has been studied to a great 
extent over the few last years 43 (Figure 3).  
At pH values in the range of 5.1 to 8.0, which also includes the pH of milk (pH 6.7), β-
lactoglobulin exists as a dimer. Below pH of 3.0 and above pH of 8.0, β-lactoglobulin 
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exists in its monomeric form. Between a pH 3.1 and 5.1, at high protein contents and 
low temperatures, it even forms octamers 44. 
 
Figure 3 β-lactoglobulin 
44
 
The 3D structure of β-lactoglobulin from the protein data bank (PDB) 
entry. 
 
 
 
Beta-lactoglobulin is synthesized in the mammary gland and even though it has a 
well-deﬁned structure, its role is still an enigma. Although various roles have been 
proposed, including the phosphate metabolism in the mammary gland 45 or in the 
transfer of passive immunity to the newborn 46, no function has been definitively 
ascribed to this protein. In general, milk from ruminants like cattle, sheep, goats, and 
deer and of some non-ruminants, such as pigs, horses, dolphins, kangaroos, cats, and 
whales, contains β-lactoglobulin. Humans on the other hand, as well as rodents lack this 
protein. This may explain why the allergenicity of β-lactoglobulin is so high. As β-
casein and β-lactoglobulin from bovine and equine milk share a higher degree of 
homology with human milk, breastfed children have a chance of being sensitized to β-
lactoglobulin even if the mother’s diet is completely milk free 47. 
 
2.1.2.2 Peanut Allergy 
Peanut (Arachis hypogea) is botanically classified to the family of pulses 
(Legominosae). Allergies are often severe and typically permanent. Recent studies from 
North America and the United Kingdom (UK) place peanut allergy rates among 
children near or slightly over 1% 48, 49. Compared to milk allergy, only 20% of young 
children lose their allergy by school age 50. Grundy et al (2002) reported a doubling in 
peanut allergy and a triplication in peanut sensitization during the last years 49. 
 
2.1.2.2.1 Peanut Allergens 
Peanut is a prominent food in the world due to its high nutrition and low cost. 
However, it is also the food item that is most likely to cause an anaphylactic shock as 
even trace amounts of peanut are sufficient to cause an allergic reaction 20, 51. Most 
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peanut allergens are heat-stable, water-stable reservoir proteins with sizes ranging from 
7,000 up to 65,000 Da. To date, nine different peanut allergens have been identified. 
The allergens were numbered consecutively from Ara h 1 to Ara h 9 according to the 
find 52. Ara h 1 and Ara h 2 are considered to be the major allergens because more than 
95% of peanut-allergic patients recognize them 53. 
In the USA, about 1.3% of adults have a peanut or a tree nut allergy 54 and 100% of 
all children at two years of age have already consumed peanut-containing food 55.  
It seems that peanut avoidance is the only evidence-based treatment for peanut 
allergy. Early reports of “desensitizing” patients with oral or subcutaneous 
administration were poorly controlled and therefor not compelling 56, 57. However, 
newer placebo controlled studies 34, one now being conducted by a group in the UK led 
by Hugh Sampson, could confirm the effect of immunotherapy 58. 
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2.1.3 Inhalational Allergy  
Worldwide 10-20 million people suffer from pollen allergies. Approximately one-
third exhibits allergic reactions to tree pollen 59. In the temperate climate zone, Bet v 1, 
a major birch pollen allergen, accounts for most cases of tree pollinosis. Approximately 
20% of the people worldwide suffer from hay fever caused by pollen from trees (e.g. 
birch, alder…), shrubbery (e.g. haze…), grass, grain (e.g. rye…) and herbs (e.g. 
mugwort…). Allergic patients suffer from symptoms like watery, itchy eyes, coryza, 
sneezing, plugged nose, coughing, dyspnoea, asthma, gastrointestinal symptoms, 
eczema, headache, migraine, insomnia, fatigue, depression, and in 30-40% of all cases 
bronchitis or asthma follow 60. 
 
2.1.3.1 Birch Pollen Allergens 
In Europe birch pollen allergy ranks among the main causes of allergy from spring to 
early summer 61. Bet v 1 (Betula verrucosa), the major birch pollen allergen and one of 
the most frequent environmental allergens, has a molecular mass of 17,000 Da 62. About 
60% of birch pollen allergic patients react exclusively to this allergen and about 96% 
that are allergic to tree pollen also display IgE antibodies to Bet v 1 63. Recombinant Bet 
v 1, as the major allergen, is used for immunotherapy for birch pollen allergy. Other 
birch pollen allergens known and classified are Bet v 2, Bet v 3, and Bet v 4. Birch 
pollen is responsible for cross-reactive food allergies. Between 50% and 93% of birch 
pollen-allergic individuals develop cross-reactions to e.g. apples, hazelnut, carrots, and 
celery. This is due to cross-reactive IgE antibodies to Bet v 1 64, 65. In case of birch 
pollen allergy, Mal d 1 (Malus domesticus), the major apple allergen, bears the highest 
cross reactivity. IgE antibodies of most Bet v 1 allergic patients can bind Mal d 1 
regardless of clinical reactivity with apples 64. Next to the humoral cross-reactivity 
between pollen and food allergens, cross-reactivity at the T cell level has been 
postulated as well 66, 67. Mal d 1 shares 64% of its amino acid sequence with Bet v 1 and 
cross-inhibition experiments demonstrated the presence of common IgE epitopes 68. 
Dau c 1 (Daucus carota) from carrot and Api g 1 (Apium graveolens) from celery also 
have a high cross-reactivity potential for birch allergic people.  
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Recently, Bet v 1-specific T cells were discovered in allergic patients, shedding more 
light in the processes happening at the cellular level. Those specific cells mostly secrete 
Th2-type cytokines like IL-5, some IL-10, but no IFN-γ upon allergen contact. 
Surprisingly, also healthy, non-allergic, individuals possess Bet v 1-specific T cells, but 
with fundamental differences. These cells secrete Th1-type cytokines like IFN-γ, and 
IL-10 in response to allergen contact 69. Moreover, they express markers for regulatory 
T cells such as CTLA-4, GITR, and FoxP3.  
A very recent paper by Mobs et al (2010) 70 could show an increase in Bet v 1-
specific, IL-10 secreting T regulatory 1 (Tr1) cells combined with a decreased ration of 
IL-5 producing Th2/Tr1 cells upon specific birch pollen immunotherapy. Interestingly, 
the number of CD4+CD25+CD127low regulatory T cells did not change. Moreover the 
allergen-specific IgE and IgA levels remained the same whereas the allergen-specific 
IgG levels increased 70. Another recent study by Grindebacke et al (2009) could show 
elevated IL-10 levels of SIT-treated patients as well as a stable expression of FoxP3 and 
CD25high Tregs compared to allergic controls throughout the study 71. Interestingly, both 
studies seem to favour suppression due to an increase of Tr1 cells and not due to a 
reduction or suppression of Th2 cells 70-72. The therapeutic approach favours an allergy 
vaccine that should epitomize protective Th1/regulatory T cell responses 69. 
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2.2  T Cells 
2.2.1 T Helper Cell Subsets 
T helper cells are a subgroup of lymphocytes that mature in the thymus and express 
special surface markers (e.g. CD3 and CD4). The subsets are distinguished by their 
specialized cytokine profile and protect the body from many types of pathogens 73. Th 
cells per se do not possess phagocytic or cytolytic activity but are crucial for activating 
and directing other immune cells, such as macrophages, mast cells, eosinophils, 
neutrophils, natural killer (NK) cells, and B cells 74. When naïve, CD4 positive (CD4+) 
T cells only produce IL-2 and they pass a transient, pre-activation state (Th0) to become 
either Th1, Th2, Th9, Th17 or T follicular helper (Tfh) cells, depending on the co-
stimulatory and cytokine signals they receive (Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4 T helper cell subsets 
Precursor T cells derive from hematopoietic stem cells in the bone marrow and have to pass various 
differentiation stages until maturing into functional T cells. Major Th-cell subsets include Th1, Th2, and 
Th17, and also recently discovered Th9 and Tfh cells. Regulatory T cells can either derive directly from 
the thymus (nTregs) or can be induced upon stimulation from Th cells (iTregs). 
Thymus 
Th0 
  activated Th 
Th17 
Th1 
Th2 Th9 Tfh 
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nTreg 
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2.2.1.1 Th1 Cells 
T helper 1 (Th1) cells are characterized by their production of IL-2, TNF-α, TNF-β 
and IFN-γ. They are involved in the cellular immune response and host defence fighting 
intracellular pathogens and viruses, as well as cancer cells. IFN-γ, for example, activates 
the lysosome activity in macrophages to destroy microorganisms. They express the 
transcription factors T-bet and STAT-4 and have been linked to many chronic auto-
inﬂammatory disorders, such as multiple sclerosis, diabetes, and rheumatoid arthritis 1.  
 
2.2.1.2 Th2 Cells 
T helper 2 (Th2) cells can be distinguished by their production of mainly IL-4, IL-5, 
IL-6, IL-10, and IL-13 1. They are involved in the humoral immune response and host 
defence fighting extracellular organisms by up-regulating antibody production. Th2 
cells with the transcription factors GATA-3 and STAT-6 are responsible for tolerance to 
xenografts or the foetus during pregnancy and play a role in allergic responses. IL-4 is 
responsible for antibody production and IL-5 on the other hand stimulates eosinophil 
response, both are directed toward extracellular parasites 1. 
 
2.2.1.2.1 Th1/Th2 Balance 
The Th1/Th2 paradigm is a oversimplification, insufficient to explain such a Gordian 
phenomenon, but will be explained here for completeness. The homeostasis between 
Th1 and Th2 cells, distinguished by their different cytokine production, was a model 
system for explaining immune regulation that arose in 1986 by the observation that T 
helper cells in mice express different cytokine patterns 75. This hypothesis was modified 
for humans with Th1- and Th2 cells 76, 77 and suggests that those cell types counter-
regulate each other.  
A homeostasis between Th1 and Th2 cells indicates a healthy immune system, 
whereas an excess of Th-specific cytokines leads to either an inflammation or allergic 
disease, respectively. 
However, in spite of all the research focussing on the Th1 or Th2 cytokines and on 
their potential to modify the immune response, many other dynamic factors influence 
the Th1 and Th2 cell maturation such as nature of the antigen, antigen dose, direct cell-
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to-cell interaction with APCs, and the cytokine receptors available on naïve cells (as 
reviewed in Kidd et al 78). 
 
2.2.1.3 Th17 Cells 
For almost two decades the Th1/Th2 model was used to explain immuno-regulation 
and the interaction between innate and adaptive immunity and for allergy this schema is 
still in use. However the fact that IL-17 is a product of activated CD4+ T cells has been 
known for over a decade. Only recently it was discovered with the unique 
characteristics of preferentially producing IL-17, therefore called Th17 cells 79, 80. This 
previously unknown branch of T helper cells - the Th17 lineage was defined in 2005 by 
Harrington et al 80. This additional cell subset mediates autoimmune diseases and is 
characterized by a production of IL-17A, IL-17F, IL-21, IL-22, and IL-26 80, 81. 
They are located in the skin and the gastrointestinal tract, as well as in the interface 
between the external and the internal environment to fight bacteria. They do this by 
recruiting e.g. neutrophils to get rid of the intruders by secreting inflammatory 
cytokines like IL-6, IL-8, IL-13, IL-23, GMCSF, CXCL5, and metalloproteinases.  
Nevertheless, inflammation is a “double-edged sword”. IL-17 is overproduced in 
autoimmune diseases like inflammatory bowel diseases, multiple sclerosis, rheumatoid 
arthritis, and psoriasis (reviewed in Chen et al 82). As a consequence, activation of these 
cells leads to the recruitment of granulocytes and maintenance of chronic tissue 
inflammation 83. Cytokines such as IL-1, IL-6, TGF-β and IL-23 lead to a Th17 
differentiation. The transcription factor retinoic acid receptor-related orphan receptor γ t 
(RORγt) regulates Th17 differentiation as shown in table 2. 
 
2.2.1.4 Th9 Cells 
Th9 cells, a distinct Th subpopulation, have first been described by Veldhoen et al 
(2008) only recently 84. Th9 cells can either differentiate from Th2 cells in the presence 
of TGF-β, a cytokine that is also crucial for differentiating Th17 cells, or directly from 
naïve CD4+ T cells together with IL-4 and TGF-β. Although the IL-9 production has 
always been ascribed to Th2 cells, recent publications suggest that the lately discovered 
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Th9 cells are the main source for this cytokine 84. These cells may be involved in 
asthma and tissue inflammation 85 and are known to fight extracellular parasites. The 
main transcription factors are early GATA-3 and STAT-6, identical to Th2 cells (Table 
2). Clear evidence for the existence of this lineage in humans remains lacking. 
 
2.2.1.5 Tfh Cells 
Follicular helper T (Tfh) cells are a recently (2009) discovered T cell subset that is 
characterized by providing help for B cell responses 86 and displays one of the most 
important subsets of effector T cells in the lymphoid tissue 87. They can be 
discriminated from other T helper subsets phenotypically by a high CXCR5 together 
with a low CCR7 expression that aid their homing to B cell follicles 86, 
location/migration as well as their function in helping B cells. The main transcription 
factor for Tfh cells is Bcl-6, known to inhibit GATA-3 and therefore Th2 cell 
differentiation 88. Tfh cells produce IL-21, which can stimulate B cell differentiation 
into Ab-forming cells through IL-21R 87 (Figure 4; Table 2). 
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Type 
Cytokine 
Stimulus 
Master 
Transcription 
Factor 
Effector 
Cytokines 
Effector Functions 
Pathological 
Effects 
Th1 IL-12 T-bet IFN-γ 
Immunity to 
intracellular 
pathogens 
Autoimmunity; 
cell-mediated 
allergies 
Th2 IL-4 GATA-3 IL-4 
Immunity to 
extracellular 
pathogens 
Asthma and IgE-
mediated allergies 
Th17 
TGF-β  
+ IL-6 
RORγ 
IL-17 
IL-22 
Immunity to 
extracellular bacterial 
and fungal infection 
Autoimmune 
diseases 
Treg - FoxP3 
TGF-β 
IL-10 
Regulation, 
Tolerance 
Cancer? 
Treg 
TGF-β 
- IL-6 
FoxP3 
TGF-β 
IL-10 
Regulation, 
Tolerance 
Cancer? 
Th9 
TGF-β 
IL-4 
GATA-3 
(early) 
IL-9 Immunity to parasites Unknown 
Tfh 
IL-21 
IL-6 
Bcl-6 IL-21 T cell help for B cells Unknown 
Table 2 Th1, Th2, Th17, Tregs, Th9, and Tfh: an overview modified after Kimball et 
al 89 
It can be presumed that current T helper subsets will be renamed after their cytokine 
profile or their function in the coming years. Additionally, new T helper subsets may be 
discovered as this field is focus of great scientific interest. 
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2.2.2 Recent Thymic Emigrants, a Subset of aïve T cells 
As T cells originate in the bone marrow, mature in the thymus - undergoing the 
positive and negative selection - and only then migrate to the periphery, the thymus is 
madatory for T cell development. Naïve T cells (Th0 cells) are already fully developed 
cells that have not yet encountered antigen in the periphery. These antigen-
inexperienced T cells express CD45RA, CD62L, CD27, CD28, and CCR7 but lack 
expression of CD45RO, CD11a, CD95, CXCR3, and CCR4 90, and activation markers 
such as CD25, CD69 and CD44. In this naïve state, T cells are characterized by 
quiescence and hypoproliferation as well as the crucial requirement for IL-7 together 
with self-peptide/MHC molecules for homeostatic survival 91. 
A subgroup of naïve T cells, recent thymic emigrants (RTE), are characterized by 
their high content of T cell receptor excision cycles (TRECs), which are stable DNA 
epitopes that are formed during TCR rearrangement. They do not replicate during 
mitosis 92 and so they dilute out after every cell division 93. Therefore the TREC content 
is a very good marker for RTE 94. Apart from the TREC content, CD31 (PECAM-1; 
platelet endothelial cell adhesion molecule) is an excellent marker for RTE to 
distinguish CD31+ thymicnaïve (RTE) and CD31– centralnaïve CD4+ T cells in the 
peripheral blood of healthy humans 95. In cord blood and neonates CD31+ thymicnaïve 
RTE dominate with a percentage of 90% to 95% of the CD4+CD45RA+ T cell pool 
whereas in adults the majority of the naïve T cell pool lacks CD31 expression (CD31– 
centralnaïve) 96. RTE decrease during ageing and this correlates with the decline in 
TRECs 97. Interestingly, the TREC amount decreases 50 to 100 fold 98 whereas the 
naïve T cell amount (CD45RA+) decreases only by a factor of 2 or 3 with age 99. This 
can be explained by a considerable expansion of naïve T cells in the periphery (Figure 
5) whereas the RTE dilute out during age. Furthermore, RTE may differentiate into 
centralnaïve CD4+ T cells upon contact with self-peptides and MHC. Both populations 
however, thymicnaïve and centralnaïve T cells, can differentiate to memory/effector 
CD45RO+ T cells upon antigen exposure 100. 
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Figure 5 aïve human CD4
+
 
T cells 
100 
T cells undergo selection and 
maturation in the thymus. RTEs 
emigrate directly from the thymus 
and express CD31 (thymic) and a 
high content of TRECs (TREChi). 
Upon contact with self-peptides and 
MHC thymicnaïve T cells proliferate 
and differentiate into central naïve T 
cells (central naïve T cells). They do not 
display CD31 on their surface and 
also lack TRECs (TREClo). 
centralNaïve CD4+ T cells originate 
from the RTE in a post-thymic selection and are crucial for the maintenance of the naïve CD4+ T cell 
pool. On foreign antigen exposure, both subsets can differentiate directly into memory/effector CD4+ T 
cells. 
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2.2.3 Regulatory T Cells 
Several mechanisms of immune tolerance have been 
postulated to protect self tissues. One mechanism for 
maintaining “self-tolerance” is eliminating self-reactive 
T cells during the negative selection in the thymus. The 
immune system itself has peripheral mechanisms to 
cope with cells that escape central tolerance and cells 
that police the immune system.  
In the early 1970s the concept of regulatory T cells 
was described first by Gershon et al 101. Then, maybe 
also due to insufficient technologies neither the cell type 
nor the soluble factors could be defined. Hence, despite 
important studies, extensive scepticism arose about the 
existence of these cells 102. The concept of suppressive 
T cells left centre stage of immunologic research for 
decades.  
25 years later, in 1995 Sakaguchi et al were first to 
find and characterize a subpopulation of CD4+ T cells 
with regulatory function in a mouse model 103. The elimination of the suppressor cells, 
then newly named regulatory T cells (Tregs), led to autoimmune diseases, like 
autoimmune gastritis or thyroiditis. Co-transfer of those newly discovered regulatory T 
cells prevented the disease 103. Three years later Thornton et al (1998) could further 
demonstrate that the suppressive activity of CD4+CD25+ T cells persists in in vitro 
testing 104. Eventually Jonuleit and Enk (2001) could isolate a regulatory CD4+ T cells 
from peripheral blood 105 and characterize them as CD4+ T cells expressing CD25 (the 
IL-2 receptor (IL-2R) α-chain), CD45RO and the cytotoxic T-lymphocyte-associated 
molecule-4 (CTLA-4). 
Since then, research in the field of regulatory T cells exploded. Ever since 
researchers found out that Tregs play an important role in the pathogenesis of cancer 106-
108, autoimmune disease 106, 109, transplantation immunology 110, pathogenesis of 
atherosclerosis 111, allergy and asthma 112, and immune tolerance in pregnancy 108, 113. 
 
The terminology positive (+), 
negative (-), high (high), 
intermediate (int) and low (low) 
comes from the field of 
fluorescence activated cell sorting 
(FACS). It characterizes the 
expression of the protein, either on 
the surface or intracellularly. 
CD25+ e.g. means that all cells 
express CD25 on their surface, 
whereas CD25- indicates that those 
cells lack CD25. CD25+ again can 
be subclassified for their CD25 
expression in CD25high, CD25int 
and CD25low. However the 
distinction between high, 
intermediate and low is not strictly 
objective but depends on the 
researcher’s judgement and can 
vary slightly. 
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The mechanism and the potential clinical application of regulatory T cells in the 
treatment of many diseases are widely but also controversially discussed as an overload 
of Tregs may support the survival of cancer cells as well 114. 
CD4+CD25+ Treg cells are typified by hypoproliferation, little IL-2 but no IL-4 
production. In specific, Tregs stand out by their suppressive capacity. They are able to 
suppress T cell proliferation, and cytokine production. In addition they are capable of 
suppressing the function of B cells 115, natural killer T (NKT) cells 116, natural killer 
(NK) cells 117, and dendritic cells (DCs) 118. After Treg removal, proliferation of 
peripheral blood mononuclear cells (PBMCs) from healthy individuals to various 
stimuli is enhanced 119, 120.  
Besides CD25, several other surface markers are known to be expressed on 
regulatory T cells (intracellular CTLA-4high, surface CTLA-4low, HLA-DRhigh, GITR+, 
CD27+, CD28+, CD38+, CD39+, CD45RBlow, CD45RAlow, CD45ROhigh, CD5+, 
CD62Lhigh, CD73+, LAG3, CD122high, CD127low, BUNny, CD103+, CD130-, OX40high, 
LFA-3int, CCR4+, CCR7+, CCR8+, TNFR2+).  
Recently, GARP (LRRC32) 121 and latency-associated peptide (LAP) 122 have been 
implicated to be preferentially expressed in Tregs activated through the TCR. GARP 
expression on the surface was postulated to mediate suppressive activity and to result in 
a Treg phenotype of increased FoxP3, CD25 and CD62L expression, a decreased IFN-γ 
and IL-2 production as well as an impaired proliferative capacity 123-125. On the other 
hand, silencing GARP in Tregs could diminish their suppressive activity 123. Moreover, 
GARP was highly expressed in the placenta 126 which could be crucial for a “tolerant” 
environment and protect the fetus against rejection.  
LAP, the latency-associated peptide, was identified to be an excellent marker to 
identify the TGF-β producing CD4+CD25+ regulatory T cells 127. These cells secrete 
TGF-β, and express surface TGF-β as well as surface receptors for TGF-β. Moreover, 
LAP+ Tregs possess elevated FoxP3 levels and Treg-associated molecules (e.g. CTLA-4 
and glucocorticoid-induced tumour necrosis factor receptor (GITR)-related gene). Most 
importantly, cells that express LAP show an increased suppressive function via a cell 
contact and soluble factor dependent mechanism 127. 
Runx (runt-related transcription factor) factors are expressed on hematopoietic stem 
cells and three different types (RUNX 1 - RUNX 3) are known to date. They are crucial 
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for hematopoiesis 128 and the differentiation and function of peripheral T cells 129 as well 
as thymic T cell development 130. Runx proteins only possess transcriptional activity 
when forming heterodimers with CBFβ 131 which stabilizes the Runx-DNA interaction 
and prevents degradation 132. RUNX 1 (AML1, CBFα2 or PEBP2αB) and RUNX 3 
(AML2, CBFα3 or PEBP2αC) are crucial in repressing CD4 expression 133. An over 
expression of RUNX 1 in mature CD4+ T cells promotes a differentiation into Th1 cells, 
whereas a differentiation into Th2 cells is inhibited by GATA-3 expression 134. The 
transcription factors T-bet together with RUNX 3 activate IFN-γ and silence IL-4 in 
Th1 cells 135.  
Very recently, RUNX 1 and RUNX 3 have been postulated to play a vital role for 
regulatory T cells. The transcription factors Runx and CBFβ are required for 
maintenance of FoxP3 mRNA and protein expression in Treg cells 132. 
It has been shown that RUNX 1 can bind to the IL-2 and IFN-γ promoters and 
therefore up-regulate IL-2 and IFN-γ production, respectively. When FoxP3 binds to 
RUNX 1 however, IL-2 und IFN-γ production is repressed and on the other hand genes 
encoding CD25 and CTLA-4 are activated 136. Knockdown of RUNX 1 and RUNX 3 
(with siRNA) leads to a decreased FoxP3 expression indicating that those proteins are 
indispensable for in vivo regulatory T cell function (suppressive activity and optimal 
expression of FoxP3) 132, 137, 138. Moreover, RUNX 3 was found in direct proximity in 
human tonsil regulatory T cells, making RUNX 1 and RUNX 3 crucial molecules for 
Treg function 138. 
Literature Review 
24 
 
IPEX 
IPEX, a fatal, recessive disorder 
characterized by immune dysregulation, 
polyendocrinopathy, enteropathy and X-
linked inheritance and a mutation in 
FOXP3. It is characterized by insulin-
dependent diabetes mellitus (IDDM), 
infections, enteropathy, thrombocytopenia 
and anemia, other endocrinopathy, eczema 
and cachexia 2. 
 
WAS 
The Wiskott-Aldrich syndrome is a 
lifethreatening immunodefficiency caused 
by mutation in the WAS protein. It is 
characterized by thrombocytopenia with 
small platelets, eczema, recurrent 
infections caused by immunodefficiency 
and increased incidence of autoimmune 
manifestations and malignacies. 
 
APS type 2 
The autoimmune polyglandular syndrome 
type 1 is caused by the loss of central 
tolerance due to mutations in autoimmune 
regulator (AIRE), whereas APS type 2 
apart from an association with 
polymorphisms in CTLA-4 and an HLA-
extended haplotype is of unknown 
pathogenesis. It is characterized by 
multiple endocrine diseases initiated by an 
autoimmune process. 
 
ALPS 
The Autoimmune lymphoproliferative 
syndrome is associated with diffuse 
autoimmune manifestations. 
ALPS type Ia patients have mutations in 
TNFRSF6, which encodes CD95; ALPS 
type Ib patients have mutations in 
TNFSF6, which encodes CD95 ligand; 
ALPS type II patients have mutations in 
CASP10, which encodes caspase-10. 
 
However, none of these markers seem to be 
exclusively expressed on regulatory T cells. Eight 
years after Sakaguchi et al (1995) 103 had 
discovered the regulatory T cells, the gene 
forkhead box P3 (foxp3, Scurfin), that codes for a 
transcription factor, gained increased interest as it 
is specifically expressed in CD4+CD25+ 
regulatory T cells 139. Studies could demonstrate 
that T cells from Foxp3 transgenic mice and naïve 
T cells that were transfected with foxp3 acquired 
CD4+CD25+ regulatory T cell features, like 
expression of Treg markers (CD25, CTLA-4, 
CD103, and GITR), decreased IL-2, IFN-γ and 
IL-4 production and suppression of effector CD4+ 
cells 139. In mice there is an exemplary correlation 
between the Foxp3 and CD25 expression. In 
humans, the situation is considerably more 
complex. Almost all CD4+CD25hi cells are 
FoxP3+, although there is a variable percentage of 
CD25int cells that express considerable, but lower, 
amounts of FoxP3. Unfortunately, FoxP3 
expression is not exclusively specific to Tregs 140 
nevertheless it is currently the best Treg marker 
we have 141. 
Next to FoxP3 the Treg specific demethylated 
region (TSDR) can give higher information about 
a transient or “real” FoxP3 expression. Although 
FoxP3 is the best marker we have, CD25- T cells 
may transiently express FoxP3 upon activation. 
Using epigenetic analysis the transient FoxP3 
expression can be ruled out. Within the analysis a 
defined FOXP3 region is checked for 
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demethylation 142. “Real” Tregs possess a demethylated FOXP3 locus whereas the 
transient expressed FoxP3 cells have this region methylated. 
Isolation and identification of Tregs therefore is problematic. As FoxP3 only appears 
intracellularily it cannot be used for isolation with the common sorting techniques. 
CD25 expression (5-10% of CD4+ cells) is widely used for regulatory T cell isolation 
105, 143. Only cells with the highest levels of CD25 expression (~2% of CD4+ cells) are 
postulated to carry suppressive effects 144 as CD25 is also expressed on activated T 
cells. Moreover almost all CD25highFoxP3+ cells express low levels of the IL-7 receptor 
(CD127). However CD127 is down regulated in the early course of T cell activation. 
Only 40% of the CD127low population are FoxP3+ and even the CD4+CD25+CD127low 
cells are only 85-90% FoxP3+ 145. From the recent point of view, expression of CD127-
/low in combination with CD25high, allows the most reliable sorting to gain regulatory T 
cells (CD4+CD25+CD127high) and to discriminate them from effector cells ex and in vivo 
141.  
Some groups 139, 146 have demonstrated that mice that miss or have mutations in the 
foxp3 gene (scurfy mice) suffer from a systemic autoimmune disease associated with the 
absence of Tregs, emphasizing that Foxp3 is a master switch gene for Tregs 147. This 
species of mouse is characterized by the scurfiness of its skin from which the name is 
derived. The defect results in death of affected males at about 3-4 weeks of age 148. In 
humans mutations in FoxP3 cause an immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked (IPEX) syndrome 149. Loss of FoxP3 expression leads to immune 
disorders and a reduction of regulatory T cells.  
Wiskott-Aldrich syndrome (WAS) 150 and autoimmune polyglandular syndrome type 
2 (APS type 2) 151 are further examples for autoimmune diseases that are caused by 
genetic defects and also affect the Treg suppressive function 152. Another genetic defect, 
autoimmune lymphoproliferative syndrome (ALPS) 153, is characterized by a T cell 
expansion together with a decline in the number of Tregs. Although the underlying 
mechanisms still remain unclear, hope lies in the prospect that one day these genetic 
diseases could be treated with regulatory T cells. 
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2.2.3.1 Natural Regulatory T Cells 
Natural regulatory T cells originate in the thymus and are CD4+ T cells that express 
CD25 and FoxP3 154. Tolerance towards “self” is “educated” in exactly this period and 
is an alternative mechanism to elimination of autoreactive T cells in the thymus. For 
Treg development a T cell receptor (TCR) with high affinity for a self peptide is a 
precondition 155. Because of the necessity for high affinity it can be assured that only a 
minimal percentage becomes regulatory. The remaining cells however are very sensitive 
for special antigens.  
Natural Tregs are not only committed to self-tolerance but also of immune responses 
to non-self (such as pathogenic or communal microbes 156 or allogenic organ transplants 
157 or quasi-self (such as autologuous tumour cells 158). Another important role of 
natural Tregs is to create and maintain tolerance toward the foetus expressing 
alloantigens during pregnancy, thereby preventing abortion 113. 
 
2.2.3.2 Inducible Regulatory T Cells 
Although Tregs are relatively short-lived they are present throughout life at a steady 
state 159. As thymic function declines with age and the number of Tregs stays constant it 
is unlikely that all CD4+CD25+FoxP3+ Tregs are generated in the thymus alone but are 
also induced in the periphery 159 (Figure 6). They derive in the periphery from the 
memory T cell pool or from naïve T cells that are CD4+CD25- by following adequate 
stimulation, especially in a particular cytokine milieu, e.g. TGF-β, IL-10 and IL-4 160.  
Once differentiated, iTregs, like nTregs, express CD25 and FoxP3. In humans, 
FoxP3 can be induced in CD4+CD25-FoxP3- cells by T cell receptor (TCR) stimulation 
together with TGF-β 161. In mice, Foxp3 does not seem to be induced under the same 
stimulation conditions. The discrimination of nTregs and iTregs, is not always easy 162 
(Table 3). 
Yamagiva et al (2001) were the first to demonstrate that naïve human CD4+ T cells 
can be induced by TGF-β to develop contact-dependent suppressor activity that is 
mediated by TGF-β or IL-10 163. 
T regulatory 1 (Tr1) cells differentiate from T cells together with IL-10 and 
antigens or when immature DCs present their antigens to T cells. They were first 
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characterized for their role in preventing autoimmune colitis 164. IL-10 is their marker 
cytokine, although they produce TGF-β and IFN-γ as well 162, 165. It is presumed that 
Tr1 cells are derived in vivo from antigen-specific anerg T cells. The repeated 
exposition to a specific antigen is crucial for this process. They express CD132 rather 
than CD25 and also may be FoxP3low 166. 
Th3 cells were first identified because of their role in oral tolerance due to their 
TGF-β production 167. There is a recent report that suggests that children who develop 
egg allergy in the early years of life have reduced Treg function in cord blood 168.  
 
 
 
 
Figure 6 Model for nTreg and 
iTreg induction 
Natural Tregs directly migrate from the 
thymus. Th3 and Tr1 as well as CD8+ 
induced regulatory T cells can be induced 
from naïve CD4+CD25- or CD8+CD25-, 
respectively, in the periphery. 156, 169 
 
 
 
 
2.2.3.3 Oral Tolerance and Tregs 
Oral tolerance is defined as “specific suppression of cellular and/or humoral immune 
responses to an antigen by prior administration of the antigen by the oral route” 170. 
Therefore the effects are not restricted to the local immunity within the gut 171. Low 
antigen doses favour active suppression, whereas higher doses favour clonal anergy 171. 
Oral tolerance effector mechanisms do not only include apoptosis or anergy of antigen-
specific T cells in the gut but additionally active suppression of antigen-specific Tregs 
172. Long-lasting oral tolerance can be explained by memory cells with antigen-specific 
regulatory functions 173. 
Already 24-48 h after oral antigen administration, antigen-specific Tregs could be 
observed in the Payer’s patches, and mesenteric lymph nodes 174, suggesting that the 
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APCs that cause the tolerogenic response primarily exist in the draining lymphoid 
organs as well as the gut associated lymphoid tissue (GALT). The question remains 
whether the T cells that originate in the gut are solely responsible for the immune 
regulation or whether tolerogens and/or DCs enter the lymph node isolated and generate 
Tregs in situ 170. 
On the current level of knowledge, various regulatory T cells are involved in 
tolerance induction like Tr1, Th3, nTregs, and CD4+LAP+ T cells 171. TGF-β, mainly 
produced by Th3 cells, plays a central role in oral tolerance induction and was first 
described by Faria et al 175. Tr1 cells by secreting IL-10 also enhance the TGF-β 
production by Th3 cells. A compelling connection has been reported between TGF-β 
and FoxP3, that TGF-β induces FoxP3 expression in effector T cells (CD4+CD25+) to 
become inhibitory functional 176. On the other hand FoxP3 can also down regulate 
Smad7 expression which in return blocks TGF-β signalling thus making T cells 177. 
Moreover TGF-β also plays a role in differentiation of Th1 and Th2 cells as it blocks 
the subtype specific transcription factors T-bet and GATA-3 178. CD4+LAP+ T cells 
suppress cells in a TGF-β-dependent manner and possess a membrane-bound form of 
TGF-β 179. They resemble Th3 cells due to their cytokine secretion profile, except that 
they also produce mentionable amounts of IFN-γ 180. 
 
2.2.3.4 Additional Regulatory Populations 
A subgroup of regulatory T cells, only mentioned for completeness, are certain γ/δ 
TCR-expressing CD4-CD8- T cells and CD8+CD28- T cells. Even a subgroup of NK 
cells were found to possess regulatory properties as they could suppress autoimmunity 
181. Very recently B cells with regulatory function (Bregs) have been identified that are 
able to supress in an IL-10 dependent manner 182. Further subtypes may be discovered 
in the future.  
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Cell 
Type 
Treg 
subset 
Regulatory 
mechanisms 
Phenotype 
Target 
cells 
Function 
CD4
+
 
Tregs 
nTregs  
(thymic-
derived) 
Cell-cell 
contact-
dependent, 
cytokines 
CD4+CD25+ 
FoxP3+ 
T cells, 
APCs 
Suppression of 
autoimmunity; inhibition of 
allograft rejection and 
immune responses induced 
by microbial infection; 
mediation of UV-induced 
immunosuppression 
nTregs 
(peripheral-
induced) 
CD4+CD25+ 
FoxP3+ 
CD4+CD25- 
Tregs 
cytokines 
CD4+CD25- 
FoxP3+ 
T/B cells, 
APCs 
Suppression of 
autoimmunity 
Tr1 cells IL-10 
CD4+CD25-/+ 
FoxP3-IL-10hi 
T cells 
Suppression of 
autoimmunity 
Th3 cells TGF-β 
CD4+CD25-/+ 
FoxP3+TGF-
βhi 
T cells 
Suppression of 
autoimmunity 
TGF-β IL-
10 double 
positive 
  
TGF-β+IL-10+ 
CD4+CD25- 
FoxP3- 
T cells 
Suppression of 
autoimmunity 
K 
Tregs 
NKTregs 
IL-4, IL-10, 
TGF-β, 
cytotoxicity 
CD3-CD56bright 
T cells, 
APCs, 
tumour 
cells 
Elimination of tumours and 
pathogens; suppression of 
autoimmunity; mediation of 
UV-induced suppression of 
protective tumour immunity 
CD8
+
 
Tregs 
IL-10 
producing 
CD8 T cells 
Cell contact-
dependent, 
cytotoxicity, 
cytokines 
CD8+IL10+ T cells 
Suppression of 
autoimmunity; regulation of 
peripheral TCR repertoire 
T 
suppressor 
cells 
Induction of 
ILT3/ILT4 in 
DCs 
CD8+CD28- 
DCs/ 
APCs 
Regulation of autoimmunity 
Table 3 atural and induced regulatory T cells 
183
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2.2.3.5 Mechanisms of Suppression 
CD4+CD25+FoxP3+ natural regulatory T cells are able to inhibit different cell types 
and cytokine production as explained in the chapter “natural Tregs 1.2.3.1”. The mode 
of suppression of Tregs, however, is not completely understood. In vitro experiments 
indicate that cell-cell contact dependent mechanisms are crucial for suppression of 
conventional T cells. Low amounts of antigen are required for Tregs due to the high T 
cell receptor affinity. After the initial antigen dependent activation Tregs seem to be 
stimulation-independent in their mechanism and are capable of suppression even in the 
absence of the appropriate antigen 184. Conventional T cells with different antigen-
specificities can be suppressed in vicinity to the Tregs. This mechanism is known as 
“bystander suppression”. 
One way of suppression is the interaction between the CTLA-4 or the lymphocyte-
activation gene 3 (LAG3; CD223) with CD80 and CD86 on the surface of APCs which 
inhibits T cell activation 185. CTLA-4 induces the tryptophan-catabolic enzyme 
indoleamine 2,3-dioxygenase (IDO) in DCs 186. The enzyme IDO catalyzes the essential 
amino acid tryptophan into kynurenine, which has immunosuppressive effects (Figure 
7).  
Tregs can kill target cells cell-cell contact dependent via different pathways 187. For 
instance, Tregs use the same pathway (granzyme/perforin) to induce cell contact-
mediated suppression as cytotoxic T lymphocytes and natural killer cells for killing 
virally infected cells and tumour cells. The release of perforin, granzyme A and B can 
kill T cells and monocytes through a cell contact-mediated mechanism 188. Another 
pathway for suppressing alloreactive responses of CD4+CD25- T cells is the 
programmed death (PD)-1/PD-1 ligand (PD-L1) pathway. A blockade of this pathway 
restores the CD4+CD25- T cell proliferation by inhibiting the Treg function 187. IL-2 is 
of great importance for Tregs as the addition of IL-2 abolishes Treg anergy but the 
suppressive function maintains. Neutralization of IL-2 on the other side abolishes 
suppression 189.  
IL-2 is important for all Tregs but in contrast to nTregs, Tr1 and Th3 cells suppress 
in an independent cell-cell-contact manner and through the secretion of 
immunosuppressive cytokines IL-10 and TGF-β, respectively 190.  
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Recent studies imply a suppressive function of adenosine produced by Tregs 191. 
Adenosine is a signaling molecule that binds to various adenosine receptors (A1, A2a, 
A2b and A3). Ligation of adenosin to the receptors triggers immunoinhibitory potential 
through cytoplasmic cAMP 192 as well as inhibiting proliferation and cytokine 
production 193. Tissue derived adenosine did not only play a role in regulating T cell 
function but also in the adenosinergic pathway to the functional activity of human 
Tregs. Expression of CD39 and CD73 together with low levels of CD26 and adenosine 
deaminase (ADA) are characteristic markers for Tregs. One factor responsible for 
suppressive activity in Tregs can be explained by the ability of Tregs to hydrolyze ATP 
and therefore generate high pericellular concentrations of adenosine 194. 
Nevertheless, not all aspects of suppression can be explained with the known 
mechanisms. Most probably it is a combination of miscellaneous mechanisms 
depending on the environment and also the cells present. There is a great chance 
however that still unknown key mechanisms will soon be discovered 195. 
 
 
 
Figure 7 Various 
mechanisms of suppression 
196
 
Various suppressive mechanisms of 
Treg are known by now like weak 
stimulation with CTLA-4 and 
LAG3 interaction with the co-
stimulatory molecules on APCs (a), 
immunosuppressive IL-10 and 
TGF-β secretion (b), tryptophan 
catabolism induction with CTLA-4 
(c), cytotoxicity (d) and maybe an 
unknown key mechanism 195. 
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2.2.3.6 Regulatory T Cells in Pregnancy 
Regulatory T cells are a necessary component of maternal immune tolerance of 
paternal alloantigens present on the trophoblast. The type of antigen that is recognized 
by Tregs in pregnancy however is not known.  
They might recognize maternal self antigens on semi-allogenic trophoblasts and then 
suppress alloreactive effector cells by "bystander suppression". CD4+CD25highFoxP3+ 
Tregs could suppress effector T cells to allogenic dendritic cells 197 whereas the 
possibility of direct alloantigen recognition by Tregs could not be excluded 198. This 
observation could be confirmed by transferring CD4+CD25+ Tregs into abortion-prone 
mice. Abortion could only be prevented when Tregs directly originate from normal 
pregnant mice indicating that Tregs previously need to be exposed to paternal 
alloantigens to exert regulatory activity 113. Anti-CD25 antibody addition to pregnant 
mice before mating resulted in depletion of Tregs and foetus rejection 198, 199 
The proportion of CD4+CD25+ Tregs significantly increased in the spleen in 
pregnant mice uterine-draining lymph nodes and peripheral blood, starting from the 
early post-implantation period. During early pregnancy an increase in circulating Tregs 
was observed. The highest level however was monitored in the second trimester and 
then the level declines post partum. CD4+CD25high Tregs were increased in peripheral 
blood of women having a normal pregnancy compared to women with spontaneous 
abortion and non-pregnant subjects 200. 
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2.3 Antigen-Presenting Cells 
As their name implies, antigen-presenting cells (APCs) process and present antigen 
material on their cell surface for T helper cells. During the last years, APCs, DCs in 
specific, have gained interest because they play a key role in immunobiology of 
tolerance and autoimmunity as well as anti-cancer responses with a possible use in 
tumour vaccines. They play a pivotal role in CD4+ and CD8+ T cell activation 201. 
Antigens that are re-expressed on the cell surface interact with Th cells which have 
profound immune-regulatory effects, after they have been activated 202. Functionally 
DCs are the most potent APCs and are essential for the induction of the first immune 
response and initiating the T cell immunity 203. They migrate to secondary lymphoid 
compartments (e.g. lymph nodes (LNs)) to present antigen-peptide-complexes to naïve 
CD4+ T cells and CD8+ cytotoxic T cells. Subsequently, naïve CD4+ T cells 
differentiate into memory Th cells (reviewed in Satthaporn et al (2001) 204).  
Various subtypes of DCs differ in their surface markers (e.g. expression of CD11c 
integrin). Depending on the DC subpopulation, different cytokines skew T cells into a 
Th1 or a Th2 immune response 105. Jonuleit et al (2000) demonstrated that repetitive 
stimulation from naïve CD4+ T cells with allogous, immature DCs induce Tregs 205.  
Immature APCs are the predominant DCs especially in the neonatal period. 
Immature and defective APCs have reduced co-stimulatory and a pro-Th1 cytokine 
signals 206. Infants that have a prolonged functional immaturity in APC function are 
more prone to develop a Th2-mediated allergic disease 207. IL-12 produced by APCs 
provides activating signals for neonatal cells. A weaker pro-Th1 signal also favours a 
Th2 response 208. The findings of Langrish (2002) 209 concur with other studies, which 
have shown that cord blood derived DCs have decreased functional activity as well as a 
different and decreased phenotypic expression of surface markers 210. Moreover, not 
only T cell proliferation (both adult and cord blood) is less effective in the presence of 
cord blood derived DCs 210 but they also fail to direct a Th1 polarization 209. Thus, 
APCs have an important role in postnatal development of immune competence, 
particularly in maturation of Th1 responses. 
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2.4 Cord Blood  
2.4.1 Cord Blood and Allergy 
Some evidence exists that T helper cells from neonates are primed in utero. First, 
allergen-specific IgE was found in cord blood and amniotic fluid, so it is either 
transferred through the foetal membranes from the maternal circulation or it is produced 
by the foetus itself 211. Second, many studies have demonstrated that T cell proliferate 
and produce cytokines upon stimulation with allergens 212-220 suggesting that the cells 
already had contact with the stimulus. CBMCs exerted a generally higher proliferation 
against birch pollen when mothers were exposed to this allergen at a certain period of 
gestation 221. No effect of seasonal exposure to pollens on proliferation on CBMCs 
could be shown however in a larger observation group 222. 
Based on the fact that neonatal PBMCs proliferated upon stimulation with allergens, 
in utero sensitization was taken for granted. It was assumed that this proliferative 
response reflected immunological memory induced by intrauterine exposure to dietary 
or environmental allergens via diaplacental transfer. However, CBMCs also proliferate 
in the presence of the keyhole limpet antigen, to which natural in utero exposure is 
extremely unlikely.Therefore lymphoproliferation in cord blood may be more unspecific 
than originally suggested 223. 
The foetus’ immune system is strongly skewed towards Th2 cytokines, especially 
when the mother is atopic 224. Because of that allergen priming in utero was thought to 
be a key factor for predisposition to allergy. Our group showed that allergens can dia-
placentally cross the maternal-foetal barrier. Beta-lactoglobulin for example could even 
be detected within the first minutes of perfusion in the cotyledon 222. Transplacental 
allergen transfer is coupled with the actively transmitted immunoglobulin G (IgG) 225 
and children with asthma displayed higher IgG4 levels than the asthmatic adults 226. 
Another hypothesis states that the foetus gets in contact with the allergens via the 
amniotic fluid because ovalbumin and the major allergen of house dust mite, Der p 1 
(Dermatophagoides pteronyssinus) have been found in amniotic fluid 227. 
In the 80’s elevated IgE-levels in cord blood were thought to be a marker for atopic 
disease 228. However, intensive research demonstrated that the IgE-level alone was not 
Literature Review 
35 
 
sensitive enough for an allergy prediction. A study by Magnusson et al (1988), for 
example, screened 190 newborns and found a specificity of 93% - the sensitivity 
however only reached 68.4% 229. A recent, Danish study found matching allergen-
specific IgE against inhalant allergens in 14% of the screened cord blood samples. The 
allergen-specific IgE disappeared at the age of 6 months indicating that the specific IgE 
was either related to contamination by the mothers’ blood or was transferred from the 
mother to the foetus and not produced from the foetus due to intrauterine sensitization 
230.  
Supernatants of stimulated CBMCs mainly contain Th2 cytokines 214 therefore many 
researchers focused on cytokine production as a predictive marker for allergy. Some 
groups concluded that a decreased cytokine production (especially IFN-γ) at birth leads 
to an atopic illness later on 213, 219, other research groups could not find that connection 
231. Taken together, no reliable and safe marker in newborns exists for predicting 
allergic diseases.  
 
Literature Review 
36 
 
2.4.2 Differences between CBMCs and PBMCs  
The foetal and the adult immune systems differ in phenotypic and functional 
characteristics 232, 233. Cord blood can be distinguished from peripheral blood due to 
different response to allergens, a lower cytokine production, a diminished cytotoxicity 
and due to differential surface markers 234. Umbilical cord blood T cells are mainly 
naïve antigen-inexperienced cells, and greater than 90% of CD3+ T cells express a 
CD45RA+ naïve-phenotype. Adult CD4+ T cells have a predominantly CD45RO+ 
memory-phenotype 235. Cord blood derived T cells differ from naïve cells in adult 
blood. They do not produce IL-2 upon stimulation whereas the PB derived naïve T cells 
do 236. Thus the cord blood derived CD4+CD45RA+ subset may be more naïve than the 
adult cells. However other studies ascribed this effect to the numerous immature 
dendritic cells in cord blood as they can induce T cell tolerance 237. The immature DCs 
may capture antigens but are said to be unable to process and present them to T cells 
and therefore induce T cell anergy as well as Tregs 238.  
Cord blood and thymic derived naïve T cells (CD4+CD45RA+) express a number of 
characteristics that distinguish them from naïve T cells that are present later in life. 
They have more similarities to RTEs 239. Neonatal T cells in general also express CD38 
240, the IL-7Rα which makes them highly responsive to IL-7 and harbour a high 
expression level of TRECs. The TREC content indicates that those cells are more akin 
to RTEs than to the naïve T cells from adult individuals 241. In adults, CD38 is not 
expressed by all CD4+ T cells and is mainly expressed by CD45RO− T cells 242. 
Interestingly, it was shown that even upon removal of the low numbers of memory 
cells from cord blood still 50% of the donors were responsive to the allergen 212. 
PBMCs from the mother secrete a significantly stronger Th1 response (higher IL-12 
levels) than neonatal PBMCs. There was a positive correlation when maternal and 
infants were matched for house dust mite (HDM) and a negative correlation when 
matched for neonatal Th2 response (IL-13) 208. Prescott et al (2003) indicated that the 
changed allergen-specific cytokine responses may be associated with differences in the 
function of the APCs in early life and later allergy 208. 
In general one can say that the cytokine profile of cord blood T cells is skewed 
towards a Th2 phenotype: higher IL-4, IL-5 and IL-13 levels which are involved in the 
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induction of the IgE synthesis together with reduced IFN-γ levels compared to adult T 
cells. A reduced IFN-γ level appears to be associated with the subsequent development 
of atopic eczema 243, allergic rhinitis, or asthma 219. This cytokine pattern may play an 
important role in allergy development. Evidence is increasing that the aberrant cytokine 
responses of CBMCs rather relate to different regulatory properties and immaturity of 
the APC 244. 
In cord blood, the frequency of CD4+CD25high regulatory T cells is higher at 
gestational week 25 (12% of CD4+ T cells) than at birth. At birth the same frequency as 
in adult donors was measured 245. Naïve Tregs represent 0.2 – 0.8% of total CD4 cells, 
whereas in cord blood the majority of Tregs belong to the naïve apoptosis-resistant 
population 246. Naïve natural Tregs are more prominent in young adults and decrease 
with age together with the total naïve CD4+ population. In cord blood 7% and in adult 
blood 0.2-.3.3% of total CD4+ T cells display this naïve Treg phenotype 247. This may 
be an explanation why cord blood derived Tregs have a reduced regulatory function 248-
250. Cord blood derived regulatory T cells (CD4+CD25high) do no control allergen-
specific proliferative responses in CB per se as is the case in adult blood cells. However, 
cord blood derived Tregs can become functional when pre-activated with different 
stimuli 122, 251. Furthermore, the Th17 function in cord blood was impaired as well 252. 
Taken this together, it is suggsted that potent immune stimulation early in life may 
counteract an allergic disease. 
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2.4.3 The Perinatal Period 
The perinatal period delineates the period around the time of birth. “This period 
commences at 22 completed weeks (154 days) of gestation and ends seven completed 
days after birth” 253. T cells as well as the cytokine profile play a decisive role in the 
perinatal immunity. 
 
2.4.3.1 The Prenatal Period 
The development of the immune system, especially in the prenatal period, has far-
reaching consequences not only for health during early childhood but also throughout 
life 254. 
Pregnancy is an immense alteration for the maternal and innate immune system. 
Nevertheless, the maternal immune system tolerates the foetal tissue during normal 
pregnancy. As 50% of its genetic material derives from its father, Medawar et al (1953) 
were first to propose that the growing foetus should be viewed as an allotransplant 255. 
The foetus’ susceptibility to rejection by the maternal immune system is very high and 
similar to transplanted organs. An appropriate regulation is essential for the foetal 
survival. The maternal immune system tolerates the fetus whereas it still can fight 
adequately against infections. This “paradox of pregnancy" is a ambiguous topic in 
immunology as a skewing towards Th2 cytokines helps the survival of the foetus from 
the critical time point of implantation onwards 256 and reduce the risk for 
preeclampsia257. Pregnant women produce augmented Th2-cytokine and diminished 
Th1-cytokine levels 256, 258. This mechanism is reasonable, because cytotoxic Th1 
immune responses (e.g. IFN-γ)  would activate natural killer-cells (NK-cells) which 
would be disadvantageous for maintenance of pregnancy. In animal models IL-2 and 
IFN-γ doses can induce elevated abortion levels. There is also evidence in humans as 
well that high concentrations of Th1-cytokines (TNF-α/β, INF-γ and IL-2 levels) can 
induce labour. Although studies reject the Th2-paradigm as the major mechanism 
providing foetal allograft survival, women with higher Th1 levels are found to have 
more abortions 259. It is considered that only CD4+ T cells are responsible for this 
cytokine production in pregnancy. Nevertheless, also CD8+ cytotoxic T cells, NK cells 
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and NKT cells 260, 261 are responsible for this cytokine shift. Borzychowski et al (2005) 
could demonstrate that the Th2 shift during pregnancy could be better explained by NK 
CD56+CD3- and CD56+CD3+ cells instead of T helper cells or cytotoxic T cells 262. 
They announced that the innate immune system, involving NK and NKT cells, is the 
predominant cell population of the peripheral blood in pregnancy, which stands in 
controversy to Wegemann’s first hypothesis, who was an advocate of the theory that 
Th2 cytokines inhibit the Th1 response 262. Shi et al (2007) manifested these findings 
showing that the percentages of NK cells and NKT cells were increased in peripheral 
blood and IFN-γ expression was suppressed for women during early pregnancy 263. On 
the other hand no difference of IL-4 expression was seen in NK and NKT cells between 
non-pregnant and pregnant women. Matching other data, no difference of IL-4 and IFN-
γ cytokines was detected between pregnant and non-pregnant women in T helper 
lymphocytes.  
Apparently, the initial Th2 (IL-4, IL-5, IL-6, IL-10, and IL-13) cytokine-shift of 
neonates reforms within the first 2 years of life, as long as no atopy has evolved. These 
Th1 dampening effects may be amplified by the placenta, through synthesis of high 
levels of prostaglandin E2 264, which selectively inhibits INF-γ and local progesterone as 
well as stimulating IL-4 production 258. Based on both murine and human studies there 
were several mechanisms proposed to contribute to that tolerance: First of all Rouas-
Freiss et al (1997) could show that HLA-G protects cytotrophoblasts against natural 
killer (NK) cytolysis 265. As HLA-G expression is limited to the gestational period, the 
hypothesis arose that this played an essential role in the immunological tolerance of the 
foetus by the mother 266. So far, several mechanisms have been proposed for tolerating 
the foetus by the mother. One known mechanism is that the maternal uterine NK cells 
protect the foetus by lytic activity. Second, heme oxygenase (HO)-1 expression on 
decidual and placental tissues 267 was shown to increase trophoblast-induced apoptosis 
of maternal effector cells and therefore protect the fetus 268. Third, indoleamine 2,3-
dioxygenase (IDO) 269, 270 also may contribute to tolerance. Fourth, placenta-derived 
exosome particles present in the maternal circulation could regulate immune activation 
by mediating activation-induced apoptosis of maternal reactive lymphocytes 271. 
Moreover an adequate Th1/Th2 cytokine cross-talk 272, 273 can induce tolerance after 
birth. 
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2.4.3.2 The Postnatal Period 
Directly after birth, newborns possess a Th2 type cytokine profile 214, 218 combined 
with a decreased ability to produce cytokines. The postnatal maturation of the immune 
system is regulated by contact with microbial exposure. Exposure to bacterial products 
has a protective effect and promotes a Th1 response 274. A deficiency in receptors, like 
CD14 or Toll like receptors (TLR), that are important for lipopolysaccharide (LPS) 
interaction with immune cells, could decrease appropriate Th1 and default in Th2 
responses 275. Allergen-specific Th1/Th2-cytokines 276 and especially a reduced IFN-γ 
production 214 can be observed in children in a family with a history of atopic disease. 
Hence the IFN-γ production of T cells plays an important role in developing a Th1 
cytokine profile. CMBCs produce higher levels of IL-13 than adult PBMCs and CD8+ T 
cells are found to be the major source 277. No cytokine-pattern has been found yet to 
predict a later sensitization or develop an atopic disease later in life. A diminished IL-12 
production by APCs leads to reduced lymphoproliferation, stronger Th1 and weaker 
Th2 response to allergens. Early life seems to be crucial for a Th1 or Th2 cytokine 
response as well as a possible development of allergy later on 208. This frequently 
discussed “window of opportunity“ in the postnatal period offers perspectives for 
allergy prevention. For primary intervention maturation of the immune system via 
modulation of the innate immune system in particular may provide a potential 
explanation. The Th2 pattern in the first years of life is most probably the initial phase 
for the pathogenesis of atopic diseases and is therefore principal for investigations. 
However, the underlying factors that lead to a Th1 or Th2 response still remain unclear. 
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2.5 Factors Influencing Immune Deviation 
Numberous factors that influence the immune deviation are known. Genetic 
predisposition and more importantly environmental factors play a major role in the 
genesis of allergy. 
 
2.5.1 Genetic Predisposition 
Twin studies have shown that genetic predisposition comprises the strongest risk 
factors for asthma and allergy development 278, 279. Various genes on different 
chromosomes were identified for being responsible for allergic diseases (e.g. coding for 
a mast cell tryptase on chromosome 5q23-33, 11q13, 14q11.2 and coding for the α-
chain of the IL-4 receptor on 16p12) 280.  
Takahashi (2005) found a connection between the IL-12RB1-gene and an increased 
serum level of Th2-cytokines. A variant of the gene that codes for an arginase correlates 
with an increased risk for atopic dermatitis 281. The increasing prevalence of becoming 
allergic in the last decade however cannot be explained via genetic predisposition. 
Environmental factors as well as lifestyle and gene-interactions must play a major role 
as well 282. 
 
2.5.2 Environmental Conditions 
The impact of the environment can be monitored in the “natural experiment” of the 
German reunion in 1989. For forty years, two genetically similar groups had been 
exposed to different environmental conditions 283. In the industrial zone of Eastern 
Germany high concentrations of sulphur dioxide and pollutants were present 203 and the 
prevalence of atopic eczema was significantly higher than in Western Germany 283.  
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2.5.2.1 Inhalational Substances 
2.5.2.1.1 Smoke 
In utero exposure to smoke can cause long-lasting effects. Organic functions, such as 
respiration, can be profoundly affected. Maternal smoking is a relevant factor for atopic 
diseases in utero and during the first years of life (reviewed by Pauly et al 284). One 
smoking person per household doubles the risk for wheezing and other asthma-related 
symptoms. Neonates and children that are exposed to tobacco smoke have a 
significantly increased prevalence to developing asthma 285. However, this could only 
be seen with cigarette smoking and, very interestingly, only for children with allergic 
predisposition from a longitudinal analysis from birth to 10 years 286.  
 
2.5.2.1.2 Chemicals and Pollutants 
Sulfur dioxide 287, nitrogen oxide 288, diesel particles 289, and ozone 290 can also result 
in allergic diseases and asthma. Children that are exposed to air pollutants during fetal 
development and early life acquire health problems such as abnormal development (low 
birth weight, decreased lung growth) preterm birth, intrauterine growth restriction, 
childhood asthma, increased rates of respiratory tract infections, as well as behavioral 
problems, and neurocognitive decrements 291. 
 
2.5.2.2 Nutrition 
Some studies link the increased prevalence in childhood allergy to an impaired 
nutrient supply (reviewed in Enke et al 292). A well-developed placenta as well as an 
excellent foetal nutrition is an important prerequisite for a functional immune system. 
An increase in atopy is attributed to a decreased intake of fruits and vegetables 
containing a large amount of antioxidants 293 and n-3 polyunsaturated fatty acid 
(PUFA), rich in ﬁsh 294 intake as well as an increased n-6 PUFA (rich in vegetable oil, 
margarine) intake 294. A decreased antioxidant intake could result in a lower lung 
antioxidant defence and an increased airway susceptibility to oxidative damage that may 
result in asthma and airway inﬂammation 295. Various metabolic processes and gene 
expression of vital proteins like certain cytokines and enzymes demand fatty acids and 
their derivatives for early immune development and immune maturation. An increased 
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n-6 linoleic acid intake leads to elevated arachidonic acid and prostaglandin E2 (PGE2) 
production which could lead to a Th2 sensitization, asthma, and atopic disease 294. N-3 
as well as n-6 PUFAs affect the cell membrane ﬂuidity, cell signalling, and gene 
transcription and therefore modulate T cell function 295. 
An inverse correlation has been found between dietary vitamin E and C intake and 
asthma 296 and atopy 297 as it is positively correlated with the ventilatory function of the 
lungs in children and adults 298. Vitamin E as a strong antioxidant prevents membrane 
injury but has non-antioxidative effects on immune function as well. Vitamin A is 
important for lung and normal epithelial development in the respiratory tract 295. As 
much as for vitamins E and C also vitamin A and carotenoids are essential for the 
ventilatory function, and respiratory symptoms 299. 
Folate (its natural occurring form) and folic acid play a major role in preventing 
neural-tube defect in newborns 300 and supplementation for young women of 
childbearing potential is recommended. Folic acid is also proven to have beneficial 
effects on coronary heart disease, colon cancer as well as dementia 301. Interestingly, 
some new studies suggest that folic acid supplementation during early pregnancy is not 
merely beneficial but increases the risk of asthma wheezing, and respiratory disease 302. 
However, only isolated substances, such as vitamins and fatty acids could be 
correlated with a positive effect on the immune system. Neither fruit syrup nor orange 
juice, or honey at 1 month appeared to be a significant risk factor for atopic 
sensitization. Only sterilized water was shown to be a significant risk factor for asthma 
303. 
However, interventional studies resulted in disappointing results for the dietary 
hypothesis 295. Foetal and numerous factors in early life inﬂuence the development of 
asthma and atopic disease, therefore focus was shifted on these factors for preventing 
allergy in early childhood. 
In summary, a balanced diet is a precondition to give birth to a heathy child. 
Malnutrition in every form generates several problems. Those cannot be ascribed to 
single substances as the whole metabolism is too complex to draw causal conclusions. 
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2.5.2.2.1 Infant Feeding 
2.5.2.2.1.1 Breastfeeding 
Breastfeeding is the preferable method of infant feeding. Exclusive breast-feeding for 
at least 4 months (preferably 6 months) seems to be advantageous to at least delay 
atopic dermatitis and milk allergy 304. Some studies could show that breastfeeding alone 
in the first 6 months of life reduced allergies and asthma 305 and decreased the risk of 
atopy 306. Possible explanations for a protective effect of breastfeeding are the special 
composition of human milk promoting an intestinal environment rich in bifidum 
bacteria that induce a Th1 shift. The avoidance of cow’s milk protein is another factor 
for the beneficial effects of breastfeeding. In a detailed analysis of systematic reviews 
from the US Agency of Healthcare Research and Quality (AHRQ) in 2007 307 a possible 
protective effect of breastfeeding on allergy and eczema is suggested 308 but as all 
studies included observational sudies no direct conclusion can be drawn. 
Not only allergy protection is one of the major advantages for breastfeeding. A 
significant lower infection rate (e.g. diarrhea 309, otitis media 310, haemophilus 
influenza311, respiratory infections 312 together with an enhanced vaccine response 313), 
an enhanced protection against illnesses (e.g. AIDS 314, multiple sclerosis 315, 
cryptorchidism316, infant survival 317) and also an enhanced development and 
intelligence (318has been observed in breastfed childen. 
Therefore, breastfeeding is strongly recommended for its multiple benefits on child 
health.  
 
2.5.2.2.1.2 Hydrolyzed Formula Feeding 
To eliminate the allergenicity of the cow’s milk proteins, protein hydrolysate formula 
is commercially available to reduce the antigenic load as well as the risk for 
sensitization. A hypoallergenic formula should be well tolerated by at least 90% of the 
milk-allergic patients 319. One can distinguish between an elemental formula with free 
amino-acids that can be tolerated by all individuals, extensively hydrolyzed formula 
(EHFs) and partially hydrolyzed whey formula (PHWFs). 95% of all cow’s milk 
allergic people tolerate EHF, whereas PHWF can cause allergic reactions in 30-50% of 
milk allergic individuals and are therefore not considered to be hypoallergenic 319. A 
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meta-analysis of 15 randomized controlled trials revealed that PHWFs is effective in 
allergy prevention for children at high risk for allergy. For already allergic individuals 
only elemental formula and EHFs are an optimal substitute 320 
 
2.5.2.2.2 Mother’s Diet 
The type of the mother’s diet can affect the development of allergy-related diseases. 
In a Cochrane study an “antigen-free diet” for women at high risk of giving birth to an 
atopic child does not seem to have a strong protective effect on the incidence of atopic 
eczema or asthma during the first 18 months of life 321. 
Intake of fish oil during pregnancy seemed to be beneficial for asthma whereas 
consumption of processed fish, a source of trans-fatty acids, increased the risk of asthma 
in children. The type of fish ingested can be important because of the different pattern 
of fatty acids 322 and intake of fish is recommended during pregnancy. Dunstan et al 
(2003) found a reduced risk for infant allergy after maternal polyunsaturated fatty acid 
(PUFA) supplementation 323. The mechanism could be explained by a reduced neonatal 
oxidative stress, reduced production of inflammatory leucotriene B4 (LTB4), and an 
altered T cell function 324. 
 
2.5.2.2.3 Obesity 
Obesity is associated with an increased prevalence of asthma, especially in women, 
and asthma also seems to be more severe in the obese. Obesity goes along with low-
grade systemic inflammation, as well as with increased levels of inflammatory 
cytokines, adipokines, and acute phase proteins, including leptin, IL-6, TNF-α, and C 
reactive protein 325. Taylor et al (2008) could also demonstrate a significant association 
between asthma severity and obesity 326. The underlying mechanisms are not completely 
understood but could be related to a impaired function of regulatory T cells 327.  
Independent of exercise, a Mediterranean diet (higher intake of monounsaturated to 
saturated fats; rich in vegetables, fruits, grains and pulses, and a moderate dairy 
consumption) had a slight protective effect for current severe asthma in schoolchildren 
328. They concluded that obese people can perceive their asthma as more severe than 
normal-weight people. Calorie restriction resulting in weight loss, independent of 
specific food and nutrient intake, seems to improve asthma best 325.  
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Not surprisingly, children that have untreated asthma are less fit and have a higher 
rate of body fat and higher obesity 329. However, to date, there is little data about obesity 
and asthma and most study outcomes are from badly designed studies. For that obesity 
and asthma remains controversial and no causal correlation could be established. Most 
likely physical factors, such as higher mobility and an increased quality of life are 
involved in this process.  
It has also been suggested that induction of Treg development might be a useful tool 
for asthma treatment 330. However, increasing Treg might also increase the cancer risk 
by impairing host anti-tumour immune response. Thus the safest way to improve asthma 
in obese patients is as hard as weight reduction. 
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2.5.3 Hygiene Hypothesis 
The hygiene hypothesis arose from many different observations, starting in 
Switzerland, and was first published by Strachnan et al in 1989 331. One major 
observation was that children growing up in rural areas (e.g. a farm) are by far less 
likely to become allergic later in life than compared to children growing up in urban 
areas. An interesting observation was that the risk for allergy is more prevalent in 
western industrialized countries than in developing nations and immigrants adapt the 
risk of the community to which they move 332. Furthermore, smaller and wealthier 
families bear a higher risk for developing atopic dermatitis (AD) 333. Moreover 
cleanliness and frequency of washing is linked to an increase in AD 334. Taken together, 
these observations link westernized lifestyle to AD and allergy. 
The hypothesis states that a lacking microbial burden in context with allergens leads 
to an increased susceptibility to develop allergic diseases. Children growing up on a 
farm have a significantly lower prevalence of allergic diseases like allergic rhinitis or 
allergic asthma as compared to children growing up in urban areas. Regular presence in 
the stable, drinking non-pasteurized milk, presence of older siblings, frequent contact 
with endotoxins within the first year were defined as independent protective factors 335, 
336. Improved hygienic conditions in western or developed countries result in less 
infection-driven or microbial illnesses. Immunologically, this can be explained by the 
imbalance of Th1 and Th2 cells with a Th2 shift. This Th2 shift that predominates from 
birth through critical childhood periods results in a higher incidence of atopy and 
asthma. A more recent explanation is the impact of regulatory T cells that become more 
regulatory in the presence of farm dust and other stimuli. 
 
2.5.3.1 Anthroposophic Lifestyle 
Anthroposophy is based upon the writings of the philosopher Rudolf Steiner (1861-
1925). Together with the popular interest in the hygiene hypothesis anthroposophic 
lifestyle and its impact on allergy development have gained interest. It includes a 
restrictive use of antibiotics, fever-reducing agents and (certain) vaccination. Atopic 
dermatitis (AD) was 70% less common in children that were raised according to the 
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anthroposophic lifestyle compared to schoolchildren from non-anthroposophic 
background 337. The “Prevention of Allergy-Risk Factors for Sensitization Related to 
Farming and Anthroposophic Lifestyle” (PARSIFAL) study focused on more than 
6,600 children aged between 5 to 13 years conducted in five European countries 
(Austria, Germany, Netherlands, Sweden, and Switzerland). Certain features of the 
anthroposophic lifestyle, such as restrictive use of antibiotics and antipyretics, were 
associated with a reduced risk of allergic disease in children 338. Blood samples were 
taken and the children’s infection history, diet, animal contact, environmental 
exposures, anthroposophic lifestyle factors as well as symptoms and diagnoses of 
allergic illnesses were interviewed in a parental questionnaire. Children with an 
anthroposophic background had a significantly reduced risk for atopic eczema, 
rhinoconjunctivitis, and atopic sensitization 338. This anthroposophic lifestyle 
phenomenon can be explained by more childhood infections in this group as well as a 
reduced antibiotic use and by different eating habits, like eating more fermented 
vegetables rich in Lactobacillus. Taken together these facts affect the immune system in 
an allergen preventive way 339. Mechanisms will be explained in more detail in the 
following chapters.  
 
2.5.3.2 Childhood Infections 
Childhood infections, such as chickenpox, measles, mumps, whooping cough, 
diarrheal disease, and pneumonia are associated with an allergy-related illness 340. 
Factors influencing allergic diseases are age, severity, type of virus, location and timing 
of the infection together with the interplay with allergens 216.  
A protective effect could be found for certain types of pathogens 341. Illi et al (2001) 
found a negative association between atopic eczema, asthma, episodic wheezing in 
children that had several viral infections of the herpes type and a runny nose before the 
age of 3 years 342. McKeever et al (2001) 333 could affirm the data of Strachnan et al 
(1989) 331 that the presence of older siblings seems to be protective against hay fever 
suggesting that this effect may be directed by infections. A measles infection in 
childhood seems to be protective against the risk of IgE-mediated eczema 343. Floistrup 
et al (2006) could show that children who received the measles-mumps-rubella (MMR) 
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vaccine are at higher risk of having rhinoconjunctivitis 338. On the other hand, wheezing 
up to the age of 7 correlated with diminished respiratory tract infections in the first three 
years of life. The topic remains controversial however because several other studies 
could not find former mentioned beneficial effects 344. McKeever et al (2004) for 
example, who screened 29,238 children in an observational cohort study, could indeed 
find a correlation between MMR, diphtheria, polio, pertussis, and tetanus (DPPT) 
vaccination and the incidence of asthma and eczema. Importantly, this correlation was 
biased by the fact that those children, where the correlation was found, were also those 
who barely quested care from a general practitioner. They concluded that the observed 
correlation was more likely to be caused by a study bias than a biological effect 344. 
Additionally, a population-based cohort study by Schmitt et al (2009) could not find any 
evidence that infections per se significantly increased the risk for atopic dermatitis 345. 
An evidence-based relationship between vaccination and the development of allergic 
diseases are hard to fullfill as most children are vaccinated and do not develop an 
allergic disease. On the other hand, unvaccinated children are rare and therefore a very 
atypical group with a generally different lifestyle – thus difficult to compare. 
Moreover in this context it needs to be mentioned that the positive effects of 
vaccination are outweighing the side-effects by far. Many diseases (e.g. poliomyelitis, 
tuberculosis, etc.) have been eradicated from most countries all over the world because 
of the area-wide vaccination 346. 
 
2.5.3.3 Antibiotics 
The frequent administration of antibiotics during the first year of life leads to 
alteration in the intestinal flora and because of that to a Th1/Th2-imbalance that induces 
a higher incidence of allergic diseases 347. A two-fold increased risk of asthma could be 
reported in the first year of life after antibiotic use 348. A 1.5 times higher risk of having 
asthma at the age 7 was reported for children who had received more than four courses 
of antibiotics when compared to those who had not received any antibiotics 349. 
Controversial to that, Celedon et al (2004) could not find any association for asthma 
until the age of five years in children receiving multiple courses of antibiotics 350. 
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The discrepant findings can be explained by a different population studied. 
Kozyrskyj et al (2007) enrolled half of the cohort from rural areas whereas Celedon et al 
(2004) drew the data from an urban population 349, 350. The type of antibiotics used in 
rural children may also lead to an increased risk for asthma. Broad-spectrum 
cephalosporins leads to the significant suppression of Lactobacilli or Bifidobacteria, 
combined with an increase of C. difficile 351 which is considered to increase the risk of 
developing allergy. 
The epidemiologic evidence is conflicting. Four cross-sectional studies 352, 353 found 
a positive correlation between the early use of antibiotics and the development of atopic 
dermatitis, three longitudinal studies 347, 354, 355, and a case–control study 356 did not find 
any association between antibiotic exposure in infancy and subsequent incident atopic 
dermatitis. Recent findings suggest that broad-spectrum antibiotics (cephalosporines or 
macrolides) increase the risk for atopic dermatitis. Therefore antibiotics with a narrow 
stectrum, like penicillin, should be administered as first choice antibiotics if indicated 
345. 
 
2.5.3.4 The Intestinal Flora 
The intestine of the newborn is sterile at birth. The colonization of commensal 
bacterial flora takes place immediately after birth. This process is assumed to play a 
critical role in immune deviation.  
Children in agriculturally dominated countries have a special microbiota composition 
in the gut. Their gut comprises higher levels of anaerobic bacteria, like Lactobacilli or 
Bifidobacteria and lower levels of Clostridium difficile 357. The same pattern of gut 
microbiota is seen in non-allergic infants who discern them from allergic infants 358. 
The gastrointestinal microflora promotes potential anti-allergenic processes. Two 
pathways are assumed to induce a predominant Th2 cytokine pattern. The first, works 
through bacterial derived LPS resulting in stimulation of the immune system with Th1 
dominated properties 359. Simultaneously for the second pathway, the generation of 
TGF-β is essential for the suppression of Th2-mediated allergic inflammation and 
induction of oral tolerance 360. 
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The bacterial composition in the gut is crucial for immunological tolerance and 
consequently may impact allergy development 361. This theory is supported by the study 
of Kalliomaki et al (2001) that could demonstrate a 50% decrease of the clinical 
phenotype of atopic dermatitis after oral administration of Lactobacillus GG 361. 
Lactobacilli are able to inhibit antigen-induced IgE production and can change the 
interleukin pattern. Majamaa et al (1997) found out that infant milk formula 
supplemented with Lactobacilli is advantageous for infants that suffer from milk allergy 
and atopic dermatitis as it can reduce allergy symptoms as well as intestinal 
inflammation 362. On a T cell level the induction of Tregs by different probiotic strains 
is discussed controversially. Some studies could prove that the number and the potency 
of Tregs increased after probiotic implementation 363, 364 whereas others could not show 
this effect 365.  
However, probiotics alone cannot cure everything 366. Only few of the potential 
health benefits could be confirmed in randomized, controlled trials - especially in the 
paediatric population. There is convincing evidence for using probiotics in treatment for 
acute viral diarrheal disease, antibiotic associated diarrhoea and pouchitis. The role in 
irritable bowel syndrome, necrotising enterocolitis, inflammatory bowel disease and 
atopy remains controversial and needs to be backed up with evidence 367. However, only 
a small number of probiotic strains have been tested and many candiates are in the 
pipeline. Hence, the effects of different probiotic microorganisms are not equivalent; 
therefore results cannot be generalized 368. 
 
2.5.3.4.1 Microflora Hypothesis and Regulatory T Cells 
The explanations in the former chapter are most likely inaccurate due to over-
simplification. Direct examination could indicate that Th1 cells were able to reduce 
mucus production and airway eosinophilia but failed to inhibit Th2 cell-induced airway 
hyperreactivity 369. Hence other mechanisms than the Th1 and Th2 shift are needed for 
the switch between atopic and non-atopic phenotypes. Consequently regulatory T cells 
became the main focus of research 207, 370. Tregs that can be induced via different kinds 
of microbial stimulation can control an immune response through IL-10 and TGF-β 
production 340. The “microflora hypothesis” postulates that the microbial flora in the 
gastrointestinal tract (GI) tract is indispensable for immunological tolerance with 
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Tregs 371. Allergens can pass through an impaired barrier of the epithelium (also in 
the GI) shown by inflammatory skin infections early in life. Antibiotic application 
disrupts the intestinal microflora and can subsequently increase the inflammation by 
preventing immunologic tolerance via regulatory T cells 372. Chronic stimulation of the 
gut-associated lymphoid tissue (GALT) through microbial antigens accounts for 
developing a Th1- as well as a regulatory T cell dominated cytokine milieu. This can 
prevent the clinical expression of allergic disease.  
 
2.5.3.5 Endotoxins 
Lipopolysaccharide (LPS) is a structural component of gram-negative bacteria that is 
released when bacteria are lysed and unlike bacteria is thermo-stable.  
LPS consists of a hydrophilic polysaccharide chain and a lipophilic lipid moiety 
(Figure 8). The polysaccharide chain varies between different bacteria and endotoxins 
and has an approximate size of 10 kDa up to 1000 kDa. It is associated with 
immunogenicity. The lipid moiety (lipid A) is responsible for the toxic effect. Hence, 
LPS mediates proinflammatory and toxic functions that lead to severe infections like 
sepsis and septic shock. In human volunteers endotoxin injection produces fever, 
shaking chills 373, a reduced blood pressure together with blood and lung inflammatory 
reaction in which different immune cells, such as monocytes, macrophages, B cells, 
polymorphic nuclear- and endothelial vascular cells are involved 374. 
 
Figure 8 Three part 
construction of LPS  
LPS consists of 3 parts: a variable 
chain with repeating oligosaccharides, 
a conserved region with hetero 
oligosaccharides and lipid A 
 
 
LPS binds to the lipid binding protein (LBP) in the serum. This complex is 
transferred to CD14, a protein abundantly expressed on the cell membrane, and Toll-
like receptor-4 (TLR-4). TLR-4 and CD14 are expressed on macrophages and dendritic 
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cells and are indispensable for secreting pro-inflammatory cytokines that usually are 
beneficial and effective but may also become excessive in their effects and lead to an 
"endotoxic shock" 375. 
LPS induces different proinflammatory cytokines (IL-10, IFN-γ, and TNF-α) by 
activating transcription factors like NFκB or IRF-3 376. These cytokines explain the 
protective effects of pets and farm environment against allergic disease 377. Children 
living in a household with two or more dogs, together with a high level of indoor 
endotoxins (e.g. house dust) were a third less likely to develop wheezing than infants 
brought up without dogs 378. Pets in early childhood seem to be protective against 
allergen sensitization or asthma in children 379. The presence of animals (e.g. pigs) even 
in rural areas is associated with a lower likelihood of allergy 380, 381. 
A recent mouse-study conducted by Conrad et al (2009) could show a direct 
involvement of the bacterium Acinetobacter lwoffii F78, as a model organism for 
maternal bacterial exposure and the functional maternal TLR signaling inducing an 
asthma protection later on 382. 
 
2.5.3.6 Peptidoglycan 
Peptidoglycan is a cell wall component of all bacteria (except some bacteria such as 
Mycoplasma species, Planctomyces, Rickettsia and Chlamidiae). Unlike endotoxins 
which are only present in gram-negative bacteria, peptidoglycan is a good marker for 
microbial exposure 383.  
 
 
 
 
 
 
 
Figure 9 Cell wall of gram positive and gram negative bacteria 
385
 
Gram positive bacteria possess a thicker cell wall with higher amounts of peptidoglycan compared to 
gram negative bacteria. Gram negative bacteria have an extra outer membrane carrying additional LPS. 
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N-acetyl-muramic acid (2-acetamido-3-O-[(R)-1-carboxy-ethyl]-2-deoxy-D-
glucose), a peptidoglycan, is only present in bacteria and not found elsewhere in nature 
384. As gram-positive bacteria possess a thicker cell wall compared to gram-negative 
bacteria, peptidoglycan is more abundant in gram-positive bacteria (Figure 9 and 10).In 
contrast to endotoxin, which acts via TLR-4, peptidoglycan acts via TLR-2 and 
therefore causes a different cellular innate immune response compared to endotoxin 386. 
This is concordant with the fact that TLR-2 genes are more strongly expressed in farm 
children 387. Peptidoglycan induces IL-6, TNF-α, and IL-1 in monocytes, although a 
higher dose is required to get the same load compared to endotoxin 388. Exposition to 
muramic acid, measured in mattress dust, was inversely related to wheezing and asthma, 
whereas no association with atopy could be observed 386. This is in contrast to the 
hygiene hypothesis as bacterial exposure mediates a Th1 immune response with a 
reduced apoptotic response.  
 
 
Figure 10 -acetylmuramic acid--
acetylglucosamine 
Peptidoglycan is composed of two sugars, N-acetyl 
glucosamine and N-acetyl muramic acid cross-linked by 
amino acid bridges. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Expendable Items 
Dish Company 
Cellstar® Test tubes, sterile, 50 mL Greiner, Austria 
Cellulose acetate syringe filter, sterile, 
0,20 µm pore size 
Iwaki, Tokyo, Japan 
 
Culture Flask 25 cm2 (0.2 µm seal cap) Becton Dickinson; San José, CA, USA 
Culture plates:   
 24-well flat-bottom  Becton Dickinson; San José, CA, USA 
 48-well flat bottom Becton Dickinson; San José, CA, USA 
 96-well round-bottom  Iwaki, Tokyo, Japan, 
 96-well flat-bottom Costar-Corporation, Cambridge, MA, USA 
ELISA plates Costar-Corporation, Cambridge, MA, USA 
FalconTM FACS tubes, 5 mL Becton Dickinson, San José, CA, USA 
MACS-columns 
 LD-column 
 LS-column 
 MS-column 
Miltenyi Biotec, Bergisch Gladbach, Germany  
 
MACS-tubes 13mL Miltenyi Biotec, Bergisch Gladbach, Germany  
Nalgene® MF75™ Sterile Bottle-Top Filters, 
0,20 µm pore size )alge )unc International, Rochester, )Y, USA 
PCR heat sealing film Eppendorf, Hamburg, Germany 
PCR plate, ep.twintec 96-well skirted Eppendorf, Hamburg, Germany 
PCR tips Eppendorf, Hamburg, Germany 
PCR tubes (thin-walled, clear) Eppendorf, Hamburg, Germany 
Pipette tips  Eppendorf, Hamburg, Germany 
Polypropylen Tubes; 1,4 mL Micronic Systems, Lelystad, Holland 
Sodium heparin tubes, Vacuette® Greiner, Austria 
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Sterilin, sterile, 30 mL )o label 
Stripette® serological pipetts Costar-Corporation, Cambridge, MA, USA 
Wallac filter mate Perkin Elmer, Boston, MA, USA 
Wallac sample bag Perkin Elmer, Boston, MA, USA 
Table 4 Expendable items 
 
3.1.2 Additives and Kits 
Additive Company 
3.1.2.1 Cell culture 
[3H]-thymidine (37MBq) Amersham-Pharmacia, Freiburg 
Anti-TLR-2 eBioscience, San Diego, CA, USA 
Anti-TLR-4 eBioscience, San Diego, CA, USA 
Anti-IgG2 eBioscience, San Diego, CA, USA 
Brefeldin A  Sigma–Aldrich, St. Louis, MO, USA  
BSA Sigma–Aldrich, St. Louis, MO, USA 
CFSE (5 mM in DMSO) Sigma–Aldrich, St. Louis, MO, USA 
Cytometric bead array (Flex set) Becton Dickinson, San José, CA, USA 
DMEM (Eagle’s medium) PAA laboratories GmbH, Pasching, Austria 
DMSO  Merck, Darmstadt, Germany  
Dynalbeads® CD3/CD28 T Cell Expander Invitrogen, Dynal®, Carlsbad, CA, USA 
EDTA Sigma–Aldrich, St. Louis, MO, USA 
IL-8 ELISA BenderMedSystems, Vienna, Austria 
IL-13 ELISA BenderMedSystems, Vienna, Austria 
FCS  Gibco, Life Technologies Inc., Rockville, MD 
Ficoll-Paque™ PLUS  Amersham-Pharmacia, Freiburg 
FOXP3 staining set, PE, anti-human eBioscience, San Diego, CA, USA 
Gentamycine-sulfate  Sigma–Aldrich, St. Louis, MO, USA 
IgG1 (heavy chain) anti-mouse Sigma–Aldrich, St. Louis, MO, USA 
IntraPrep BeckmanCoulter, Fullerton, CA, USA 
Ionomycin  Sigma–Aldrich, St. Louis, MO, USA  
KCl Merck, Darmstadt, Germany 
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KHCO3 Merck, Darmstadt, Germany 
KH2PO4 Merck, Darmstadt, Germany 
L-glutamine  Sigma–Aldrich, St. Louis, MO, USA 
Limulus assay (LAL)  Cambrex Bio Science, Walkersville, USA 
Magnet for Dynalbeads® MPC-15  Dynal, Oslo, )orwegen 
NaCl Fluka Chemica, Buchs, Switzerland 
Na2HPO3 x 2H2O Merck, Darmstadt, Germany 
NH4Cl Merck, Darmstadt, Germany 
Paraformaldehyde Merck, Darmstadt, Germany  
Phorbol mystrate acetate Sigma–Aldrich, St. Louis, MO, USA 
Puromycin Sigma–Aldrich, St. Louis, MO, USA 
RPMI 1640 ohne L-Glutamin  Sigma–Aldrich, St. Louis, MO, USA 
Saponin Sigma–Aldrich, St. Louis, MO, USA 
Scintillation solution for β-Counter  Rotiscint eco, Roth 
TMB-Substrate Becton Dickinson; San José, CA, USA 
Trypane blue solution 0.4% Sigma–Aldrich, St. Louis, MO, USA 
Tuerk Solution, 100 mL Fluka Chemica, Buchs, Switzerland 
Tween 20, 500 mL Sigma–Aldrich, St. Louis, MO, USA,  
Ultra culture medium (serum-free) Bio Whittaker, Walkersville, MD, USA 
3.1.2.2 MACS 
CD4+ T cell Isolation Kit II, human Miltenyi Biotec, Bergisch Gladbach, Germany 
CD4+CD25+ regulatory T cell Isolation Kit  Miltenyi Biotec, Bergisch Gladbach, Germany 
CD25+ MicroBeads Miltenyi Biotec, Bergisch Gladbach, Germany 
3.1.2.3 PCR 
Ethanol abs. Carl Roth, Karlsruhe, Germany 
GenElute™ Mammalian Total RNA Miniprep Kit Sigma–Aldrich, St. Louis, MO, USA 
iScript cDNA synthesis kit Bio-Rad Laboratories, Hercules, CA, USA 
Nuclease free water (not DEPC-treated) Ambion Inc, Austin, TX, USA 
iQ SYBR Green Supermix Bio-Rad Laboratories, Hercules, CA, USA 
RNaseZap® RNase Decontamination Solution Ambion Inc, Austin, TX, USA 
QuantiTect Primer Assays Qiagen,GeneGlobe Valencia, CA, USA 
Table 5 Additives and Kits 
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3.1.3 Laboratory Units 
Unit Company 
BetaCounter Wallac 1450-024 MicroBeta  Perkin Elmer, Boston, MA, USA 
C1000, Thermal cycler Bio-Rad Laboratories, Hercules, CA, USA 
Centrifuges  
 Biofuge fresco Heraeus Instruments, Hanau, Germany 
 LMC-3000 HVD Life Sciences, Vienna, Austria 
 4K15 Sigma–Aldrich, St. Louis, MO, USA 
CO2-Incubator, CB210 Binder, Tuttlingen, Germany 
137Cs-γ-irradiator   
ELISA-Reader Anthos 2010, Salzburg, Austria 
ELISA-Software ADAP Software, HVD 
FACSCalibur  Becton Dickinson; San José, CA, USA 
FACSCanto  Becton Dickinson; San José, CA, USA 
FACS Sorter Aria Becton Dickinson; San José, CA, USA 
Harvester Perkin Elmer, Boston, MA, USA 
Heat Sealer  Eppendorf, Hamburg, Germany 
NanoDropTM ND-1000 )anoDrop Technologies, Wilmington, DE, USA,  
pH-Meter  WTW, inoLab®, Weilheim, Germany 
Pipettes Eppendorf, research; Hamburg, Germany 
Precision scale, AT261 DeltaRange® Mettler Toledo, Vienna, Austria 
RT-PCR, CFX96 Optical Reaction Module Bio-Rad Laboratories, Hercules, CA, USA 
RT-PCR, Mastercycler® ep realplex 4S Eppendorf, Hamburg, Germany 
Scale, digital Mettler, Vienna, Austria 
Sterile bench, biosafe2  Ehret, Emmendingen, Germany 
Vortex  HVD Life sciences, Vienna, Austria, 
QubitTM fluorometer 
Invitrogen, Molecular Probes, Carlsbad, CA, 
USA 
Table 6 Laboratory units 
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3.1.4 Allergens and Other Stimuli 
Special emphasis was put on the major milk allergen β-lactoglobulin (BLG) and the 
major peanut allergen Ara h 1 which are among the most important food allergens in 
childhood. The milk-derived allergen (BLG) is a prominent food antigen often used as a 
model food allergen which leads to a high frequency of proliferative responses in cord 
blood and other cell types such as PBMCs, lymphocytes of the lamina propria and 
payer’s patches of mononuclear cells 216, 220, 389-392. To investigate potential LPS 
contamination and the impact thereof following BLG preparations were used: (BLG 
3908, BLG 3908 (purified), BLG L-0130, BLG L-0130 (purified) (all Sigma Aldrich) 
and BLG (LPS-free [LF]; generated by Brix et al 393). Purification procedure was 
performed using endotoxin removal columns (Pierce) with trace amounts of LPS 
remaining present (named as purified). Because of that, and for the fact that the protein 
content was decreased a purified BLG fraction, manufactured by Brix et al 393 served as 
the internal LPS-free control (BLG [LF]). In short, whey was separated and size-
exclusion chromatography was performed with the Superdex 75 column (Hiload 26/60, 
AP Biotech, Uppsala, Sweden) using 150 mmol/L ammonium acetate at the pH of 6.0. 
The two collected BLG peaks were pooled, dialyzed (Spectra/Por, with a cut-off of 12 
to 14 kDa) in water (MilliQ, Millipore), and lyophilized. The endotoxin content of this 
LPS-free BLG 100 times lower than the un-purified sample and 15 times lower than the 
purified (Pierce column) BLG (Table 10). 
Size-exclusion chromatography of commercially available BLG (Sigma Aldrich, L-
0130) was performed using a Superdex 75 column (Hiload 26/60, AP biotech, Sweden) 
as described in detail by Brix et al 393. Briefly BLG was dissolved in ammonium acetate 
(0.15 M, pH 6.0), and 5 mL [20 mg/mL] was applied to the column. Elution was carried 
out using the same buffer at 2.5 mL/min. Fractions of 10 mL were collected and frozen. 
Before inclusion in cell cultures, 2 x 1 mL from each fraction was vacuum-dried, and 
twice evaporated with distilled water to remove any remnants of eluting buffer. 
The recombinant Bet v 1 was used representative for inhalational allergens and 
purchased from Biomay, Vienna, Austria.  
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Plate-bound anti-CD3 (UCTH1 clone, Dako), a polyclonal TCR dependent T cell 
activator, was used for proliferation and inhibition assays and tetanus toxoid (TT) was 
used only in peripheral blood proliferation assays representative for a recall-antigen. 
For LPS proliferation LPS from Escherichia coli serotype 055:B50 and Salmonella 
minnesota strain R595 were used. The highly purified LPS S. minnesota strain R595 
“ultra pure” was used for TLR-inhibition experiments. 
 
Stimulus Abbreviation Source Preparation 
 Anti-human T cell CD3 
aCD3  
(UCTH1 clone) 
DAKO, Golstrup, 
Denmark 
Product No. M0835 
Birch Betula verrucosa rBet v 1 
Biomay, Vienna, 
Austria 
Lot #22 
Isoform Bet v 1.0101 
Egg Ovalbumin OVA 
Sigma–Aldrich, 
St. Louis, MO, 
USA 
Product No. A5503 
Human Interleukin-2 rIL-2 
Roche Applied 
Science, I), USA 
Product No. 1 147 528 
Lipopolysaccharide 
LPS  
E.coli 
Sigma–Aldrich, 
St. Louis, MO, 
USA
 
Escherichia coli serotype 
055:B50 
LPS  
S. minnesota 
LuBio Science, 
Lucerne, 
Switzerland
 
Salmonella. minnesota 
strain R595 
LPS  
S. minnesota 
(Ultra pure) 
LuBio Science, 
Lucerne, 
Switzerland
 
PURE Salmonella. 
minnesota strain R595 
Milk  
 
β-lactoglobulin 
 
BLG 3908 
BLG L-0130 
Sigma–Aldrich, 
St. Louis, MO, 
USA 
Product No. 3908 
Product No L-0130 
BLG [LF] 
Susanne Brix 
(BioCentrum-
DTU, Technical 
University of 
Denmark, 
Lyngby, 
Denmark) 
Protein obtained from raw 
milk. 
Purification and analysis 
as described in Brix et al 
(2003) 393 
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Peanut 
Arachis 
hypogea 
Ara h 1 
Clare Mills (IFR 
)orwich) 
Allergen obtained from 
whole Virginia red variety 
peanuts. 
Procedure described by 394, 
395 
Phytohem-
agglutinin 
M Form PHA 
Gibco Invitrogen 
Corporation, )J, 
USA 
Product No. 10576-015 
Tetanus toxoid 
Clostridium 
tetani 
TT 
Calbiochem, La 
Jolla, CA, USA 
Product No. 582231 
Table 7 Stimuli used 
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3.1.5 Antibodies 
3.1.5.1 Monoclonal antibodies for flow cytometry 
Specificity 
Fluorescent 
labelling 
Origin 
Ig-
Isotype 
Clone Dilution Company 
CD 3 PerCP Mouse IgG1 SK7 1:10 BD 
CD 3 APC Mouse IgG1 SK7 1:100 BD 
CD 4 FITC Mouse IgG1 SK3 1:10 BD 
CD 4 PE Mouse IgG1 SK3 1:10 BD 
CD 4 FITC Mouse IgG2a VIT4 1:10 Miltenyi 
Biotech 
CD 8 PerCP Mouse IgG1 SK1 1:10 BD 
CD 8 PE Mouse IgG1 SK1 1:10 BD 
CD 25 APC Mouse IgG1 2A3 1:100 BD 
CD 25 PE Mouse IgG2b 4E3 1:10 Miltenyi 
Biotech 
CD31 PE Mouse IgG1 AC128 1:10 Miltenyi 
Biotech 
CD45RA PE Mouse IgG2b HI100 1:10 BD 
CD45RB PE Mouse IgG1 MT4 (6B6) 1:10 BD 
CD45RO PE Mouse IgG2a UCHL-1 1:10 BD 
CD45RO PE-Cy5 Mouse IgG2a UCHL-1 1:10 Miltenyi 
Biotech 
CD45RO APC Mouse IgG2a UCHL1 1:100 BD 
CD62L APC Mouse IgG 145.15.3 1:10 Miltenyi 
Biotech 
CD69 PE Mouse IgG1 L78 1:10 BD 
CTLA4 PE Mouse IgG2a BNI3 1:10 BD 
HLA-DR PE Mouse IgG2a L243 (G46-6) 1:10 BD 
CD103 PE Mouse IgG1 Ber-ACT8 1:10 BD 
CD127 PE Rat IgG2b SB/199 1:10 BD 
CD127 APC Mouse IgG1 40131 1:100 R&D 
FOXP3 PE Rat IgG2a PCH101 1:10 eBioscience 
GARP PE 
hybridoma 
tissue culture 
supernatant 
IgG2b Plato-1 1:1000 
Alexis 
Corporation 
Table 8 Monoclonal antibodies for flow cytometry 
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3.2 Medium and Cells 
3.2.1 Media and Buffers 
Buffer/medium Abbreviation Ingrediens Storage 
Ammonium-Chloride buffer Ery-Lys 
NH4Cl [155mM] 46 g 
KHCO3 [10mM] 500,6 mg 
EDTA [0,1mM] 14,6 mg 
4° C 
CFSE buffer - 
500 mL PBS 
500 mg BSA 
4° C 
Eagle´s medium DMEM 
10% foetal bovine serum,  
100 mg/L gentamycine-sulfate 
5 µg/mL puromycin  
4° C 
ELISA antibody diluent buffer - 
1% BSA 
PBS 
4° C 
ELISA biotinylated diluent 
buffer 
- 
1% BSA 
PBS 
4° C 
ELISA HRP-streptavidin 
diluent buffer 
- 
1% BSA 
0,1% Tween 20 
PBS 
4° C 
ELISA Saturation buffer - 
5% BSA 
PBS 
4° C 
ELISA Wash buffer - 
0.05% Tween 20 
PBS 
4° C 
Freezing medium - 
25 mL RPMI 1640 
5 mL DMSO 
20 mL heat inactivated FCS 
170 mg/L gentamycine-
sulphate 
4° C 
MACS buffer - 
500 mL PBS (pH=7,3) 
2,5 g BSA 
0,3684 g EDTA 
4° C 
Phosphate buffered saline PBS 
8 g NaCl 
0,2 g KCl 
1,8 g Na2HPO4 2H2O 
0,24 g KH2PO4 
A.d. ad 1000 mL 
4° C 
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RPMI 1640 complete medium 
 
 
- 
RPMI 1640 
2mM L-glutamine 
85 mg/L gentamycine-
sulphate 
10% heat inactivated FCS 
4° C 
 
Saponin-Buffer 
Stock-Solution 10% 
 
 
- 
10g Saponin 
23,8g HEPES 
100 mL PBS 
4° C 
 
Serum-free Ultra culture 
complete medium 
 
UCC 
UC-medium 
2mM L-glutamine 
170 mg/L gentamycine-
sulphate 
4° C 
Table 9 Media and Buffers 
Experiments were performed using sterile buffers and media listed in table 9. All 
media and buffers were sterile-filtered with bottle top filters (BD, San José, CA) or 
syringe filters if less than 20 mL was needed (e.g. freezing medium). The pH value was 
always adjusted between 7.2 and 7.4. For washing procedure and counting cells sterile 
PBS (pH 7.2-7.4) was used if not otherwise noted. If fetal calf serum (FCS) was used it 
has before been inactivated 30 min. at 56°C and then stored at -20° C.  
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3.2.2 Cord Blood and Patient Characteristics 
Human umbilical cord blood was collected at the Medical University of Vienna at 
the Department of gynaecology. The protocol was approved by the local Ethics 
Committee of the Medical University of Vienna. 
Cord blood from randomly chosen full term healthy infants was obtained by 
venopuncture of the umbilical vein immediately after delivery and placed in sterile 
sodium heparin tubes (VACUETTE®, Greiner). 
As a homogenous population of healthy neonates was recquired, following exclusion 
criteria needed to be met to prevent potential T cell influence: 
• < 37 week of gestation and body weight <2500g) 396; 
• Neonates with infections, assisted respiration, metabolic problems, organ failure, 
chromosome abberations 396; 
• Chronical illness of the mother (autoimmune diseases like diabetes mellitus, 
rheuma, morbus crohn, colitis ulcerosa etc.; chronical inflammation (e.g. HIV397, 
chronical hepatitis 398); 
• and/or drug addiction 399. 
 
Individuals with no history of food allergy and no sensitization (no specific IgE 
measured with CAP/Phadia, skin prick testing (SPT) negative (wheal diameter < 3 mm) 
with a mean age of 30 years were used as controls. 
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3.3 Methods 
3.3.1 Cell Isolation Techniques 
3.3.1.1 Separation of Cells via Density-Gradient Centrifugation 
Density gradient centrifugation is an efficient way to separate blood cells. During 
centrifugation, cells are preserved on an area matching their own density. Mononuclear 
cells, which are mainly lymphocytes, monocytes, and granulocytes with a density 
between 1.04 and 1.14 g/mL are concentrated in the interphase after centrifugation.  
Human plasma    ~1.03 g/mL 
Monocytes and Lymphocytes:   ~1.08 g/mL 
Neutrophils:    ~1.12 g/mL 
Neutrophils and Eosinophils:  ~1.13 g/mL 
Eosinophils:    ~1.14 g/mL 
 
 
 
Figure 11 Separation of 
cells via Ficoll 
Ficoll was used for separating 
mononuclear cells from 
whole blood.  
 
Heparinized blood was diluted 1:2 with PBS, and was drawn over Ficoll-PaqueTM 
PLUS (Pharmacia, Uppsala, Sweden), a neutral, highly branched, hydrophilic sucrose 
polymer (400,000 Da) with a specific density of 1.077 g/mL at 10°C. After 
centrifugation at 300 g (1250 rpm) for 30 minutes with no brakes at room temperature 
(Sigma centrifuge) the light thrombocytes remain in the plasma phase and granulocytes 
and erythrocytes sediment through the Ficoll (Figure 11). Lymphocytes and monocytes 
are kept in the interphase in a fleecy band that was recovered with a 5 mL stripette 
(Eppendorf). Cells were washed three times with PBS by centrifugation to separate 
Plasma 
Lymphocyte 
band 
Precipitated 
red cells 
Plasma: Blood 
1:2 
Ficoll 
Tube with 
Ficoll 
Addition of blood After 
centrifugation 
Material and Methods 
67 
 
them from Ficoll and plasma. Where erythrocyte lysis was needed isotonic ammonium-
chloride buffer was applied for 5-7 minutes. Cells were always freshly isolated and 
immediately used, if not otherwise noted. For inhibition assays after priming, CBMCs 
and CD4+CD25- T cells needed to be frozen. They were frozen immediately in 1 mL 
ice-cold freezing-media in cryotubes which contained the cryoprotectant DMSO. 
For thawing cryotubes were held in 37° C water while gently shaking. Immediately 
when only a small ice cube remained cells were transferred into culture media (10x 
volume) and centrifuged at 300 g for 10 minutes. Afterwards the supernatant was 
decanted and cells were cultured in fresh medium. 
Cells were counted in a Buerker-Tuerk chamber (Figure 12 (a)). An aliquot (10 µL) 
of the cell suspension was mixed with the same volume of either Tuerk solution (for 
freshly isolated cells) or Trypan blue (for thawed cells). Using the Tuerk dye, nuclei are 
colored in purple and round cells were counted. When Trypan blue was used the blue-
coloured cells were left out and not counted as dead cells appear blue with this dye 
because when dead cells lose their potential to actively discharge the dye. 
The chamber comprises of 9 squares (Figure 12 (b)). Each square has a defined area 
of 1 mm2 with 0.1 mm sample depth hence a defined volume of 0.1 µL can be 
calculated. Five squares were counted in the Buerker-Tuerk chamber for receiving a 
representative mean and the total cell count per 1 µL is determined using the following 
equation: 
 
 
 
 
 
 
 
 
 
Figure 12 Buerker-Tuerk chamber 
All mononuclear cells were counted with this Buerker-Tuerk chamber. 9 squares, each with 1 mm2 area 
and 0.1 mm sample depth comprise this chamber and five squares were counted to get a representative 
result. 
cells counted 
 
 counted area (mm
2
) * sample depth (mm) * dilution 
= 
(a) (b) 
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3.3.1.2 MACS Separation 
Magnetic cell sorting (MACS©, Miltenyi Biotech) is a technique that uses 
monoclonal antibodies coupled to magnetical microbeads to isolate cell fractions. 
Magnetically labeled cells can be separated over ferreous columns. For CD4+CD25+ 
Treg isolation, a two step isolation procedure was used (CD4+CD25+ regulatory T cell 
isolation kit, Miltenyi Biotech). As a first step, non-CD4+ cells (monocytes, B cells, NK 
cells, cytotoxic T cells, dendritic cells, normocytes, thrombocytes and basophile 
granulocytes) were indirectly labeled with biotin-conjugated antibodies and then 
magnetically labeled with anti-Biotin beads. CD4+ cells were negatively depleted with a 
MACS-LD-column and obtained in the flow-through. In a second step, CD4+ cells were 
directly labeled with CD25-microbeads and then positively depleted by a MACS-MS-
column. The last step was repeated 1-2 times to gain a higher purity. After the magnetic 
field was removed, cells were flushed with 1 mL MACS buffer to get the positively 
selected (labeled) CD4+CD25+ Tregs (Figure 13).  
To isolate the effector T cells from the same cell population CD4+CD25--cells were 
negatively selected from the first flow-through from the MS-column (Figure 13). The 
enriched CD4+CD25- T cells were washed, centrifuged and negatively selected with a 
LS column to deplete remaining CD25+ cells. 
 
 
 
 
 
 
 
 
 
 
Figure 13 Model for MACS separation 
At the first step, cells of interest are labeled with specific microbeads (e.g. CD25). Cells are separated 
over a magentic column andretrieved after the magnetic field is removed. 
1. Label cells of 
interest with magnetic 
MicroBeads 
2. Pass over separation 
column place in the magnetic 
field. 
Flow through = nonlabeld 
cells 
3. Remove magnetic field 
4. Flush 
separation 
column to get 
positively 
selected 
(labeled) cells 
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3.3.2 Proliferation Assays 
For the proliferation assay CBMCs or PBMCs were seeded at a density of 105 
cells/200 µL if not otherwise noted. For all experiments serum free media was applied 
(UCC; Ultra culture medium; Bio Whittaker, Walkersville, MD).  
Initially, LPS dependent proliferation was assessed in cord blood to define the time 
point with maximal response. Consequently proliferation assays were performed after 
72h (LPS-response) and 7 days (allergen-specific proliferation) at a humidified 
atmosphere with 5% CO2 at 37°C as previously described 
217, 218. Recombinant IL-2 [25 
IU/mL] served as a positive control and medium alone with cells was used as negative 
control. Cells were pulsed with [3H]-thymidine ([3H]TdR; 0.5 µCi [0.0185MBq]) per 
well for the last 16 h of the culture. Thereafter cells were directly harvested or frozen at 
-20°C to stop the incorporation. The incorporated radioactivity (cpm, counts per minute) 
was measured by liquid scintillation. Proliferation was expressed as stimulation index 
(SI) of a geometric mean of triplicates. The SI is determined using the following 
equation: 
 
 
According to literature an SI > 2 was considered positive 217. 
 
For LPS proliferation, CBMC were isolated and co-cultured with LPS in limiting 
dilution. At the two defined read-out time points (72h (day 3) and day 7), proliferation 
and TNF-α production was measured (Proliferation n=8; TNF-α measurement n=5; 
standard error of the mean (SEM)). 
For antigen-specific proliferation assays, dose response experiments applying 
allergen concentrations from 0.1-100 µg/mL and the corresponding LPS-content were 
assessed to define the explicit relevance of different amounts of contamination present. 
For the tetanus toxoid proliferation assay, tetanus toxoid (TT) was chosen as a model 
antigen known to induce a positive proliferative response in vaccinated individuals. TT 
was initially proven (via certificate and via internal limulus control) to contain 
endotoxin below the limit of relevance (Table 10). A sub-maximal dose of 1 µg/mL was 
culture edunstimulatin  cpm
culture stimulatedin  cpmSI =
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spiked with increasing levels of endotoxin corresponding to the amount of 
contamination present in BLG.  
3.3.3 LPS Measurement via Limulus Amoebocyte Lysate  
The limulus amoebocyte lysate (LAL) method bases on the fact that the blood of the 
horseshoe crab, Limulus polyphemus, coagulates upon endotoxin exposure. The toxin of 
gram-negative bacteria can be quantified with this LAL test (Cambrex, 50647U). The 
sample and the LAL is mixed and incubated at 37°C for 10 minutes. Subsequently a 
substrate solution is mixed with the LAL-sample and incubated at 37°C. Concentration 
is determined spectrophotometrically at 405-410 nm (limit of detection: 0.035 EU/mL). 
 
3.3.4 Cytokine Measurement 
Cytokine measurement was performed either via ELISA (BenderMedSystems, 
Vienna, Austria) or cytometric bead array (Flex set, Becton Dickinson, San José, CA, 
USA). CBMCs (5 x 105/mL UCC) were cultured in 96-well round-bottom plates in the 
presence of the respective antigen in a dose dependent manner in triplicates. For 
monocytes, in case of TLR-inhibition experiments, 48-well flat-bottom wells were used. 
Medium with cells alone served as negative control. Cell-free supernatants were 
harvested at the respective time points and immediately frozen at -80° Celsius. 
IL-1β, IL-5, IL-10, TNF-α and INF-γ levels were measured via cytometric bead 
array (CBA; Flex Kit, Becton Dickinson, San José, CA, USA) using a FACS Canto 
(Becton Dickinson, San José, CA, USA) according to the instructions provided by the 
manufacturer. IL-13 was measured via ELISA (limit of detection [1.56 pg/mL]; 
BenderMedSystems, Vienna, Austria).  
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3.3.5 TLR Assays  
3.3.5.1 TLR Inhibition Assays 
Cord blood derived monocytes were isolated via adherence in 48-well flat-bottom 
plates. TLR-inhibitory antibody (anti-TLR-4 [1 µg/mL]) and the respective isotype 
control (IgG2a [1 µg/mL]) were added (all from eBioscience, San Diego, CA, USA) for 
1 hour. Samples or positive control (LPS) were added and cell free supernatant removed 
after 6 hours of incubation and stored at -80°C. TNF-α served as read-out parameter 
and was measured via sandwich-ELISA (limit of detection [8 pg/mL]; 
 BenderMedSystems, Vienna, Austria). 
 
3.3.5.2 TLR-2 and TLR-4 Transfected Human Embryonic Kidney Cells (HEK293)A 
Human embryonic kidney cells (HEK293) were stably transfected with an expression 
vector for human CD14 (293-hCD14), CD14 and TLR-2 (293-hCD14/TLR-2) and 
CD14 and TLR-4 (293-hCD14/TLR-4) (a kind gift of Dr. M. Yazdanbakhsh, Leiden 
University Medical Center, The Netherlands). Cells were cultured in standard 
Dulbecco’s modified Eagle´s medium (DMEM; PAA laboratories GmbH, Pasching, 
Austria) for 24h. For stimulation experiments, 4 x 104 cells/well were placed in 96-well 
flat-bottom plates (Costar) in complete medium and co-incubated with the respective 
antigen at 37°C in 5% CO2. Cell-free supernatants for cytokine measurements were 
collected. Untreated cells served as controls. For stimulation of 293-hCD14/TLR-4 
cells, MD-2 (a protein imperative for the responsiveness to LPS) was added to the 
culture medium. The concentration of IL-8 in the supernatant was used as the read-out 
parameter and measured via ELISA (Endogene) according to the manufacturer’s 
instructions.  
 
 
 
A This experiment was performed by Irma Schabussova, Medical University of Vienna 
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3.3.6 Flow Cytometry 
The analysis and the phenotypical characterization of lymphocytes is one of the most 
important techniques in immunological research and diagnostics. With fluorescence 
activated cell sorting (FACS-analysis) different cell populations and cell types can be 
identified. Different types of lymphocytes can be recognized due to their surface 
antigens that are usually defined through their binding to specific monoclonal 
antibodies. When those antibodies are marked with a fluorescent dye (fluorochrome), 
the expression of the corresponding protein on cells is analyzed with the FACS. 
Different parameters of one cell can be detected by using this method. Hence, it is 
possible to extrapolate the gathered information of each individual cell. 
  
Figure 14 Model for a flow cytometer 
 
Using extra- and intracellular staining cellular activation (transcription factors (e.g. 
FoxP3) and cytokine production etc. can be analyzed. A laser beam with a single 
wavelength aims on a focused flow of fluid. The FSC (Forward Scatter, FSC; 2°-15° 
from laser) correlates with the cell volume. SSC (Side Scatter, SSC, 90°) depends on the 
granularity of the particle. Dead cells are normally smaller and also possess more 
granularity than live cells. Therefore a differentiation between dead and alive cells is 
laser 
Side Scatter 
Detector 
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Detector 
Flourochrome 2 
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Dichroic Mirror 
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Collection Lens 
Forward Scatter 
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possible. Flow cytometry is an excellent method for counting, examining and sorting 
cells. Each cell scatters the light in a specific way. Fluorescent antibodies attached to the 
cell surface emit light of a specific wave length which can be detected and differentiated 
through analysis with special software. 
Acquisition of cells was performed on a FACS-Calibur four-colour cytometer and 
subsequent analysis of the measured parameters was done with the Cell Quest software 
(both Becton Dickinson, San José, CA). A total of 105 cells were analyzed in case of 
intracellular staining and a minimum of 2x104 for surface staining.  
For both surface and intracellular staining, human mononuclear cells and the 
standard protocol were used. For intracellular staining a permeabilization/fixation kit 
(IntraPrep; BeckmanCoulter, USA) or saponine detergent as an alternative protocol, 
which reversibly forms holes in cell membranes, were used. Fluorescent antibodies as 
listed in table 8 and the respective isotype control were utilized for all experiments. 
 
3.3.6.1 CFSE  
5(6)-Carboxyfluorescein N-succinimidyl ester (CFSE) is a fluorescent cell staining 
dye to visualize and qualify division of cells. CFDA-SE (Carboxyfluorescein diacetate, 
succinimidyl ester), the pre-form, enters the cell cytoplasm by diffusion and is cleaved 
by intracellular esterase and converted to CFSE. CFSE is not cell permeable and 
irreversibly binds to free proteins (Figure 15).  
 
 
 
 
 
Figure 15 CFSE 
CFDA-SE enters the cell membranes and intracellular esterase converts it to CFSE. CFSE binds to 
proteins which results in a stable intracellular fluorescence that is equally distributed between two 
daughter cells after division. 
Whenever a stained cell divides, CFSE labelling is partitioned equally between the 
two daughter cells 148(Figure 16 (a, b).  
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Figure 16 Division of CFSE labeled cells 
The highly fluorescent, CFSE stained parental cell gives half of its fluorescent dye to the daughter cells 
(a) which can be visualized in a flow cytometer. Figure (b) shows a CFSE histogram. Here, the highly 
fluorescent parental cells are seen on the green vertex on the right, whereas all the peaks to the left show 
one divided daughter population (green). The red line represents the CFSE stained cells that have not 
undergone proliferation. 
 
The two-fold decrement in cellular fluorescence intensity can be analyzed with flow 
cytometry using excitation at 488 nm. CFSE labelling is a standard technique to assess 
proliferation similar to [3H]-thymidine incorporation but providing a higher information 
content. With CFSE labelling one can distinguish whether an entire population divides 
once or one fourth of a population divides three times which cannot be distinguished 
with [3H]-thymidine incorporation alone. This is a big advantage compared to the [3H]-
thymidine incorporation assay which allows only measurement of proliferation within a 
specific time frame.  
Prior to use a 1 mM CFSE stock solution (Sigma-Aldrich, 21888) was prepared in 
1000 µL pre-warmed PBS/0.1% BSA. The fresh isolated lymphocytes were 
resuspended in pre-warmed PBS/0.1% BSA at a final concentration of 107 cells/mL. Via 
titration an optimal working concentration of 5 µM was defined. The staining (10 min. 
gently shaking at room temperature) was quenched by the addition of 5 volumes of ice-
cold PBS/0.1% BSA to the cells and then pelleted. Cells were washed three times in 
fresh media. Afterwards cells were placed in appropriate well plates for further 
experiments and analyzed in a FACS Calibur at 488 nm. 
Parental Cell 
D
aughter C
ells 
(a) (b) 
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3.3.6.2 FACS Sorting 
Fluorescence activated cell sorting (FACS) uses the technique of flow cytometry as 
explained before. The main difference here is that cells cannot only be analyzed but also 
sorted due to different flourescent surface markers. As the information from the scatter 
and the fluorescence the computer can process the information and hence determine 
which cells are to be separated. A very high purity (>99%) can be achieved with that 
method (Figure 17). 
 
 
 
 
Figure 17 FACS sorting 
scheme 
The required cells are fluorescently 
labeled with specific flourescent 
antibodies (shown in red or green). 
As not every cell expresses the 
epitope some are not labeled in 
either colour (yellow). Those cells 
are discarded due to their electrical 
charge in the waste tube. 
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3.3.6.2.1 Sorting according to CD25 and CD127 Expression 
CD4+ T cells were purified via negative isolation applying MACS sorting. Cells were 
labeled with CD4, CD127, CD3 and CD25. 
After staining and washing cells were FACS sorted and 4 different fractions were 
gained as shown in figure 18. 
 
 
 
 
 
 
 
 
 
Figure 18 Scheme of fractions that were FACS sorted according to their CD25 and 
CD127 expression 
 
F1  CD4+CD25highCD127low 
F2  CD4+CD25intCD127low  
F3  CD4+CD25intCD127high 
F4, Teff  CD4+CD25- (effector T cells) 
 
 
3.3.6.2.2 Sorting According to CFSE Intensity and CD25 Expression 
To distinguish which cell population gains inhibitory potential after the priming 
procedure FACS sorting due to CFSE intensity was applied. 
CBMCs were stained with CFSE according the protocol described above and 
cultured with BLG L-0130, BLG [LF] and Ara h 1 (all [50 µg/mL]) in 25 cm2 culture 
flasks (Falcon, BD, San José). At day 6 cells were CD4 (untouched) MACS-sorted and 
stained for CD3 (PerCP) and CD25 (APC). The fluorescent dye PE was not used due to 
possible overlapping into the CFSE channel. We sorted the cells according to their 
CFSE and CD25 expression presented in figure 19. 
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Figure 19 Scheme of fractions that were sorted due to their CFSE and CD25 
expression 
 
Subsequently inhibition assays were performed with autologous irradiated CBMCs 
and CD4+CD25- T cells in the presence of α-CD3, BLG L-0130, BLG [LF], Ara h 1, 
and without stimulus (control). In case of limited cell counts only TCR crosslinking was 
performed (α-CD3). 
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3.3.7 Treg Inhibition Assay 
The regulatory potential of cellular fractions can be assessed by adding an increasing 
numbers of cells (2.5×103 – 2.5×104 cells/well) to effector T cells defined as 
CD4+CD25− (Teff; 2.5x104 cells/well). Cell subsets alone (either only Tregs or Teff) as 
well as combined cells were stimulated with 250 ng/mL plate-bound anti-CD3 (UCTH1 
clone, Dako) or the respective antigen in the presence of autologuous, irradiated (3,000 
rad) CBMCs or PBMCs (5×104 cells/well), respectively. Proliferation was assessed with 
[3H]-thymidine incorporation assay on day 3 and 7. Inhibition is expressed as relative 
proliferation compared to the CD4+CD25- cells. 
 
3.3.8 Priming Assay  
The CD4+CD25- T cell subset was MACS-sorted as explained above and frozen. 
CBMCs were first stimulated with BLG L-0130, BLG [LF] or Ara h 1 (all [50 µg/mL]) 
in a 25 cm2 culture flask (BD Falcon) for 6 days. On day 6, the “allergen-primed” 
CD4+CD25+ Tregs were isolated via magnetic cell sorting (MACS) and inhibition 
assays were performed with the newly generated Tregs, together with the antigen-
inexperienced effector T cells (CD4+CD25-) ( Figure 20). 
 
 
Figure 20 Scheme of priming CBMCs 
Cord blood derived mononuclear cells were co-cultured with the antigen. At day six CD4+CD25+ T cells 
were MACS-sorted and an inhibition assay was performed with the CD4+CD25- (that had been frozen on 
day 0) with stimulation with anti-CD3, BLG L-0130 or BLG [LF]. 
 
 
d0 d6=d0 
• MACS-isolation of Tregs 
• Inhibition assay 
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3.3.9 RA Isolation 
RNA was isolated using the “GenElute Mammalian Total RNA Miniprep Kit” 
(Sigma Aldrich) according to the manufacturer’s instructions.  
The RNA content was measured with the NanoDropTM (ND-1000 spectrophotometer; 
(260/280 and 260/230 nm ratios)). NanoDrop delivers the most accurate result available 
with remarkable reproducibility together with only 1.5 µL sample needed. Especially 
for RNA measurement for Tregs this is crucial, as only very little RNA is extracted. 
Moreover no cuvettes and capillaries are needed.  
 
3.3.10  cDA Synthesis 
The RNA was reverse-transcribed applying “iScript cDNA synthesis kit” from 
BioRad according to the manufacturer’s instructions using oligo dT primers. For all 
experiments in this thesis 25 ng RNA was applied and reverse transcribed with the 
thermal cycler C1000 (BioRad). 
 
3.3.11  Semi-Quantitative Real-Time RT-PCR 
3.3.11.1 PCR Overview 
Polymerase chain reaction (PCR) allows exponential amplification of short (100 to 
600 bases) DNA sequences. PCR requires a pair of primers (~20 nucleotides) that is 
complementary to a defined sequence on each of the two strands of the DNA. DNA 
polymerase extends the primers by copying the designated sequence. As the same 
primers can be reused to amplify the DNA, theoretically a logarithmic amplification is 
the result. Quantitative RT-PCR can be sub-classified into three phases: Denaturation, 
Annealing and Extension. In the first phase, double stranded cDNA is separated at about 
90° C. In the annealing phase (50 to 60°C) specific primers can bind to the sample and 
in the expansion phase polymerases lead to an exponential amplification.  
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Figure 21 Diagram of single a PCR cycle 
in a Real- time PCR machine 
400
 
The X-axis shows the PCR cycle number and in the 
the copy number is plotted on Y-axis. The dotted 
threshold line is user-defined and used to determine 
the cycle threshold (Ct). The curve has a sigmoidal 
course with an exponential phase and a plateau 
phase. A negative control, the blue line, is performed 
with RNAse free water alone.  
 
A negative control (RNAse free water alone without template) and a positive control 
(a housekeeping gene, e.g. 18S) are always applied to have a blank value and a 
reference gene, respectively. 
SYBR® Green with its high fluorescence in the presence of double stranded DNA is 
used in this experimental setting. For validation, the samples are analyzed at the melting 
temperature. This is the temperature at which a DNA double helix dissociates into 
single strands to check for contamination, mispriming or primer-dimer artefacts (Figure 
22). 
 
Figure 22 Schematic Real-Time PCR with 
SYBR
®
 Green 
401
 
Schematic representation of real-time PCR (Denaturation - 
Annealing - Extension) with SYBR Green dye. SYBR Green 
dye (black rhomb) becomes fluorescent (green rhomb) upon 
binding to double-stranded DNA, providing a direct method to 
quantify PCR products. 
 
 
3.3.11.2 PCR Methodology Used 
The iQ SYBR Green Supermix (BioRad) together with QuantiTect primers were 
used. Primers (Qiagen) were dissolved in 1.1 mL nuclease-free water prior to use. After 
sealing each plate with a microseal “B” Heat sealing film (BioRad), a two step 
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temperature program was run on the RT-PCR machine CFX96 and recorded via the 
included software CFX manager vs. 1.1 (both BioRad). 
Thermal protocol used: 
95°C 2 min. Initial template denaturation (1x) 
95°C 15 sec. Cycled template denaturation 
60°C 1 min. Annealing/extension 
 
The stage at which the fluorescence crosses the threshold is called the cycle threshold 
(Ct). The lower the Ct value, the more copies are present in the specific sample. The 
mRNA expression levels were calculated using the [DELTA] Ct calculation. The 
relative expression of a target gene (e.g. FOXP3) was calculated based on the Ct 
deviation of this target gene versus the housekeeping gene: (Delta Ct sample = Ct gene 
(e.g. FOXP3) – Ct housekeeping gene (e.g. 18S). 
To compare expression of genes, the sample with the lowest amount of the respective 
gene was set as internal standard to 1, and relative expression was calculated as follows 
402: 
 
 
After 40 cycles the melting curve is checked using the following thermal protocol: 
60°C-90°C for 20 seconds (Figure 23).  
Figure 23 Melting curve for the 
housekeeping gene 18S 
The melting temperature of the amplicon 
occurs at 87°C. No contaminating products are 
present in this reaction. Contaminated DNA or 
primer dimers would show up as additional 
peaks. 
40x 
 
2−(∆Ct sample of interest-∆Ct lowest sample) 
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3.3.12  Expanding Tregs with CD3/CD28 Dynalbeads® 
Dynalbeads® are used to expand T cells since they provide both TCR signal and the 
co-stimulatory signal. When rIL-2 is present Tregs 
can expand properly. Dynalbead® CD3/CD28 T Cell 
Expander are 4.5 µm, super paramagnetic polystyrene 
beads coated with monoclonal antibodies against the 
CD3 and CD28 cell surface molecules of human T 
cells. Both antibodies are coupled to the same 
Dynalbead®, mimicking in vivo stimulation by 
antigen presenting cells. 
Tregs (CD4+CD25+ T cells) were isolated via 
MACS (Miltenyi Biotech) as described above. A 
CD4+CD25- and a CD3-cell depleted fraction were 
stored in liquid nitrogen. Those two fractions served 
as effector T cells and APCs, respectively, for the 
inhibition assay after the expansion. 
105 Treg cells were expanded according to the 
manufacturer’s protocol (Figure 24) using a cell: bead 
ratio of 1:4 in the presence of 500U/mL rIL-2 in UCC 
medium. Cells were held under strict control - 
medium /w 500U/mL rIL-2 was replenished and cells 
were split when needed.  
          Figure 24 Schematic Dynalbead
®
 expansion 
 
On day eight the Dynalbeads® were removed by a special Magnet (Dylan®) and re-
stimulated on day 15-18. Expanded Tregs were subjected to functional assays to 
evaluate their potential to inhibit mentioned activation using [3H]-thymidine 
incorporation assay.  
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3.3.13   Statistics 
For statistical evaluation non-parametrical tests were applied (in case of matched 
pairs Wilcoxon signed rank test otherwise Mann Whitney U-Test). In some cases t-tests 
(student t-test or matched pairs t-test) were performed if Gaussian distribution was 
given. For all analysis SPSS for WINDOWS Release 17.0.1 (SPSS Inc, Chicago, USA) 
or GraphPad Prism 4 for Windows (GraphPad Software, San Diego, CA, USA) was 
used. A p value of less than 0.05 was considered statistically significant and marked 
with an asterisk (*). P values of less than 0.01 and 0.001 were considered highly 
significant and marked with two (**) and three (***) asterisks, respectively. 
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4 RESULTS 
The thesis aims at showing the effect of endotoxin on allergen-specific responses in 
cord blood compared to adult blood. Moreover the effect of endotoxin and allergens on 
the generation of regulatory T cells and on neonatal tolerance induction has been 
observed. 
During the last years several studies could show a high rate of proliferation of 
various cell types (e.g. lymphocytes of the lamina propria, mononuclear cells of the 
peyer’s patches, PBMCs, CBMCs,….)  upon BLG 216-218, 403. This observation has 
raised increased interest for this effect in cord blood. Several explanations for this 
phenomenon exist. Firstly, the transplacental priming, where cells from the mother 
diffuse to the fetus and thence induce proliferation 404, 405. Secondly, thymic emigrants 
which represent a considerable fraction in cord blood proliferate in response to antigens 
with limited specificity before they become apoptotic 249.Thirdly, high amounts of 
endotoxins are present in commercially available BLG preparations 393 as well as in 
other allergens. This may contribute to the increased frequency of allergen-specific 
proliferation of cord blood derived T cells despite of limited exposure in utero. 
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4.1 The Impact of Endotoxin Contamination on Allergen-
Specific Responses in Cord Blood and Peripheral Blood 
4.1.1 LPS-Content in Allergens 
Initially, the LPS content of different allergen preparations/reagents used was 
measured via limulus amoebocyte lysate (LAL) assay. One endotoxin unit (EU), an 
entity to declare the LPS content, is a standardized unit of biological activity measured 
with the LAL test and calibrated to a reference endotoxin: 1 EU = 0.1 ng LPS. 
 
Reagents LPS-content (EU/mL) LPS-content (EU/well) 
BLG 3908 [100 µg] 515 103 
BLG 3908 (purified) 
[100µg] 
52.8 10.56 
BLG L-0130 [100 µg] 118 23.6 
BLG L-0130 
(purified) [100 µg] 
16 3.3 
BLG [LF] [100 µg] 0.95 0.19 
Ara h 1 [50 µg] <0.05 <0.05 
UCC 0.7 0.14 
TT [1 µg] 0.55 0.11 
rBet v 1 [100 µg] 
1.94 
(according to the producer) 
0.388 
Table 10 LPS-content (EU/mL) of various reagents 
Different reagents were tested for their endotoxin content with the LAL test. Removal with polymyxin B 
columns reduced the LPS content to a tenth (BLG purified). The generated BLG (BLG [LF]), which was 
intendend to be free of LPS contamination served as our LPS-free control. 
 
In the experimental settings different BLG formulations were utilized. BLG 3908 
and BLG L-0130 are commercially available BLG preparations purchased from Sigma-
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Aldrich. Conventional endotoxin removal strategies like polymyxin columns were able 
to reduce the endotoxin amount to a tenth (BLG 3908 and BLG L-0130 from 515 EU to 
52.8 EU and from 118 EU to 16 EU, respectively). However, there was still a 
considerable amount of endotoxin present (Table 10; BLG 3908 (purified) and BLG L-
0130 (purified)).  
Polymyxin B, a polycationic antibiotic, binds to the lipid A domain of the LPS and 
therefore neutralizes LPS and its biological and toxic effects 406, 407. This has been 
proven to be the most effective adsorption technique to deplete LPS, however 
significant protein loss during passage through the column has been noted (e.g. 20% for 
BSA (Mw 6.9 x 10
4)) even more pronounced when using a larger pore size (molecular 
mass exclusion of polysaccharide, Mlim >2 x 10
6; 78% for BSA) 408. 
A BLG preparation, virtually devoid of LPS was generated by Susanne Brix and 
Vibeke Barkhold (University of Kopenhagen) and published in 2003. It has been 
purified from raw milk as explained in detail in Brix et al (2003) 393 and in the methods 
section. This highly purified BLG was a generous gift and was used as LPS-free 
control. Upon re-evaluation it contained trace amounts of LPS (50 µg BLG/200µL ~ 
0.095 EU/well = ~ 0.01ng). According to literature which affirms that a level below 1 
EU has to be considered LPS-free [LF] 408. Based on various tests, we are confident that 
these low amounts do not induce biological effects and impact the outcome. 
The purified major peanut allergen Ara h 1 was chosen as an alternative food 
allergen containing endotoxin below the measurable threshold measured by LAL assay 
(threshold 0.035 EU).  
Recombinant birch allergen, rBet v 1, served as a representative for both inhalational 
allergen and recombinantly expressed protein. According to the producer the LPS 
content was in a similar low range as our BLG [LF] (0.95 EU/mL; table 10). 
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 (a) 
 
 
 
 
 
 
 
 
 
 
 
 (b) 
4.1.2 Defining Kinetics and Thresholds for LPS Sensing in CB 
Initially proliferation experiments were performed to define suitable read-out time 
points reflecting the peak of LPS-specific and allergen-specific responses (day 1- day 7; 
d1-d7) in cord blood using CBMCs. Inferentially two read-out time points were set. Day 
3 (d3) was chosen to serve representative for endotoxin-dependent proliferation and day 
7 (d7) for allergen-specific responses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Defining a threshold of CBMCs to LPS at a proliferation and a cytokine 
level 
CBMCs were isolated and co-cultured with LPS in limiting dilution. At two defined read-out points (72h 
(day 3) and day 7) proliferation (a) and TNF-α production (b) was measured with [3H]-thymidine 
incorporation assay and ELISA, respectively. 
(Proliferation n=8; TNF-α measurement n=5; Mean +/- SEM). A stimulation index >2 was considered 
positive. 
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Limiting dilution of LPS revealed a critical amount of approximately 1 ng LPS (~10 
EU) to induce a positive proliferation response. This threshold has been defined by a 
stimulation index >2 measured by [3H]-thymidine assay. However, it became apparent 
that a 10-fold lower concentration affects the proliferation outcome too (Figure 25 (a)). 
TNF-α, an important proinflammatory cytokine, was used as a read-out parameter 
for LPS induction. At a level of 0.07 ng LPS (~0.7 EU) TNF-α was measured via 
ELISA and therefore this amount was set as critical amount to induce cytokine 
production being relevant for a cellular system measured in cord blood (Figure 25 (b)). 
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4.1.3 Allergen- and LPS-Specific Proliferation of Cord Blood 
Mononuclear Cells 
Dose response experiments applying allergen concentrations from 0.1-50 µg/mL and 
the corresponding LPS-content were assessed to define the explicit relevance of 
different amounts of contamination present. The relevance of LPS in BLG preparations 
used is shown in figure 26.  
 
 
 
 
 
 
 
 
 
Figure 26 Relevance of LPS contamination in BLG preparations used 
The LPS contamination of BLG [LF] is below the level of TNF-α detection (red permanent line; 0.7 
ng/mL). The limit of detection for the limulus assay is at 0.035 ng/mL and very sensitive. Hence, BLG 
[LF] can be used equivalent to LPS-free BLG as even the highest concentration does not induce TNF-α 
production and only 5 µg/mL allergen can be detected via limulus assay.  
 
BLG L-0130 (“contaminated”, un-purified allergen) induced a proliferative response 
on CBMCs as opposed to purified BLG (BLG [LF]) at day 3 and day 7. This effect 
disappeared at the highest applied concentration at day 7 (Figure 27 (a)). By adding an 
identical LPS-amount that was present in the un-purified BLG L-0130 to the purified 
allergen (BLG [LF]), the proliferative response could be restored and the proliferation 
profile was similar to the LPS contamination alone. A significant difference between 
contaminated allergen (BLG L-0130) and LPS spiked purified allergen (BLG [LF] 
could only be observed between the lowest concentrations (Figure 27 (a)). 
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Figure 27 The impact of endotoxin contamination on allergen-specific proliferation 
of cord blood mononuclear cells 
Cord blood-derived mononuclear cells were co-cultured with different food allergens (BLG, Ara h 1) 
either in its contaminated form (BLG L-0130) (a), its purified form (BLG [LF]; Ara h 1(b)) or with LPS 
matching the degree of contamination present in the respective contaminated allergen [BLG L-0130]. The 
calculated amount of endotoxin contamination present served as internal control (contamination) (BLG: 
n=13; Ara h 1: n=7; camel caseinate (c): n=3; mean±SEM) 
*
p<0.05 purified allergen+LPS vs purified allergen; #p<0.05 contaminated allergen vs purified 
allergen+LPS; □p<0.05 contaminated allergen vs purified allergen; op<0.05 LPS contamination vs 
purified allergen).  
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The exact same pattern was observed using Ara h 1 (Figure 27 (b)). Here the LPS 
dependent effect is even more striking. The LPS-spiked pure Ara h 1 showed an almost 
identical proliferative pattern when compared to LPS contamination alone. A significant 
difference could be observed between spiked allergen and contamination alone when 
compared to the purified Ara h 1. Again, the significant differences disappeared only at 
the highest concentration.  
Camel caseinate was chosen as irrelevant allergen since exposure is extremely 
unlikely. Camel caseinate itself did not induce a proliferation ( SI >2) neither on day 3 
nor on day 7. However, spiking with LPS significantly affected the proliferation on day 
3 and on day 7. A positive stimulation index could be observed at day 3 at the highest 
concentration (Figure 27 (c)). 
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4.1.4 Cytokine Induction by Different BLG Preparations in CB 
As a next step various cytokines (IL-1β, IL-5, IL-10, IL12p70, IFN-γ, TNF-α) were 
measured in different BLG preparations.  
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Figure 28 Cytokine pattern of CB after stimulation with different BLG 
preparations 
The cytokine pattern was determined in CBMCs in the presence of different BLG preparations (BLG 
3908, BLG [LF]) and measured via cytometric bead array technology (Flex kit; BD) at day 3 and day 7. 
The graph represents data from one out of three independent experiments. 
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Supernatants of CBMCs stimulated with contaminated (BLG 3908) and purified 
BLG (BLG [LF]) were harvested on day 3 and day 7. Cytokine production was 
measured with cytometric bead array (Flex kit, BD) at both read-out time points. 
Contaminated BLG (3908) led to an increased cytokine production; particularly of 
IFN-γ, IL-1β, and TNF-α on day 3 and day 7. In contrast. purified BLG [LF] did not 
induce cytokine production neither on day 3 nor on day 7 (Figure 28) indicating that 
only the contamination but not the allergen per se had a significant impact on cytokine 
production. 
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4.1.5 Proliferative Responses are Significantly Higher in Cord Blood 
than in Peripheral Blood from Adult Donors 
To evaluate the relevance of these findings for adult blood, PBMCs of healthy adult 
donors without a clinically relevant allergy to milk proteins (IgE, and skin prick test 
negative) were stimulated with BLG and LPS.  
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Figure 29 Proliferative responses to allergen and allergen plus endotoxin are 
significantly higher in cord blood than in peripheral blood from adult donors 
Proliferative responses to allergen and allergen plus endotoxin are significantly higher in cord blood 
(green) than in peripheral blood (red) from adult donors. The impact of endotoxin contamination is 
significantly stronger in CB (green) as compared with PB from adult donors (CB: n=17; PB: n=10).  
Graph indicates the mean +/- SEM. 
 
Purified allergen (BLG [LF]), and BLG [LF] + LPS were used. BLG [LF] + LPS 
emulates the contamination present in the BLG L-0130 preparation.  
In all experiments, CBMCs showed a significantly higher proliferative response to 
purified as well as spiked allergen. Again, a distinct influence of endotoxin on 
proliferation was detectable in cord and peripheral adult blood (Figure 29). However, 
any effect of allergen alone remained detectable at day 7. 
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4.1.6 rBet v 1, Representative for Inhalational Allergens, Affected the 
Proliferative Response of PBMCs and together with LPS also 
CBMCs 
In order to evaluate the relevance of endotoxin contamination in response to an 
inhalantional allergen, the recombinant major birch pollen allergen rBet v 1 was chosen. 
CBMCs and PBMCs of non-allergic donors (IgE- and skin prick test-negative) were 
stimulated with titrated concentrations of rBet v 1 in the range of 0.1–50 µg/mL. No 
proliferative response was detected in CBMCs (Figure 30 (a), green line) whereas rBet 
v 1 induced proliferation in PBMCs from three out of six non-allergic donors (Figure 30 
(a), red line). Based on dose response experiments a concentration of 10µg/ml was 
chosen for proliferation assays to investigate the impact of LPS. rBet v 1 was spiked 
with 10 fold increasing concentrations of LPS starting from 20 pg/mL up to 20 ng/mL. 
While CBMCs responsed already in the presence of 200 pg LPS/mL, PBMCs only 
displayed a trend towards an impact of LPS within that range that did not reach 
statistical significance.  
 
 
 
 
 
 
 
 
Figure 30 Allergen-specific proliferation of PBMCs and CBMCs to rBet v 1 
Cord blood (CB; green) and peripheral blood (PB; red)-derived mononuclear cells were co-cultured for 3 
and 7 days with the recombinant Bet v 1 (20 pg endotoxin/10 µg rBet v 1). Three out of six PBMC 
samples proliferated in the presence of the allergen at a concentration of 10 µg/mL. None of the CB-
derived samples did (0/6) (a). Contamination at the relevant concentration of 10 µg/mL did not affect 
proliferation, neither in CB nor in adult blood (b). (n=6 independent experiments CB and PB; results are 
expressed as mean+/-SEM).  
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4.1.7 A Recall-antigen, Tetanus Toxoid (TT), together with LPS, 
Induced Proliferation in PBMCs on Day 7 
To investigate the impact of endotoxin contamination on a more Th1 type memory 
response, tetanus toxoid (TT), a recall-antigen, was chosen as a model antigen.TT was 
initially proven (via certificate and via internal limulus control) to contain endotoxin 
below the limit of relevance (Table 10; 0.55 EU/1 µg TT). A sub-maximal dose of 1 
µg/mL TT was spiked with increasing levels (0.35 – 350 ng/mL) of endotoxin 
corresponding to the amount of contamination present in BLG (3908).  
TT + LPS (even at the lowest concentration of 0.35 ng/mL) induced a proliferative 
response of PBMCs at day seven (red lines) compared to TT alone, that only induced a 
positive stimulation index (SI) on day 7. The highest amount of endotoxin added to the 
TT did not additionally increase the proliferative response significantly compared to TT 
or LPS alone (Figure 31). This is most likely due to the fact that kinetics is modified by 
the presence of endotoxin. At day 3 (black lines) spiking did not modify proliferation. 
TT alone could not increase proliferation. 
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Figure 31 Low level LPS contaminants affect proliferative response to Th1 type 
recall-antigen TT at day 7 in adult individuals 
Tetanus toxoid was applied at a constant concentration of 1 µg/mL and LPS was added according to the 
amount present in contaminated Sigma BLG (BLG 3908, Sigma). At day 3 (black lines) no effect on the 
read-out parameters was measurable whereas on day 7 (red lines) significances were detected. Graph 
indicates the mean and the standard error of the mean (n=6). 
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4.1.8 Immunomodulatory Properties of Un-puriﬁed BLG Relate to 
High Molecular Weight Fractions 
To determine the size of immuno-reactive components within the contaminated BLG 
sample [BLG L-0130], size exclusion chromatography (SEC) was performed and 18 
sub-fractions were gained (Figure 32 (a)). The high molecular weight fractions (fraction 
1-3; F1-3; >100kDa) are most likely to represent the endotoxin fraction, whereas the 
medium weight fraction (Fraction 5-6, F5-6, ~36kDa) most probably corresponds to be 
the dimeric BLG fraction. 
At day 3, only the high molecular weight fraction, represents the endotoxin-fraction 
(F1, F2), induced a positive proliferative response (Figure 32 (b), upper panel), whereas 
at day 7 the BLG-corresponding fraction (F5 and F6, representing BLG dimers) also 
induced clonal expansion (Figure 32 (b), lower panel). This ﬁnding is in accordance 
with our previous experiments. 
Extremely low amounts of LPS induce a positive proliferative response (Figure 25 
(a)). Assuming a BLG-content of more than 90%, an at least 100-fold higher potency 
can be attributed to the high molecular weight, endotoxin-contaminated fraction. 
Puriﬁed BLG [LF] and the BLG-corresponding fractions (F5, F6) did not induce 
significant cytokine production (Figure 32 (c)). In contrast, the contaminated BLG-
fraction stimulated cytokine production substantially at very low doses suggesting an 
innate immunity-driven response as refleced by the LPS-titration results (Figure 25).  
 
  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
0.25
0.5
1
2
4
8
16
32
64
S
I
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
0.25
0.5
1
2
4
8
16
32
64
Fractions
S
I
Day 3 
Day 7 
(b) 
(a) 
Results 
98 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 High molecular weight fractions and endotoxin fractions induce 
proliferation 
High molecular weight fragments isolated by size exclusion chromatography (a) led to a BLG-
independent proliferative response of CBMCs (Wilcoxon signed rank test (b)). Dose response 
experiments of high molecular contaminants and dimeric BLG revealed - despite of > 90% purity of the 
BLG preparation - a more than 10-times higher potency of the contaminants (c). Dots represent data from 
seven independent experiments (*P<0.05; Wilcoxon signed rank test). The fractions 1 and 2 (F1; F2) are 
representative for the endotoxin contamination whereas fraction 5 and 6 (F5, F6) equal the dimeric BLG. 
Graph indicates 7 independent experiments (n=7). 
(c) 
Results 
99 
 
4.1.9 Un-purified BLG Acts via a Toll-like Receptor 4 Dependent 
Mechanism 
To investigate the involvement of the most prominent receptors for endotoxins 
(TLR-4) and to delineate whether LPS is mainly responsible for the described effects, 
an assay using TLR-2 and TLR-4 transfected HEK293 (Human embryonic kidney 
cells)-cells (generated and kindly provided by the group of M. Yazdanbakhsh; Leiden 
University Medical Center, The Netherlands) was applied. IL-8 was used as read-out 
cytokine as it is produced in response to LPS.. TNF-α and LPS were used as a positive 
control for TLR-4 transfected cells 409, 410, whereas TNF-α and Pam3Cys (a TLR-2 
ligand) for TLR-2 transfected cells. Medium alone was set as a negative reference 
value.  
The contaminated BLG initiated a robust IL-8 response via a TLR-4 dependent 
mechanism but had no effect in TLR-2 transfected cells (Figure 33). On the other hand 
the BLG [LF] induced IL-8 production neither on a TLR-2 nor in the TLR-4 transfected 
cells (Figure 33). 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 Contaminated BLG leads to a TLR-4 dependent release of IL-8 
HEK293 cells, stably transfected with an expression vector for human CD14 and TLR-4 (293-
hCD14/TLR-4) or CD14 and TLR-2 (293-hCD14/TLR-2). Concentration of IL-8 was used as the read-
out parameter and measured via ELISA (Endogene) (n=4, two independent experiments). 
This experiment has been carried out by Irma Schabussova at the Experimental Pathology, Medical 
University of Vienna. 
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To further investigate the relevance of TLR-4 in an in vitro system with all innate 
immunity receptors co-expressed, inhibition assays with anti-TLR-4 antibodies were 
performed on CBMCs. Ultra-pure LPS (LPS UP; S. minnesota; stem R595), BLG L-
0130, BLG [LF], and BLG sub-fractions generated by size exclusion chromatography 
were tested. Ultra-pure LPS induced a strong TNF-α production which was significantly 
inhibited by TLR-4 blockade. The same effect could be observed with BLG L-0130. 
TNF-α could be strongly induced but was significantly reduced by TLR-4 antibodies. 
No TNF-α production was induced by the pure BLG [LF]. The high molecular weight 
fraction (F1; Figure 34) acted via TLR-4, while the putative BLG-dimer (F5) did not 
induce TNF-α production (Figure 34). 
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Figure 34 BLG-related TF-α production is TLR-4 dependent and related to high 
molecular weight contaminants. 
Cord blood derived monocytes were pre-incubated with TLR-inhibitory antibodies or the respective 
isotype control (α-TLR-4, IgG2a [1 µg/mL]) for 1 hour. Thereafter allergens (BLG, Ara h 1), from 
fractionated Sigma BLG (L-0130 no endotoxin removal procedure) or the positive control (LPS ultra 
pure, Salmonella minnesota R 595 [0.1 µg/mL]) were added. TNF-α production was measured in the 
supernatant (n=6). 
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4.2   Regulatory T cells in the Presence of Allergens and LPS 
4.2.1 Proliferative Responses to BLG are Augmented in Cord Blood 
Compared to Adult Blood due to Significantly Reduced 
Inhibitory Capacities of CD4
+
CD25
+
 Cells 
A generally higher proliferation level has been observed in CBMCs than in PBMCs 
from adult donors (Figure 29) 252, 411. BLG is considered to induce the highest frequency 
of responses. At day 7 CFSE stained CBMCs proliferated strongly upon the 
contaminated BLG L-0130 where the surface marker CD25 was up-regulated. However, 
the LPS-free BLG [LF] per se did induce a positive proliferative response as well, when 
compared to the negative control (medium alone, Figure 35).  
 
 
 
 
 
 
 
 
 
 
Figure 35 Proliferation and CD25 expression upon stimulation with an un-
purified, a purified BLG, and negative control 
CFSE stained CBMCs were incubated for 6 days in the presence of BLG L-0130 (un-purified; (a)), BLG 
[LF] (b) and with medium alone (negative control; (c)). One out of six representative experiments. 
 
To assess whether the reasons for this altered responses in cord blood could be 
explained by immature regulatory T cells in cord blood, the inhibitory capacity of CB-
derived CD4+CD25+ Tregs were compared to those from adult blood (Figure 36).  
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Freshly isolated cells PB-derived CD4+CD25+ regulatory T cells possessed dose 
dependent inhibitory properties when co-cultured with the effector T cells (CD4+CD25-) 
at a ratio of 1:5 (data not shown) and 1:2. This effect could be observed by adding BLG 
L-0130 ((a) 70.43%+/-89.38; mean+/-SD (1:10) and 25.25%+/-19.71) or plate-bound α-
CD3 ((b) 76.86+/-51.98+/-51.98 (1:10) and 46.15%+/-24.22 (1:2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Suppressive potential of CD4
+
CD25
+
 Tregs from CB and PB 
Mononuclear cells were freshly obtained. CD4+CD25+ T cells from CB and PB were isolated via MACS. 
Inhibition experiments were performed by adding the Treg fraction (CD4+CD25+ cells) to the CD4+CD25- 
fraction in increasing amounts in presence of irradiated APCs. The PB-derived CD4+CD25+ fraction 
possessed a dose dependent inhibitory effect (red) (a-c) while CB-derived CD4+CD25+ cells did not 
(green) (d-e). The inhibitory potential is expressed as relative proliferation compared to the CD4+CD25- 
cells alone. Graphs indicate the means of 6 independent experiments +/- SEM for PB and CB and 11 
independent experiments +/- SEM for the peripheral blood of children <4a. Wilcoxon sign rank test was 
applied. P-values of less than 0.05 were considered significant. 
 
CB-derived CD4+CD25+ regulatory T cells were significantly less potent (Figure 36, 
BLG L-0130 ((d) 111.98%+/-84.13; mean+/-SD (1:10)) and α-CD3 ((e) 122.42%+/-
89.62 (1:10)) - (d) 105.14%+/-54.49) and ((e) 130.91%+/-17.39, respectively). 
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Regulatory T cells alone were hypoproliferative per se. Only a low cell growth in PB 
and CB could be observed ((a) 5.14%+/-5.34; (b) 18.15%+/-25.62; (c) 17.17%+/-21.46; 
(d) 16.70%+/-14.52; (e) 50.03%+/-29.98). In addition the regulatory properties of 11 
children with a mean age of 3.86 years were assessed in the presence of plate-bound α-
CD3 the Treg fraction exhibited an inhibitory potency as potent as those from adult 
cells (38.15%+/-48.4 at a ratio of 1:2 (c)). 
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4.2.2 Upon Priming with CD3CD28 Beads, Cord Blood Derived 
CD4
+
CD25
+
 T Cells become Highly Suppressive 
Development of tolerance to a huge number of environmental antigens has to take 
place within a short period of time after birth. Iin vitro priming assays simulating this 
procedure were conducted. Initially functional Tregs were generated via in vitro Treg 
differentiation assays to prove the validity of the system and the functionality and 
possibility of expansion of cord blood derived CD4+CD25+ cells with conventional Treg 
generation and expansion protocol.  
 
 
 
 
 
 
 
 
 
 
Figure 37 Dynalbead inhibition assay 
Cord blood derived Tregs (CD4+CD25+) were stimulated with CD3CD28 Dynalbeads in the presence of 
IL-2 for 2 weeks. After this expansion time, this subset became highly suppressive in an inhibition assay. 
The inhibitory potential is expressed as relative proliferation compared to the effector T cells 
(CD4+CD25-) cells. Graphs indicate one out of three independent experiments. 
 
Upon TCR cross-linking in the presence of the co-stimulatory molecules CD3 and 
CD28 and rIL-2 for 2 weeks this subset expanded and became highly inhibitory (Figure 
37). A 92.62% decrease in proliferation was measured at a ratio of 1:2 in the presence of 
BLG L-0130 and 92.94% in the presence of purified BLG [LF]. The regulatory T cell 
subset alone was also highly hypo-proliferative and only showed a 1.32% and 2.83% 
proliferation, compared to the effector T cells. 
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4.2.3  Expression Profile of CBMCs and to PBMCs on Day 0 
Surface (CD25, CD45RA, CD45RO, CD69, CD127) and intracellular marker 
expression (CTLA-4) for CB (green) and PB (red), was analyzed by flow cytometry at 
baseline (Figure 38).Percentages indicate mean +/- SD of CD3+CD4+ cells from 3 or 4 
independent experiments. 
In cord blood, nearly all cells express the naïve CD45RA marker (93.33% +/- 1.11), 
whereas in PB cells only 54.39% +/- 3.56; (mean+/-SD) express CD45RA. The 
memory/effector marker CD45RO on the other hand is expressed on CB in only 1.44% 
+/- 0.44 of all CD3+CD4+ cells as opposed to 17.39% +/- 5.25 in PB. CD45RA/RO 
double positive cells occur in 4.48% +/-1.61 in CB compared to 24.68% +/- 3.16 in PB. 
Observing the CD127lowCD25+ expression cells were gated on a clearly separable 
population being the most likely to comprise the Treg compartment. Not an ample 
difference was observed comparing the percentages of CB and PB (8.11% +/- 2.23 vs 
6.49 +/- 0.36, respectively). Notwithstanding, differences in the scatter dot blot could be 
monitored. In PB an altered cell distribution could be observed in cells expressing 
CD127hiCD25+.  
As the protein CTLA-4 is primarily localized in intracellular vesicles, cells had to be 
permeabilized before staining. The percentages of CTLA-4+CD25+ T cells however, 
most likely to represent the Treg subset, did not differ much in percentages (6.59% +/- 
3.65 and 5.78% +/- 3.56, respectively) but distribution differences are present.  
CD69, a surface molecule, appears to be one of the earliest indicators for leucocyte 
activation. These unstimulated cells did show a very low percentage of CD69 
expression on day 0, neither in CB nor in PB. 
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Figure 38 Cytometric analyses of CB and PB derived CD4
+
 T cells 
Representative scatter dot plot analyses of CD3CD4 gated lymphocytes. Quadrant markers were set to the 
isotype control. Surface and intracellular markers were stained and measured via flow cytometry (FACS 
Calibur, BD, San José). These figures represent one out of 4 independent experiments. Means +/- SD are 
menioned above. 
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4.2.4 Recent Thymic Emigrants in Cord and Peripheral Blood 
Recent thymic emigrants are a subpopulation of naïve T cells with a high content of 
TRECs. As they do not replicate they dilute out during cell division. The RTEs and the 
homeostatic proliferation of T cells compromise the total naïve T cell pool. For that 
reason RTE are an excellent tool to quantify the naïve T cell pool of cord and peripheral 
blood and to check which cells proliferate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 Gating strategy for RTE 
Two different gating strategies to identify the percentage of recent thymic emigrants (RTE) were applied. 
Mononuclear cells were isolated and stained with the CD4+ Recent Thymic Emigrant Enumeration Kit 
(Miltenyi Biotech) that contains antibodies against CD4 FITC, CD31 PE, CD45RO PerCP, and CD62L in 
APC. Firstly the CD4+ cells were gated (a). Within gating strategy A, CD31+CD62L+ RTE can be easily 
distinguished out of the CD4+ population (b and c). For gating strategy B, naïve cells could be defined by 
CD45RO- expression (e and f) and RTE could be easily detected (g and h). 
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In this experiment two different gating strategies were applied (Figure 39) because 
they differ slightly in their outcome. However, with both gating strategies a significant 
difference of RTE between CB and PB could be observed. CB (green) has a generally 
much higher content of RTE (92.19 +/- 6.83 (mean +/- SD) with gating strategy A 
(Figure 40 (a)) and 83 +/- 2.67 with gating strategy B (Figure 40 (b)) compared to 
peripheral blood (red; 73.09 +/- 5.54 and 35.26 +/- 6.94, respectively; Figure 40 (a and 
b)). 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 Percentage of RTE in CB and PB 
Cells were gated on using the gating strategy A for (a) and B for (b). A significant difference between the 
CB (green)- and the PB (red)-derived RTE could be seen with both gatin strategies (n=3-4). 
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4.2.5 Insufficient Control of Antigen-Specific Proliferative Responses 
in Cord Blood by Tregs cannot be Explained by a Lower 
Frequency of FoxP3
+
CD4
+
CD25
high
 Cells 
To investigate whether CD25+CD4+ T cells in cord blood differ from those in 
peripheral blood with regard to FoxP3-expression, the most important Treg transcription 
factor in Tregs. Intracellular FoxP3 staining was performed on CBMCs and PBMCs 
(Figure 41 (a) for gating strategy and (b) and (c) for FoxP3 expression) and measured 
via flow cytometry. (The purity of MACS-isolated Tregs was always >95%.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Gating strategy for FoxP3 expression 
Characterization of FoxP3 expression: PBMCs stained with anti-CD4 FITC, anti-FoxP3 PE, anti-CD3 
PerCP and anti-CD25 APC. A minimum of 50,000 events were collected to display clearly separable 
subpopulations. In Figure (a), gates for the top 2% of CD25, CD4+CD25high cells and CD25+ T cells are 
shown. In Figure (b) and (c) the gating strategy are presented for the isotype control as well as for 
identifying FoxP3+CD25highCD4+ T cells, respectively. When back gated, it can be observed that all 
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CD25+CD4+ T cells are FoxP3+ (d) and (e). CD4+CD25- T cells do not express FoxP3 (green square) 
whereas CD4+CD25high putative regulatory T cells do so (blue square). 
 
Importantly, when different gating strategies were used, different levels of FoxP3 
could be calculated with a differing outcome. Using the gating strategy of Grindebacke 
et al. (2009) who gated the top 2% of CD4+CD25+ T cells 412 (Figure 42 (a and b), 
FoxP3 expression in cord blood was decreased (50.02+/-21.58) compared to adult blood 
(59.48+/-34.12) but not significantly (Figure 42 (c); Gating strategy 1; mean+/-SD). 
 
  gating strategy 1            gating strategy 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Comparison of two different gating strategies for quantifying FoxP3 
For both gating strategies only CD3+CD4+ T cells were put into account. For gating strategy 1 
(Grindebacke et al 2009) the top 2% ((a1) for CB and (a2) for PB)) of CD4
+CD25+ T cells were gated and 
FoxP3+ cells ((b1) for CB and (b2) for PB)) were visualized (c). For gating strategy 2 ((d1) for CB and 
(d2) for PB)) CD4
+ T cells that were CD25+FoxP3+ were acquired (e). The upper panels (a1, b1, d1) 
represent cord blood and the lower panels (a2, b2, d2) peripheral blood derived FACS scatter.  
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However, when gating on FoxP3+CD25+ T cells (Figure 42 (e)), CB-derived cells 
seem to have a higher FoxP3 level (5.97+/-1.7) than PB derived cells (5.65+/-0.74) 
without a statistically significant difference (Gating 2; mean+/-SD). 
To check whether pre-exposure to the allergen increases FoxP3 CBMCs were 
exposed to BLG L-0130. An increase of FoxP3+ cells was observed for both gating 
strategies (1 and 2) for CB (87.23+/-13.72 and 7.3+/-1.3, respectively) and PB (81.92+/-
11.29 and 5.97+/-1.37, respectively) over time. Statistical significance was only 
obtained when gating strategy 1 was applied. However, when comparing CB and PB at 
day 0 and day 6 no statistically significance could be found (Figure 43 (a) and (b)). 
 
Gating Strategy 1           Gating Strategy 2 
 
 
 
 
 
 
 
 
 
 
Figure 43: FoxP3 expression in cord compared to peripheral blood 
FoxP3 and CD25 expression was measured via flow cytometry at day 0 and day 6, after CBMCs and 
PBMCs were cultured with BLG L-0130 [50 µg/mL] or medium alone. Two different gating strategies 
were applied (Gating strategy 1, Figure 42 (a) and Gating strategy 2, Figure 42 (b)). In cord blood the 
BLG L-0130 addition leads to a significant increase of FoxP3 expression when compared to day 0 with 
gating strategy 1 (a) but not with gating strategy 2 (b). In peripheral blood we could not detect any 
statistically significant increase in FoxP3 expression (a) and (b). No significant difference was detected 
between CB and PB on day 0 or on day 6 (a) and (b).  
Results are representative for 4 (day 6 CB and PB), 5 (day 0 PB), and 7 (day 0 CB) independent 
experiments and show means +/- SEM. 
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Moreover, differences, regarding the intensity (MFI; mean fluorescence intensity) of 
FoxP3 expression, were investigated (Figure 44). No Significant differences could be 
found (day 0; CB vs PB; 41.06 +/- 19.81 vs 57.85 +/- 48.18; means+/-SD).  
Summing up, neither the frequency, nor the density (MFI FoxP3 in CD4+CD25+ cells 
of FoxP3 expression) differed significantly between CB and PB on the protein level. 
 
 
 
 
 
 
 
 
 
 
Figure 44 MFI of FoxP3 expression of CB compared to PB 
Kinetic experiments were performed. The mean fluorescence intensity of FoxP3 was measured via flow 
cytometry at day 0, day 2, day 4, and day 6, after CBMCs and PBMCs were cultured with BLG L-0130 
[50 µg/mL]. No significant differences were detected between CB and PB or between different time 
points. The results are representative for 4 (day 6) to 7 (day 0) independent experiments and show the 
means +/- SEM. 
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4.2.6  o indication of Differences of FoxP3, GARP, TGF-β, IL-10, 
RUX 1, or RUX 3 Expression 
To investigate potential differences in more detail, FoxP3 and other Treg associated 
proteins, such as GARP, TGF-β, IL-10, RUNX 1, and RUNX 3, were assessed via 
quantitative real-time PCR (Figure 45). Cord blood and peripheral blood derived 
CD4+CD25- T effector cells and CD4+CD25+ regulatory T cells were MACS-sorted. 
Quantitative RT-PCR was performed to measure the content of the Treg associated 
genes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45 Constitutive FoxP3, GARP, TGF-β, RUX 1, RUX 3, and IL-10 
expression in cord blood and peripheral blood 
T effector cells (Teff; CD4+CD25-) and T regulatory cells (Tregs; CD4+CD25+) were isolated via MACS 
sorting from freshly isolated CBMCs or PBMCs. FoxP3, GARP, TGF-β, IL-10, RUNX 1, and RUNX 3 
were measured via qRT-PCR. CB-derived cells are displayed with white (Teff) and black (Tregs) squares, 
whereas PB-derived cells are illustrated with white (Teff) and black (Tregs) dots. Results are 
representative for 3 independent experiments showing the normalized expression. 
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4.2.7 The CD25+CD127low Compartment Harbours a Regulatory T 
Cell Subset with Limited et Suppressive Effect  
CD127 has been ascribed to be an excellent marker for Treg characterization in 
general. Recently, the suppressive capacity of CD4+CD25+CD127low/− Tregs in cord 
blood has been linked to the development of food allergy later on 213, 249. The CD127low 
fraction was purified by means of FACS-sorting from the CD25high and CD25int fraction 
to check for the importance of CD127 down regulation for Treg function. Three cell 
fractions (CD4+CD25highCD127low, CD4+CD25intCD127low and CD4+CD25intCD127high) 
with a putative suppressive capacity and one cell fraction (CD4+CD25-) representing T 
effector subset were obtained (all fractions had a purity of >99%; Figure 46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: Gating strategy for obtaining CD4
+
CD25
+/-
CD127
hi/low 
T cells® 
3 subgroups, CD4+CD25hi, CD4+CD25int and CD4+CD25- T cells were obtained (a). The CD4+CD25int 
fraction was further divided into two more fractions, according to their CD127 content (F2 (low), F3 
(high)) (c).  
CD3 
C
D
1
2
7
 
CD25 
C
D
1
2
7
 
CD25 
C
D
2
5
 
Teff 
Fraction 1 
Fraction 2 
Fraction 3 
(a) 
(c) 
(b) CD127hi 
 
CD127low 
 
CD127low 
 
    CD4CD25hi 
 
    CD4CD25int 
 
    CD4CD25- 
 
Results 
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Impact of CD127 on suppressive function of cord blood derived Tregs 
Frehly isolated CBMCs were FACS sorted, and gated as shown in figure 46. Subsets of CB 
(CD4+CD25highCD127low and CD4+CD25intCD127low) expressed inhibitory potential (a,d,g,j) and 
(b,e,h,k), whereas the CD4+CD25intCD127high subset even increased proliferation (c,f,i,l). The inhibitory 
potential is expressed as relative proliferation compared to the effector T cells (CD4+CD25-) cells alone. 
Graphs indicate the means of 1-4 (1: for BLG [LF] F1 and F3 1/10; 2 for BLG [LF] F1, F3 1/2and F 
alone, all Ara h 1 and all OVA; 3 for BLG L-0130 F1-F3 1/10, BLG [LF] F2 1/10; 4: BLG L-0130 F1-F3 
1/2 and F alone, BLG [LF] F2 1/2 and F alone) independent experiments +/- SEM. 
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Subsets with low CD127 expression (CD4+CD25highCD127low and 
CD4+CD25intCD127low) possessed inhibitory potential (Figure 47 (a,d,g,j) and (b,e,h,k)) 
and very limited proliferative potential (9.25+/-4.35 and 8.75+/-6.08, respectively). 
On the other hand, the fraction with high CD127 expression (F3; 
CD4+CD25intCD127high) even increased proliferation (Figure 47 (c,f,i,l)). At a ratio of 
1:10 166%+/-126.81 and at a ratio of 1:2 even 223%+/-341.62). Hence it did not exhibit 
any suppressive potential at any ratio. Moreover, fraction 3 alone was not hypo-
proliferative either ((c); right; 115.75%+/-154.98). 
The same trend (suppressive potential of CD127low fractions and proliferative 
potential of CD127high fractions) can clearly be observed at the fractions stimulated with 
BLG [LF], Ara h 1, as well as with Ova (Figure 47 d-l). 
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4.2.8 FoxP3, TGF-β, and IL-10 mRA Expression is not Substantially 
Up-regulated in the Regulatory Subsets 
Sorted fractions were checked for expression of FoxP3 and regulatory cytokines IL-
10 and TGF-β. FoxP3 was enormously increased in all three fractions (F1, F2, F3) 
compared to the effector T cell subset (a). In all experiments the FoxP3 level for the 
Teff fraction was below the limit of detection. No difference could be observed between 
the three fractions (F1-F3), although F3 showed a slightly reduced FoxP3 expression, 
however with a large standard deviation (160.21+/-255.37; Figure 48 (a)). 
The TGF-β mRNA level was not substantially up-regulated in all three fractions. A 
minor reduction of  TGF-β level could be observed in the Teff subset (Figure 48 (b)). 
The IL-10 mRNA level in the F1 fraction was the highest (716.26+/-883.17), 
although with a high standard deviation. Comparing Teff and F3 with F2, an eminent 
difference could be observed (15.71+/-16.24 and 15.68+/-3.63, respectively Figure 48 
(c). 
 
 
 
 
 
 
 
 
 
Figure 48: Relative expression of regulatory cytokines 
CBMCs were gated on CD3+CD4+ cells and then FACS sorted according to their CD25 and CD127 
expression (see figure 46) and analyzed with real-time PCR. As FoxP3 expression for Teff was below the 
limit of detection, the deltaCT value was calculated as follows: 40 (cycles used) – cycle of 18S. Results 
are representative for 3-4 independent experiments showing the normalized expression of means+ SEM. 
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4.2.9  Cord blood derived CD4+CD25+ T cells become Functional 
Tregs upon Stimulation 
Since multiple publications demonstrated the inhibitory properties of the cord blood 
derived CD4+CD25+ subset in the context of a pre-activation system, the relevance of 
allergen exposure on functional activation of Tregs and the impact of endotoxin on the 
efficiency of this process was investigated. After a six day exposure of CBMCs to BLG 
in the presence or absence of LPS, CD4+CD25+ cells were isolated. Their inhibitory 
potential on α-CD3, BLG L-0130, and BLG [LF] induced proliferation of autologous 
CD4+CD25- cells was monitored on day 3 (Figure 49) and with BLG L-0130 and BLG 
[LF] on day 7 (Figure 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49 Inhibition assay on day 3 
CBMCs were cultured for 6 days in the presence of different stimuli (“primed” with medium alone 
(a,d,g), BLG [LF] (b,e,h), and BLG L-0130 (c,f,i)) and an inhibition assay was performed with α-CD3 
(a-c), BLG L-0130 (d-f), and BLG [LF] (g-h). The inhibitory potential is expressed as relative 
proliferation compared to the effector T cells (CD4+CD25-) cells alone. Results are representative for 6-9 
independent experiments. T-test was applied (p<0.05 (*); p<0.01 (**); and p<0.001(***)). 
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At the read-out time point at day 3, a trend for regulatory T cells to become 
suppressive could be observed. It worked best upon priming with the purified BLG [LF] 
for six days then stimulating with α-CD3 (Figure 49 (b) and (e)). On day 3, no 
suppressive potential of Tregs could be monitored when stimulated with BLG [LF] at 
no prior priming stimulus (Figure 49 (g-i)). 
 
This suppressive effect gets even more pronounced on day 7, where the CD4+CD25+ 
Treg subset, that was not inhibitory on day 0, gained inhibitory potential upon the 
stimuli BLG L-0130 and BLG [LF] (Figure 50 (a-f)). The trend can be observed in all 
graphs, however a statistically significant difference could only be observed when using 
BLG L-0130 (Figure 50 (a-c) with all priming stimuli, and BLG [LF] only when primed 
with BLG L-0130 (Figure 50 (f). 
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Figure 50 Inhibition assay on day 7 
CBMCs were cultured for 6 days in the presence of different stimuli (medium alone (a,d), BLG [LF] 
(b,e), or BLG L-0130 (c,f)). Inhibition assays were performed with and BLG L-0130 (a-c), and BLG [LF] 
(d-f). Results are representative for 5-6 independent experiments. T-test was applied and SEM is shown 
(p<0.05 (*); p<0.01 (**); and p<0.001(***)). 
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4.2.10 Changes of the Transcription Factors FOXP3, RUX1, 
RUX3 and the Treg Marker GARP Upon Priming 
As priming of CBMCs led to suppressive CD4+CD25+ Tregs (Figure 48 and 49)  
changes of the trancription factors FOXP3, RUNX 1and RUNX 3 and the Treg 
associated surface marker GARP were measured via quantitative real-time PCR and 
compared to PB-derived Tregs (Figure 51).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51 FoxP3, GARP, RUX 1, and RUX 3 expression in CB and PB of 
effector and regulatory T cells after priming for six days 
CBMCs or PBMCs were primed for six days with [50 µg/mL] BLG [LF], BLG L-0130, or LPS (the 
amount present in 50 µg/mL BLG L-0130). After that, T effector cells (Teff; CD4+CD25-) and T 
regulatory cells (Tregs; CD4+CD25+) were isolated via MACS sorting. FoxP3, GARP, RUNX 1; and 
RUNX 3 were measured via qRT-PCR. CB-derived cells are displayed with white (Teff) and black 
(Tregs) squares, PB-derived cells are illustrated with white (Teff) and black (Tregs) dots. Results are 
representative for 3 independent experiments showing the normalized expression. 
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Cord blood and peripheral blood mononuclear cells were primed for six days with 
medium alone (control), BLG [LF], BLG L-0130 or LPS (with the amount present in 
BLG L-0130; at the same concentration).  
Subsequently, the CD4+CD25- T effector cell subsets and CD4+CD25+ regulatory T 
cell subsets were MACS-sorted. QRT-PCR was performed to measure the expression of 
the Treg associated genes. 
Foxp3 and GARP expression was strongly upregulated in Tregs when compared to 
Teff. There was a trend that medium or BLG [LF] primed displayed the highest FoxP3 
and GARP expression was observed.  
With RUNX 1 and RUNX 3, the expression pattern is less clear. A trend towards a 
higher expression of RUNX 1 and RUNX 3 can be monitored in CB compared to PB. 
Those CB/PB-derived cells with RUNX 1 expression also have a heightened RUNX 3 
expression (Figure 51). 
No difference in the expression profile could be found between CB and PB, only 
between the specific subsets. 
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4.2.11 Phenotypic Characterization of the T Cell Compartment Upon 
Antigen-Exposure 
Flow cytometry was applied for PBMCs (red) and CBMCs (green) after a 7 day 
culture in the presence of different stimuli (BLG L-0130, BLG [LF], LPS 
(contamination)) or medium alone (control). FACS scatter of the entity of the CD3 cells 
(M1; 100%) were assessed for all stimuli. For gaining more information, scatters for the 
proliferated cells (M2), measured with CFSE staining, are only shown for the stimulus 
BLG L-0130 as the other stimuli did not provide enough cell counts to show 
representative FACS scatters.  
As shown in previous experiments, CBMCs proliferate stronger upon stimulation 
than PBMCs (72% vs 25%; BLG L0130 (Figure 56 vs. Figure 52, respectively); 13.56% 
vs 4%; BLG [LF] (Figure 56 vs. Figure 53); 55.47% vs 19.5%; LPS (Figure 57 vs. 
Figure 54, respectively) and 4.07% vs 3.68% (Figure 56 vs. Figure 53, respectively); 
control ). 
In peripheral blood the markers CD45RO and CD25 were highly upregulated upon 
stimulation (seen with the stimuli BLG L-0130 and LPS). The same pattern has been 
observed looking at the markers CD45RB and CD45RO. After proliferation T cells 
showed an overall expression of ~ 90% that possessed these markers. In cord blood per 
contra, a different pattern has been observed.  
As cord blood cells are mainly CD45RA+ on day 0 a shift towards double positive 
CD45RA CD45RO cells can be observed. About 70% of the T cells express these 
surface markers upon proliferation. The same arrangement and percentages can be seen 
when checking the marker CD45RB.  
Next to these markers, the activation markers CD69 as well as CD25 have been 
highly upregulated during the stimulation process. The contaminated BLG L-0130 
shares the same activation profile as compared to LPS (contamination). Moreover in 
PB, comparing the surface pattern of the BLG [LF] and the control less proliferation 
with a similar pattern can be observed. 
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Figure 52 Expression profile of PBMCs stimulated with BLG L-0130 on day 7 
PBMCs were stained with CFSE on day 0, then stimulated with BLG L-0130 [50µg/mL] for seven days. 
The left panel represents all CD3 cells on day seven, the right panel represents the scatters of the 
according proliferated cells. 
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Figure 53 Expression profile of PBMCs alone and stimulated with BLG [LF] on 
day 7 
PBMCs were stained with CFSE on day 0 and then stimulated with BLG [LF] [50µg/mL] for seven days 
(right panel) or medium alone (control; left panel). The scatters show CD3 cells (M1). 
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Figure 54 Expression profile of PBMCs stimulated with LPS on day 7 
PBMCs were stained with CFSE on day 0 and then stimulated with LPS (the same amount that was 
present in 50µg/mL BLG L-0130) for 7 days. The scatters show CD3 cells (M1). 
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Figure 55 Expression profile of CBMCs stimulated with LPS on day 7 
CBMCs were stained with CFSE on day 0 and then stimulated with LPS (the same amount that was 
present in 50µg/mL BLG L-0130) for 7 days. The scatters show CD3 cells (M1).
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                                                               BLG L-0130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56 Expression profile of CBMCs stimulated with BLG L-0130 on day 7 
were stained with CFSE on day 0, then stimulated with BLG L-0130 [50µg/mL] for seven days. The left 
panel represents all CD3 cells on day seven, the right panel represents the scatters of the according 
proliferated, stimulated cells. 
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Figure 57 Expression profile of CBMCs alone and stimulated with BLG [LF] on 
day 7 
CBMCs were stained with CFSE on day 0 and then stimulated with BLG [LF] [50µg/mL] for seven days 
(right panel) or medium alone (control; left panel). The scatters show CD3 cells (M1). 
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4.2.12 Cord Blood-Derived CD4+CD25+ T Cells Expand Upon 
Antigen-Exposure 
In order to identify the proliferating cell population CD4+CD25+and CD4+CD25- 
were MACS-sorted, CFSE-labeled on day 0 then stimulated with BLG [LF] (middle), or 
BLG L-0130 (right) (Figure 58 (a and b)). 
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Figure 58 Proliferation of CD4
+
CD25
+
 Tregs and CD4
+
CD25
-
 T effector cells 
Tregs and Teff were isolated via MACS-sorting on day 0, stained with CFSE and stimulated for 7 days in 
the presence of medium alone (left), BLG [LF] (middle), and BLG L-0130 (right). Cells are gated on 
CD3+CD4+ cells. Proliferation was measured by rating the CFSE distribution. For every stimulus a scatter 
dot-plot (left) and a histogram (right) is displayed. Data represents one out of four independent 
experiments. 
 
Cord blood derived CD4+CD25+ T cells do proliferate upon BLG L-0130 stimulation 
(22.65%), and to a lesser extent when stimulated with BLG [LF] (3.37%) (Figure 58 
(a)). In contrast, CD4+CD25- T cells strongly proliferate upon stimulation with BLG L-
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0130 (64.79%). BLG [LF] (3.29%) induced proliferation in the CD4+CD25- fraction, 
CD4 however was downregulated (Figure 58 (b)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59 Crossing CFSE stained Tregs and Teff 
CBMCs were sorted according to their CD25 expression, then stained with CFSE and incubated with 
BLG L-0130 for seven days. Figure (a) summarizes the figures (b-e), the figure below shows the absolute 
cell counts. CD4+CD25- cells showed the highest proliferation whereas when CD4+CD25+ cells were 
added, less proliferation was observed. In figure (b) about 90% of CFSE stained CD4+CD25- cells alone 
proliferated upon this stimulation, whereas only 7% proliferated when CFSE stained CD4+CD25+ cells 
proliferated when alone (d). However, when observing CFSE stained CD4+CD25- co-cultured with non-
CFSE stained CD4+CD25+ ratio 1:2 at day 0 at a, only about 70% of all cells proliferated (c). When 
CD4+CD25+ cells were stained with CFSE and joined with CD4+CD25- cells, about 50% proliferated and 
were CFSE low (e). 
 
As a next step the proliferation pattern of CFSE stained cord blood derived 
Tregs/Teff cells in combination with the corresponding non-CFSE labeled subset were 
screened. Again, CD4+CD25- cells proliferate strongly upon BLG L-0130 stimulus 
(more than 90%; upper panel, Figure 59). This is also reflected in total counts. After the 
7 days of culture with BLG L-0130 the cell population doubled. However, after addition 
of Tregs less proliferation was observed (Figure 59 (c,e)).  
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As mentioned above (Figure 58) again an increased proliferation of Teff cells upon 
BLG L-0130 was observed (Figure 59 (b)). 90% of CFSE stained CD4+CD25- cells 
alone proliferated upon this stimulation, whereas only 7% proliferated when CFSE 
stained CD4+CD25+ alone cells where observed (d). Interestingly, when observing 
CFSE stained CD4+CD25- mixed together with non-CFSE stained CD4+CD25+ 
(CD4+CD25- CFSE + CD4+CD25+) at a ratio 1:2 at day 0, only about 70% of all cells 
proliferated (c). When CD4+CD25+ cells were stained with CFSE and joined with 
CD4+CD25- cells (CD4+CD25+ CFSE + CD4+CD25-), about 50% proliferated and were 
CFSE low (e). 
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4.2.13 Functional Assays Demonstrate Suppressive Properties of the 
Undividing Fraction 
In the previous experiments the suppressive potential of “primed” CD4+CD25+ Tregs 
has been revealed (Figure 49 and Figure 50). The question arose whether the cells that 
proliferated or those who did not proliferate become inhibitory during this process. 
To distinguish which cell population gains inhibitory potential after priming, cells 
were sorted according to their CFSE intensity and CD25 expression on day 6 (Figure 
60). Three different fractions (Figure 60) were obtained and inhibition assays were 
performed with fraction 1 (F1; CFSEhighCD25high), fraction 2 (F2; CFSEhighCD25-), and 
fraction 3 (F3; CFSEint/lowCD25high), in the presence of thawed, allergen-unexperienced 
CD4+CD25- T effector cells and irradiated CBMCs, which served as APCs. BLG L-
0130 (a), and BLG [LF] (b) were used as stimuli for the inhibition assays (Figure 61).  
 
 
 
 
 
 
 
 
 
Figure 60 Fractions 1-3, sorted according to their CFSE intensity and CD25 
expression 
Inhibition assays were preformed with 9 different fractions (3 “priming” stimuli x 3 fractions (F1-F3)) in 
the presence of  4 stimuli (α-CD3, BLG L-0130, BLG [LF], and OVA. Medium alone served as internal 
control. 
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Figure 61 Inhibition assay with CFSE and CD25 sorted fractions 
After a 6 day priming with 2 different stimuli (BLG L-0130, and BLG [LF]), cells were FACS sorted 
according to their CFSE intensity and CD25 expression. Three fractions of each stimulus have been 
gained (CFSEhighCD25high, CFSEhighCD25-, CFSElow/intCD25high ), an inhibition assays were performed 
with BLG L-0130 (a), and BLG [LF] (b). 
 
(a) F1-F3, stimulated with L-0130 
(b) F1-F3, stimulated with BLG [LF] 
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The experiments suggest that the undividing fraction bears the highest suppressive 
potential. The dividing fraction however, also possessed some inhibitory capacity after 
the allergen exposure. Marginal differences could be found after the “priming” with the 
BLG L-0130 (which contained trace amounts of LPS) compared to the LPS-free BLG 
[LF]. The CD4+CD25highCFSEhigh fraction stimulated with BLG L-0130 showed 
generally a diminished proliferative response (~ 3 times lower cpms). The assumption 
that cells are exhausted after the weekly allergen-experience however can be disproved. 
We could demonstrate that cells are still able to respond to various allergens and even 
showed suppressive potential after the strong stimulus BLG L-0130. 
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5 DISCUSSION 
Two main issues were addressed in this thesis: First, the differential impact of 
endotoxin contamination of commercially available antigen preparations on cord blood 
and peripheral blood from healthy adult donors in vitro. Second, cord blood specific 
features of the regulatory T cell subset and its impact on allergen-specific responses and 
tolerance.  
Endotoxin contamination in antigen preparations is one of the most important 
confounders of in vitro assays. Interestingly, despite general importance, literature about 
this issue is relatively rare. We performed a detailed investigation to define the impact 
of such contaminations. 
Although indirect evidence is strongly pointing towards a bias of in vitro assays by 
such contaminations the precise impact on an antigen-specific read-out pattern in a 
human system in general and cord blood in specific needed to be elucidated 413, 414. We 
demonstrated both, the high frequency of detectable endotoxin contamination in 
allergen preparations and the pro-proliferative effects and induction of cytokine 
production by these contaminants. 
 
Firstly, we could demonstrate that endotoxin in commercially available antigen 
preparations strongly affects in vitro cellular measurements. The proliferative responses 
as well as the cytokine production were significantly elevated of mononuclear cells 
from human sources (both cord and adult blood). This effect could be validated for food 
and inhalative allergens and for the Th1-type recall antigen tetanus toxoid. 
 
Secondly, we defined the differential impact of endotoxin on peripheral and cord 
blood derived mononuclear cells. Cord blood mononuclear cells are significantly more 
prone to proliferation in response to endotoxin and allergens than PBMCs from adult 
non-allergic donors. This is also true for antigens the fetus was most likely not exposed 
to (e.g. camel caseinate). Therefore the underlying mechanism may be more complex 
than originally suggested. Cord blood does not only harbour a higher percentage of a 
naïve T cell population but also a subset that is directly derived from the thymus and 
differs from the naïve T cells in adult blood. The naïve nature of cord blood may 
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contribute to the higher frequency of endotoxins responses. Cord blood cells from 
pregnancies without complications have not encountered endotoxin exposure and 
consequently did not develop LPS tolerance. This phenomenon has been described upon 
continuous, low LPS dose exposure in adults 415, 416. LPS tolerance may contribute to a 
higher heterogeneity of the peripheral blood mononuclear cell response. 
 
However, not only LPS-dependent responses, but also allergen-specific responses 
were significantly enhanced. Data from Thornton et al may provide another explanation: 
thymic emigrants in cord blood are highly responsive to a short initial proliferation 
boost resulting in apoptosis thereafter 249. Moreover it has been postulated that allergens 
may cross the placenta from mother to child and thereby prime cord blood derived T 
cells in utero 395, 405. This explanation was supported by the fact that allergen-specific 
IgE could be detected in the amniotic fluid. This is of particular interest as IgE was 
thought not to cross the placenta. However, the origin of amniotic IgE is still subject of 
debate230. 
Insufficient regulatory mechanisms may be a reason for the heightened response in 
cord blood. This is supported by the fact that un-primed, naïve cord blood derived 
CD4+CD25+ regulatory T cells display less inhibitory potential than CD4+CD25+ Tregs 
from aduls 248, 417.  
 
Thirdly, we could demonstrate that the contamination has to be ascribed to LPS as it 
acts through TLR-4 dependent mechanism. LPS is certainly not the only form of 
contamination. Numerous potential other confounders could be responsible for the 
measured effects (reviewed in 418, 419) such as CpG, RNA- or DNA- fragments, flagellin, 
or other bacterial cell fragments that induce an innate immune response. LPS, however, 
seems to be the most probable candidate, since high amounts were detected in different 
BLG preparations. In addition, we could prove its ability to induce proliferation and 
cytokine production via spiking experiments, where LPS was added in the same amount 
as detected by limulus assay in the contaminated BLG preparations. To date, a reliable 
assay for detection is only available for LPS. It can also be considered as a surrogate 
marker for contamination in general. The involvement of other contaminants that 
represent ligands for TLR-2, TLR-3, TLR-5, TLR-7, and TLR-9 cannot be ruled out 
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completely. Nevertheless, we believe that LPS is the main contaminant as we could 
clearly illustrate a significant cytokine decrease after TLR-4 blockade. Ergo a TLR-4 
and LPS engagement can most be certainly ascribed to contamination in the BLG 
preparation. Moreover we could confirm this data with size-exclusion chromatography 
as well as TLR-4 transfected HEK-cells. TLR-2 dependend mechanisms were not 
affected at all.  
Purification protocols are commercially available. The most popular systems are based 
on polymyxin B columns. This leads to decrease the LPS amount to a certain extent. 
They are not efficient enough to be used in practice, as trace amounts of LPS remain. 
Trace amounts present (0.7ng/mL) affect the cellular level as we have demonstarted in 
various experiments. This fact investigated in this study is of central importance when 
standardized amounts of LPS are tested. Moreover, other TLR ligands may not be 
removed by this approach and still confound measurements.  
Another important methodological consideration is the amount of antigen used for 
limulus measurement (1 mg/mL or 1 µg/mL) since the sensitivity of the limulus assay is 
limited. However the impact of these contaminations on antigen-specific proliferation 
testing is strongly related to the amount of LPS present and the thereof resulting 
kinetics.  
BLG, one of the major milk allergens, is one of the most frequent food allergens in 
infancy. Milk allergy often resolves spontaneously in the first years of life and is 
therefore suitable for studying tolerance induction. Moreover, several commercially 
available BLG preparations have been reported to contain high amounts of endotoxin 
420, 421. Thus, BLG, an allergen well-described to very efficiently and frequently induce 
proliferative responses in cord blood makes BLG a perfect model-allergen to 
investigate. Brix et al proved the endotoxin fraction of contaminated BLG to be the 
more important to induce a proliferative response of naïve T cells in BALB/c mice than 
to the allergen fraction itself 393, 420. Human cord blood mainly harbours naïve T cells 
and consequently represents a perfect model to assess whether endotoxins equally 
contribute to the proliferative capacity of un-purified BLG in the human system. 
However, human mononuclear cells are known to react with less proliferation to 
endotoxin. Therefore, the relevance of endotoxin as a confounder could be less 
prominent in human cells than in mice. Other food allergens, such as Ara h 1 (the major 
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peanut allergen) and OVA (egg allergen) were used as representative allergens that have 
not shown that great proliferative impact on cord blood. Moreover, the allergen rBet v 1 
(major birch pollen allergen) was chosen as a representative inhalational allergen known 
to induce proliferation in peripheral blood and to a lesser extent in cord blood. To assess 
the whole picture a Th1 recall-antigen, tetanus toxoid (TT), and plate-bound anti-CD3 a 
polyclonal TCR dependent T cell activator, were used for proliferation assays and anti-
CD3 also for inhibition assays. 
Pure BLG was capable of inducing proliferation in cord blood and led to a 
percentage of positive proliferative responses comparable to published data 248, 392, 422, 
423. This strengthens the hypothesis that measured proliferation in cord blood is also 
induced by the allergen itself, thus reflecting allergen-specificity.  
 
PBMCs from adult donors (whether allergic or healthy) shows a wholly different 
pattern. Little or no proliferation in response to purified BLG is measurable in non-
allergic individuals. Moreover, endotoxin related effects become visible at a later time 
point and are less prominent.  
Recombinant allergens and antigens display an important feature of immunological 
research. Although endotoxin free conditions are very difficult to achieve due to the 
expression system in E.coli, preparations with low levels are available. This is the case 
for rBet v 1 used in the present publication. Our data suggest that contaminations [20 
pg/mL] as measured in purified recombinant allergen preparations are acceptable.  
Interestingly, no positive proliferative response to rBet v 1 was observed in cord 
blood while 3 out of 6 of the adult group responded to rBet v 1. The later observation is 
in line with data of Ebner et al demonstrating allergen-specific proliferation of PBMC 
from non allergic individuals 403. 
Regarding cord blood related responses to inhalational allergens it is quite interesting 
that none of the investigated samples responded to rBet v 1. A possible explanation may 
be provided by intra-uterine priming with food allergens present at high concentrations 
in maternal peripheral blood and known to cross the placenta 395. The amount of inhaled 
birch pollen allergen is extremely low and makes intrauterine priming less likely. Thus 
BLG-specific responses are more frequent by far than proliferation to inhalational 
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allergens. Recent studies have clearly pointed out that allergen-specific proliferation to 
inhalant allergen does also occur in cord blood but at lower frequencies 248, 423.  
Our data supports the difficulty of differentiating between allergen-specific and 
unspecific responses. The results highly depend on the cellular system (cord versus 
adult blood cells), the read out assay (proliferation, cytokine production) and the 
allergen used. While cord blood mononuclear cells readily respond at day three to both 
contamination and antigen at very low levels, this is not the case for PBMCs from adult 
donors, being allergic or not. Consequently, proliferation data should be based on an 
extensive setting with caution on positive responses to low antigen concentrations. In 
our experiments, CBMCs were significantly more prone to proliferate in response to 
endotoxin and purified BLG than PBMCs from adult donors.  
In conclusion we were able to demonstrate that endotoxins present as contamination 
in commercially available allergen preparations act as a confounder on cellular 
responses via a TLR-4 dependent mechanism. However, the impact of these 
contaminations on antigen-specific proliferation is strongly dependent on the amount of 
endotoxin, the thereof resulting kinetics, the type of allergen used and the regulatory 
properties related to the maturity of the donor system. 
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The increased proliferation of cells in cord blood upon allergen stimulation is poorly 
understood. On one hand we have many confounders in CB as a different response to 
endotoxins 411. On the other hand, it could be linked to recent thymic emigrants (RTE) 
in cord blood as postulated by Thornton et al 249. RTE, frequent in CB, are known to 
initiate a quick and high proliferative response resulting in apoptosis accompanied by 
the generation of regulatory T cells and, importantly, do not possess memory function. 
In fact this is considered as one of the main mechanisms to exclude responses to 
innocuous antigens. However there is evidence for active responses that are linked to 
tolerance induction via generation of antigen specific regulatory cells. It is not known 
whether the heightened proliferative responses to allergens in cord blood are linked to 
effector cells that have been primed in utero or due to lack of control by regulatory T 
cells. 
 
Allergen-specific proliferative responses in CB vs adult blood cells were in general 
significantly higher, quantitatively and qualitatively. We provide evidence that freshly 
isolated CB derived CD4+CD25high Tregs share many phenotypic characteristics with 
their PB derived counterpart. They are both anergic with the main difference that CB 
derived CD4+CD25+ Tregs are incapable of suppressing CD4+CD25- T cells in the 
presence of irradiated APCs when compared to PB-derived Tregs. This lack of their 
regulatory function is consistent with findings of other groups 120, 143, 248-250, 417, 424. We 
hypothesize that allergen exposure directly after birth is pivotal to gain functional 
regulatory T cells.  
Re-stimulation experiments suggest that functionally active CD4+CD25+ T 
regulatory cells emerge after antigen exposure in cord blood. It is tempting to speculate 
that this mechanism plays a key role in tolerance development after birth. Some recent 
studies 425-427 can fortify this hypothesis as they suggest an antigen-specific tolerance 
that is already induced in utero. Observations and experiments described that the graft 
survival of kindney transplanted children of a sibling donor is higher when the donor 
has maternal HLA antigens not inherited by the recipient than when the donor has 
paternal HLA antigens not inherited by the recipient. This is extremely interesting in 
reference to our data, as it indicates that the regulatory T cells are generated in utero 
which is the case for maternal cells that cross the placenta and induce 
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CD4+CD25highFoxP3+ Tregs. Those cells suppress anti-maternal immunity and last until 
early adulthood 427. Contrary to popular belief strict food avoidance also has to be 
scrutinized with the data. It has been widely held that strict avoidance of food allergens 
may reduce the risk or prevent the IgE-mediated sensitization and immunological 
reactions 428. However, no association between the level of environmental exposure and 
the extent of allergen-induced proliferation could be found 429. Allergens might be 
important to prime Tregs towards potent suppressor cells after birth and therefor induce 
tolerance mechanisms and prevent allergy later on. 
 
We could confirm this theory by several experiments: Firstly we could prime 
CD4+CD25high T cells in the presence of different allergens (BLG, Ara h1) to become 
functional.  
Secondly, an expansion of the Treg-compartment upon antigen exposure is detected. 
Thirdly, both the nTreg compartment (upon activation, without proliferation) and the 
iTreg compartment (upon expansion in response to the antigen) confer to suppression. 
The fact that medium “treated” cord blood derived CD4+CD25+ cells gained 
suppressive potential can be explained by the fact that nTregs are less prone to undergo 
apoptosis and unspecific activation may take place as a result of the culture condition184. 
The expanding fraction, which possessed suppressive properties after allergen 
stimulation per contra, does not fortify an allergen-unspecific effect. 
Some other studies 122, 251 demonstrated a strong suppressive potential of CB-derived 
Tregs. At second look however, achieved potent suppression only after pre-activation 
with polyclonal stimuli. This entirely supports our data. Why the CB-derived Treg 
fraction does not possess inhibitory function in first case remains to be answered. 
However, we found out that this observation cannot be explained by a significant lower 
frequency of FoxP3+CD4+CD25high cells or mean percentages of 
CD4+CD25highCD127low only increase slightly throughout life (6.1% in CB, 7.22% 
adults (age 20-25) and 7.5 (age 60+)) 430. Moreover,expression of the Treg markers 
RUNX 1, RUNX 3, and GARP, or IL-10 and TGF-β, did not substantially differ 
between CB-Tregs and PB-Tregs in our experiments. 
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CB and PB derived mononuclear cells mainly differ in their percentage of naïve T 
cells that express a CD45RA+CD45RO-CD62Lbright phenotype whereas the adult CD4+ 
T cells exhibit a memory phenotype (CD45RA-CD45RO+) 105, 431. It is possible that 
freshly isolated CB CD4+CD25+ T cells are less suppressive due to their phenotypic 
immaturity. However, Valmori et al 247 described a naïve natural Treg population in 
adult individuals. These are more prominent in young adults and decrease with age 
together with the total naïve CD4+ population. In cord blood 7% of total CD4+ T cells 
display this phenotype whereas in adults only 0.2-3.3% of the CD4+ T cells exhibit this 
naïve Treg phenotype 245. The TREC content of naïve Tregs was similar to that of naïve 
CD25- T cells and higher than that of the antigen-experienced CD25- fraction. These 
results are also consistent with the concept that naïve Tregs are in an early 
differentiation stage and have high resemblance to cord blood derived Tregs. CB 
derived naïve Tregs only differ to naïve adult Tregs due to their suppression profile. 
Peripheral blood derived naïve Tregs from adult donors showed inhibitory potential 
compared to those of cord blood 247. The cord blood derived Tregs seem to be even 
more naïve than the naïve counterpart in adult blood. Fritzsching et al (2006) 246 and 
Santner-Nanan et al (2008) 430 could show differences in the functional properties of 
naïve and memory Tregs. The majority of adult blood derived Tregs possess high 
CD45RO and CD95 levels, prone to CD95L-mediated apoptosis. The CD95L-resistant 
Tregs in adult blood show augmented naïve markers comparable to the Tregs in cord 
blood. When stimulated with monoclonal antibodies (e.g. CD3CD28 antibodies) CB 
cells up-regulate CD95 as well as memory markers and show sensitization towards 
CD95L hypothesizing that CD95 and the memory markers are important to create 
potent regulatory T cells.  
It is possible that a specific subset of naïve CB CD4+CD25- can be “educated” and 
expanded to become suppressive CD25+FoxP3+ Tregs as also suggested by Zelenay et 
al 432. Our study is the first study that could show inhibitory potential of the regulatory T 
cell subset upon priming with allergens. These, newly generated Tregs were highly 
suppressive in an antigen-nonspecific manner. This corresponds with the observation in 
other studies as CD25+ Tregs need antigen specific stimulation via the TCR to become 
suppressive but once activated, they unspecifically suppress the antigen. 184 After the 
initial antigen dependent activation Tregs seem to be stimulation-independent in their 
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mechanism and are capable of suppression even in the absence of the appropriate 
antigen 184. Conventional T cells with different antigen-specificities can be suppressed 
in vicinity to the Tregs. This mechanism is known as “bystander suppression”. 
Naïve CB cells resemble recent thymic emigrants cells (RTEs) 239 and express a 
number of characteristics that distinguish them from naïve T cells that are present later 
in life. RTEs express "thymocyte-like" characteristics with regard to rapid rate of 
apoptosis which goes along with the observation that CB cells in contact with allergens 
are prone to apoptosis as well 216, 389-392, 403. In our experiments however, apoptotic 
markers were not of primary importance. Apoptosis is a big phenomenon regarding the 
absolute cell count upon stimulation. However as we always put our main focus on 
forward side-scatter characteristics and the CD4 expression (high/normal) of T cells and 
have always verified the data with functional assays apoptotic cells are highly unlikely 
to act as confounder in our experimental setting. The significantly increased 
proliferation of CBMCs compared to PBMCs can be related to an immature state of the 
Treg compartment. Nevertheless, after FACS sorting, a small CB-derived regulatory 
fraction (CD127low) possessed inhibitory capacity without pre-activation. This subset 
admittedly was not able to exert net-inhibitory effects The CD4+CD25+(high and 
int)CD127low compartment showed a suppressive capacity whereas an increased 
proliferation was observed at the CD4+CD25+CD127high compartment.  
Grindebacke et al (2009) 412 and Santner-Nanan et al (2008) 430 could demonstrate a 
significantly reduced FoxP3 expression in cord blood compared to peripheral blood. 
This difference can be ascribed to the gating strategy as gating on the top 2% of CD4 
cells that express high CD25 results in a lower FoxP3 expression. On the other hand 
when gating on the defined CD25FoxP3 expression, no statistically significant 
difference can be found.  
In conclusion this study contributes substantially to a better understanding of in vitro 
responses in cord blood. In particular the unique features of cord blood derived T cells 
are defined in detail. This study suggests an active acquisition of allergen-specific 
tolerance via induction of allergen specific regulatory T-cells after birth. 
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7 APPENDIX 
7.1 Abstract english 
Background: Upon antigen exposure cord blood derived T cells respond to 
ubiquitous environmental antigens by proliferation. To date it remains unclear whether 
these “heightened” responses relate to different regulatory properties of the regulatory T 
cell (Treg) compartment or whether this can be explained due to endotoxin 
contamination detected in allergen preparations. Distinct effects of endotoxin on cells in 
cord and adult blood are poorly defined.  
Objectives: To examine the specific nature of allergen-specific responses of cord 
blood derived T-cell in vitro in detail with special focus on regulatory T cells and 
determine the impact endotoxin contaminaiton in allergen preparations in this context. 
Methods: The endotoxin content was assessed via limulus assay. Proliferative and 
cytokine response of mononuclear cells were evaluated via ([3H]thymidine 
incorporation and ELISA. Size exclusion chromatography of endotoxin contaminated 
BLG was performed to define the impact of the protein on the proliferative responses 
measured. The involvement of toll like receptor 2 and 4 was investigated by blocking 
antibodies and toll like receptor-transfected HEK cells. The Treg compartment in cord 
blood and peripheral blood was characterized via flow cytometry using MACS and 
FACS sorting. The suppressive potential per se and upon in vitro priming was evaluated 
via functional inhibition assays ([3H]thymidine incorporation assay and CFSE staining). 
Suppressive properties of expanding cell populations were investigated using FACS 
sorting. 
Results: Allergen- and endotoxin-induced proliferative responses in cord blood were 
significantly enhanced compared to those in adult blood. Compared to un-primed 
CD4+CD25high cells from adult blood, the respective cord blood derived population did 
not show inhibitory capacities upon TCR activation. This could not be explained by a 
significantly lower frequency of FoxP3+CD4+CD25high cells or different expression of 
the Treg markers GARP, CD127, or the Treg associated transcription factors RUNX 1, 
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RUNX 3 and FOXP3. FACS sorting experiments of unstimulated cells revealed subsets 
in cord blood (CD4+CD25highCD127low and CD4+CD25intCD127low) that possessed 
inhibitory potential. In vitro exposure to allergens leads to both functional activation of 
both an expanding and a resting Treg population.  
Conclusion: Endotoxins in allergen preparations act as confounder in the assessment 
of allergen-specific responses. The impact of these contaminations is strongly related to 
the blood source (cord vs peripheral blood), the type of allergen, the amount of 
endotoxin and the thereof resulting kinetics and regulatory properties. Cord blood 
harbours a very small subset of Tregs that is not able to exert net inhibitory effects 
within the mononuclear cell fraction. However in case of antigen-exposure the putative 
Treg subset (CD4+CD25high) becomes highly suppressive and expands.  
 
Key words: BLG: β-lactoglobulin; cord blood; endotoxin contamination; food allergens; regulatory T 
cells; T-cells; toll like receptors 
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7.2 Abstract german 
Hintergrund: Nabelschnurblut T Zellen proliferieren trotz ihres naïven Phänotyps 
auf unterschiedlichste Allergene. Diese erhöhte Immunantwort kann nicht vollends 
erklärt werden. Sie könnte einerseits auf eine funktionelle Unreife der regulatorischen T 
Zellen (Tregs) im Nabelschnurblut als auch auf Endotoxinkontaminationen in 
Allergenpräparaten zurückgeführt werden. Funktionelle Unterschiede im T 
regulatorischen Kompartment von Nabelschnurblut und Erwachsenenblut und deren 
mögliche Relevanz für die Entstehung allergen-spezifischer Toleranz werden jedoch 
noch ungenügend verstanden. 
Ziel: Ziel ist es die Eigenheiten allergen-spezifischer Immunantworten von 
Nabelschnurblutzellen in vitro zu definieren. Spezieller Fokus wird dabei auf 
regulatorische T Zellen und auf den Einfluss von Endotoxinkontaminationen gelegt. 
Methoden: Der Endotoxingehalt unterschiedlicher Allergenpräparationen wurde 
mittels Limulus assay bestimmt. Der Einfluss von Endotoxinkontaminationen auf die 
Proliferations- und Zytokinantwort mononukleärer Zellen wurde mit [3H]Thymidin-
assay und ELISA bestimmt. Mittels „Size Exclusion Chromatography“ wurde der 
relative Anteil gereinigter Proteine im Vergleich zu Endotoxinkontaminationen im 
Bezug auf die proliferative Kapazität getestet. Die Abhängigkeit der Toll-like 
Rezeptoren (TLR2 und 4) der Kontaminationsprodukte wurde mittels 
Blockierungsversuchen und TLR-transfizierter HEK-Zellen ausgetestet. T 
regulatorische Zellen wurden durch RT-PCR und FACS charakterisiert. Sub-
Populationen wurden mit Hilfe von MACS und FACS aufgereinigt und deren 
suppressives Potential in vitro durch Inhibitionsassays ([3H]-Thymidineinbau und CFSE 
Färbung) bestimmt. 
Ergebnisse: Allergen- als auch Endotoxin induzierte Immunantworten im 
Nabelschnurblut sind im Vergleich zum Erwachsenenblut erhöht. Im Gegensatz zu den 
CD4+CD25high T Zellen im Erwachsenenblut zeigten die Nabelschnurblut T 
regulatorischen Zellen eine stark verminderte suppressive Kapazität. Dieser Effekt 
konnte weder mit einer geringeren Frequenz der FoxP3+CD4+CD25high noch durch 
differentielle Expression der Treg Marker GARP, CD127, oder den Treg-assoziierten 
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Transkriptionsfaktoren RUNX 1, RUNX 3 und FoxP3 erklärt werden. Lediglich eine 
Untergruppe der regulatorischen T Zellen (CD4+CD25highCD127low und 
CD4+CD25intCD127low) besaß inhibitorisches Potenzial. In vitro Exposition von 
Allergenen führt jedoch zu einer funktionellen Aktivierung regulatorischer T Zellen im 
Nabelschnurblut. Es kommt dabei einerseits zu einer Aktivierung und andererseits zu 
einer Proliferation der CD4+CD25high T Zellen, die in beiden Fällen allergen-spezifische 
suppressive Kapazität besitzen. 
Schlussfolgerung: Endotoxine in Allergenpräparaten wirken als systematische 
Störvariabel in in vitro Versuchen. Der Einfluss dieser Kontamination hängt stark von 
der Blutquelle (Nabelschnur- vs. Erwachsenenblut), dem Allergen, der Endotoxinmenge 
und der daraus resultierende Kinetik ab. Nabelschnurblut besitzt abgesehen von einer 
Subgruppe regulatorischer T Zellen mit inhibitorischer Kapazität eine regulatorische 
Population die funktionell unreif ist. Im Falle einer Allergen-Exposition wird diese 
CD4+CD25high Treg Population funktionell, somit suppressiv und beginnt zu 
expandieren. 
 
Schlagwörter: β-Lactoglobulin, Nabelschnurblut, Endotoxin, Kontamination, Nahrungsmittelallergene, 
Regulatorische T Zellen, Toll-like Rezeptoren 
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